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resistance	 frequently	 develops	 resulting	 in	 progressive	 metastatic	 disease.	 The	 current	
standard	of	 care	 for	 hormone-insensitive	 PCa	 includes	 the	 cytotoxic	 drugs	 docetaxel	 and	
mitoxantrone	 although	 resistance	 rapidly	 develops	 to	 all	 available	 therapies.	 We	
demonstrated	 that	 the	 replication-selective	 oncolytic	 adenoviral	mutant	 Ad∆∆	 enhanced	
drug-induced	 cell	 killing	 in	 several	 preclinical	 cancer	models.	 Ad∆∆	 is	 deleted	 in	 the	 viral	
E1ACR2	 and	 E1B19K,	 to	 prevent	 pRb-binding	 and	 enhance	 drug-mediated	 apoptotic	 cell	
killing,	 respectively.	 In	 drug-insensitive	 PCa	 tumour-xenografts,	 in	 vivo	 administration	 of	
Ad∆∆	greatly	enhanced	drug-mediated	tumour	regression.	The	aim	of	my	thesis	project	was	
to	 investigate	 the	 role	 of	 apoptosis	 and	 pro-survival	 pathways,	 including	 drug-induced	
autophagy,	in	Ad∆∆-mediated	drug-sensitisation.	
I	have	demonstrated	that	autophagy	was	activated	in	a	dose-dependent	manner	in	response	
to	 mitoxantrone	 in	 the	 human	 PCa	 cell	 lines	 PC3,	 PC3M	 and	 22Rv1.	 Low	 doses	 of	
mitoxantrone	 (<EC50-values)	 caused	 initiation	 of	 autophagy,	 determined	 as	 increased	
conversion	 of	 LC3I	 to	 LC3II	 and	 increased	 number	 of	 acidic	 vesicles,	 indicating	
autophagosome	 formation.	 At	 higher	 doses	 degradation	 of	 p62	 was	 also	 observed,	
suggesting	autophagosome	 fusion	with	 the	 lysosome.	AdΔΔ	attenuated	 the	drug-induced	
activation	 of	 autophagy	 by	 restoring	 basal	 LC3II/I	 ratios,	 and	 increasing	 apoptosis,	
determined	as	increased	PARP-cleavage	and	mitochondrial	depolarization.	The	autophagy-
inducer	 rapamycin	 prevented	 AdΔΔ-mediated	 sensitization	 in	 PC3	 cells	 increasing	






cellular	 Bcl-2-protein	 has	 important	 roles	 as	 a	mediator	 of	 both	 anti-apoptotic	 and	 anti-
autophagic	functions.	In	cells	transfected	with	siBcl-2	the	LC3II/I	ratios	increased	and	AdΔΔ-
mediated	sensitization	to	mitoxantrone	was	prevented,	indicating	initiation	of	autophagy.	In	





combination	 with	 prostate	 stromal	 cells	 and	 extracellular	matrix	 proteins	 using	 confocal	
microscopy.		














































































































































































































































































Figure	 29.	 22Rv1,	 PC3	 and	 PC3M	 cells	 show	 different	 sensitivity	 to	 adenovirus	 infection	 and	
mitoxantrone	treatment.	 127	
Figure	30.	Representative	dose-response	curves	that	generated	the	data	in	Figure	28.	 128	















Figure	 37.	 Mitoxantrone	 promotes	 autophagy	 initiation	 that	 is	 counteracted	 by	 AdΔΔ	 or	 Ad12S	
adenoviral	mutants	in	PC3	cells.	 141	
























Figure	 51.	 Chloroquine	 further	 promotes	 apoptosis	 in	 22Rv1	 cells	 treated	 with	 the	 combined	
treatment	of	mitoxantrone	and	AdΔΔ.	 168	
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The	 development	 of	 the	 prostate	 gland	 starts	 during	 embryogenesis.	 The	 embryonic	
urogenital	sinus	consists	of	the	urogenital	sinus	mesenchyme	(UGM)	and	the	urogenital	sinus	
epithelium	 (UGE)	 (Cunha,	 Hayward	 et	 al.	 2003).	 Epithelial-mesenchymal	 interactions	 are	
required	for	prostatic	development	and	their	interactions	are	reciprocal	(Cunha,	Ricke	et	al.	
2004).	 The	 development	 of	 the	 human	 prostate	 gland	 starts	 in	 the	 10th	 week	 of	 foetal	
development	 and	 is	 dependent	 on	 androgen	 stimulation	 of	 the	 androgen	 receptor	 (AR)	




During	 the	 postnatal	 period,	 the	 epithelium	 continues	 its	 differentiation	 and	 starts	 the	
synthesis	of	secretory	products	(Timms	2008).	During	puberty,	an	increase	in	testosterone	
levels	promotes	the	growth	of	the	prostate	gland	(Hayward	and	Cunha	2000).	In	the	adult	












surrounded	 by	 the	 stroma,	 which	 is	 composed	 of	 smooth	 muscle	 cells,	 fibroblast,	






androgens	 such	 as	 testosterone	 or	 dihydrotestosterone	 (DHT).	 DHT	 results	 from	 the	
conversion	of	testosterone	by	5α-reductase,	which	is	expressed	in	various	tissues,	including	
the	prostate	(Azzouni,	Godoy	et	al.	2012),	and	has	higher	affinity	for	the	receptor	(Lindzey,	
Kumar	et	 al.	 1994).	Upon	binding,	AR	undergoes	 conformational	 changes	and	dissociates	
from	cytoplasmic	 chaperones	 to	expose	 the	nuclear	 localization	 signal,	which	enables	AR	
translocation	to	the	nucleus.	Nuclear	translocation	is	mediated	by	α-	and	β-importins	and	by	
dynein-mediated	 cytoskeletal	 transport	 (Wagstaff	 and	 Jans	 2009,	 McCrea,	 Sissung	 et	 al.	
2016).	Once	in	the	nucleus,	AR	binds	to	the	DNA	and	recruits	different	cofactors	to	regulate	








Figure	 3.	 Schematic	 representation	 of	 AR	 activation.	 The	 enzyme	 5a-reductase	 mediates	 the	
conversion	of	testosterone	in	DHT.	DHT	binds	to	AR	inducing	a	conformational	change	that	exposes	a	
AR	nuclear	localization	signal.	AR	is	translocated	to	the	nucleus	by	a-	and	b-importins	or	dyneins.	Once	





























rates	 when	 compared	 to	 white	 men	 of	 European	 ancestry	 while	 the	 PCa	 incidence	 and	
mortality	 is	 lower	 in	 the	 Hispanic	 population	 (Merrill	 and	 Sloan	 2012).	 The	 study	 of	 risk	
factors	 for	 PCa	 in	 a	 multi-ethnic	 cohort	 from	 US	 population	 resulted	 in	 no	 association	
between	 lifestyle	 and	 dietary	 habits	with	 the	 increased	 PCa	 incidence	 in	 the	US	 African-
American	population	(Park,	Haiman	et	al.	2015),	suggesting	that	this	increased	PCa	incidence	
might	be	related	to	genetic	factors.	In	Europe,	there	are	also	considerable	differences,	for	









as	 a	 result	 of	 infection	 although	more	 research	 is	 needed	 to	 confirm	 this	 hypothesis	 (De	










Prostatic	 intraepithelial	 neoplasia	 (PIN)	 frequently	 precedes	 PCa.	 PIN	 is	 characterised	 by	
hyperplasia	of	the	luminal	epithelium	and	a	reduction	in	the	number	of	basal	cells,	but	not	
complete	elimination	of	basal	cells,	which	would	 later	occur	 in	PCa.	PIN	might	develop	 in	
high	grade	prostatic	intraepithelial	neoplasia	(HGPIN)	(Shen	and	Abate-Shen	2010).	During	
HGPIN,	 the	 epithelium	 loses	 its	 basal	 cell	 differentiation	 and	 is	 associated	 with	 stromal	
invasion	 (Figure	4)	 (Bonkhoff	2001).	Myc	overexpression,	 and	chromosomal	abnormalities	
































the	 PI3K/Akt/mTOR	 pathway	 promotes	 cell	 proliferation	 and	 inhibits	 apoptosis	 and	 is	
associated	with	prostate	 cancer	progression	 (Powers	and	Marker	2013).	PTEN	expression	
levels	decrease	as	the	disease	progresses.	Loss	of	PTEN,	which	drives	activation	of	PI3K,	has	




















found	 up-regulated	 in	 advanced	 PCa	 (Saramäki,	 Tammela	 et	 al.	 2006)	 and	 it	 has	 been	











AR	 signalling	 suppresses	 proliferation	 in	 the	 normal	 healthy	 prostate	 epithelium.	 During	
development	of	PCa,	AR	 selectively	 suppresses	proliferation	of	basal	 cells	 in	 the	prostate	
epithelium	enhancing	proliferation	of	luminal	cells	and	facilitating	metastasis	of	the	tumour	




















2013).	 Both	 AR-V7	 and	 AR-Vv567es	 have	 been	 associated	 with	 PCa	 progression	 and	 poor	
survival	 (Hörnberg,	 Ylitalo	 et	 al.	 2011).	 Both	 variants	 have	 been	 shown	 to	 either	
homodimerize	 or	 heterodimerize	 with	 each	 other	 or	 with	 ARfl	 (Xu,	 Zhan	 et	 al.	 2015).	
Interestingly,	AR-V7	transcription	is	dependent	on	ARfl	signalling	(Watson,	Chen	et	al.	2010).	
Although	 both	 ARfl	 and	 AR-V7	 target	 genes	 that	 are	 involved	 in	 glycolysis,	 AR-V7	 can	
differently	target	genes	 involved	 in	the	Krebs	cycle.	AR-V7	expression	results	 in	 increased	
citrate	production	and,	consequently	enhances	production	of	amino	acids	(Shafi,	Putluri	et	
























to	be	 related	 to	PCa	 incidence	 in	1991	 (Catalona,	 Smith	et	 al.	 1991)	 and,	 combined	with	
digital	 rectal	 examination,	 was	 proposed	 for	 PCa	 diagnosis.	 However,	 over	 the	 past	 two	
decades,	extensive	PSA	screening	has	resulted	in	a	 large	number	of	unnecessary	biopsies,	









PCa	 intervention	 and	 low-risk	 tumours	 can	 be	monitored	 by	 active	 surveillance.	 (3)	 PSA	
testing	 should	be	part	of	 a	multivariable	approach	 rather	 than	a	 single	examination.	Risk	





Ahlering	 et	 al.	 2014).	 The	 PSA	 screening,	 although	 imperfect,	 is	 an	 important	 tool	 for	
monitoring	the	effect	of	treatment	of	localised	disease	(Pezaro,	Woo	et	al.	2014).	The	World	
Health	 Organization	 (WHO)	 has	 recomended	 a	 PSA	 cut-off	 of	 3	 -	 3.1	 μg/l	 in	 the	 WHO-









Prostate-specific	 antigen	 (PSA),	 prostate	 cancer	 (PCa).	 Adapted	 from	 (Heidenreich,	 Bastian	 et	 al.	
2014).	
Modifications	 of	 the	 current	 PSA-testing	 strategies	 and	 the	 development	 of	 alternative	
diagnosis	methods	are	currently	being	studied.	Spacing	the	interval	between	PSA	tests	from	
1	 year	 to	 2-4	 years	 could	 diminish	 the	 overdiagnosis-associated	 harm	without	 increasing	
prostate	 cancer	mortality	 (Cuzick,	 Thorat	 et	 al.	 2014).	 An	 improved	 test	 is	 the	 so	 called	
“Kallikrein	panel”	which	measures	four	markers	secreted	by	the	prostate	gland	(free	PSA,	
total	 PSA,	 single-chain	 intact	PSA	and	human	kallikrein	2	 (hK2)	 (Rittenhouse,	 Finlay	et	 al.	
1998)).	 Increased	 levels	 of	 these	 markers	 together	 with	 age,	 serve	 as	 parameters	 in	 an	
algorithm	that	calculates	the	probability	of	finding	cancer	in	the	patient	when	performing	a	









anatomy	 and	 determine	 the	 specific	 location	 of	 cancer	 (Salerno,	 Finelli	 et	 al.	 2016).	






second	 most	 common	 patterns	 in	 an	 analysed	 sample.	 This	 system	 was	 modified	 and	
updated	 in	2005	(Epstein,	Allsbrook	et	al.	2005).	With	the	aim	to	continue	 improving	this	




























































T1	 Clinically	 inapparent	 tumour	 neither	
palpable	nor	visible	by	imaging	
There	 is	 no	 pathological	
classification	
T2	 Tumour	confined	within	the	prostate	 Organ	confined	
T3	 Tumour	 extends	 through	 the	 prostate	
capsule	(may	include	seminal	vesicles)	
Extraprostatic	extension	
T4	 Tumour	 is	 fixed	 or	 invades	 adjacent	
structures	other	than	seminal	vesicles	such	







N0	 No	regional	lymph	node	with	metastases		 No	 positive	 regional	 lymph	
nodes	



























Since	 Huggins	 and	 colleagues	 showed	 that	 androgen-ablation	 therapy	 resulted	 in	
improvement	of	the	clinical	condition	of	mCRPC	patients	in	1941	(Huggins	and	Hodges	2002),	
this	 therapy	has	been	commonly	used	with	successful	 results.	 In	1971,	Schally	 found	that	
overexpression	 of	 the	 hypothalamic	 luteinizing	 hormone	 (LH)	 releasing	 hormone	 (LHRH),	





testosterone	production.	Once	 in	the	prostate,	testosterone	 is	converted	 into	DHT	by	5-α	




which	 enables	 intermittent	 use	 (Heidenreich,	 Bastian	 et	 al.	 2014).	 GnRH	 agonists	 act	 by	
binding	to	the	gonadotropin	receptors	in	the	pituitary	gland	and	subsequently	promoting	LH	
release.	Repeated	administration	of	GnRH	agonists	promotes	downregulation	of	GnRH-R	in	





GnRH	 agonists	 had	 higher	 risk	 of	 pulmonary	 embolism	 and	 deep-vein	 thrombosis	
(Heidenreich,	 Bastian	 et	 al.	 2014).	 GnRH	 agonists	 are	 frequently	 combined	 with	 AR	
antagonists,	this	therapeutic	approach	is	termed	combined	androgen	blockage	(CAB)	(Pham,	
Sadowski	et	al.	2015).	Alternatively,	 the	combination	of	GnRH	agonists	with	 radiotherapy	
resulted	 in	higher	10-years	survival	when	compared	to	either	 treatment	alone	 (Widmark,	
Klepp	et	al.	2009,	Bolla,	Van	Tienhoven	et	al.	2010).	Similar	to	radiotherapy,	the	efficiency	of	
the	 chemotherapeutic	 drug	 docetaxel	was	 also	 enhanced	 in	 combination	with	 the	GnRH	
agonist	goserein	(Fizazi,	Faivre	et	al.	2015).		
GnRH	antagonists	directly	inhibit	GnRH	receptors	in	the	pituitary	gland	(Figure	6B).	In	contrast	
with	 GnRH	 agonist,	 GnRH	 antagonists	 do	 not	 result	 in	 an	 initial	 increase	 in	 LH	 and	


















More	 recently,	 a	 new	 generation	 of	 androgen-targeting	 drugs	 has	 emerged.	 In	 2011,	
Abiraterone	 was	 approved	 by	 the	 FDA	 for	 treatment	 of	 mCRPC	 in	 combination	 with	
prednisone	in	patients	that	have	either	been	treated	with	docetaxel	or	have	not	been	treated	
with	 any	 chemotherapy	 (Danila,	 Morris	 et	 al.	 2010,	 Reid,	 Attard	 et	 al.	 2010,	 Wong,	
Ferraldeschi	 et	 al.	 2014).	 Abiraterone	 targets	 the	 microsomal	 enzyme	 CYP17,	 which	 is	
needed	 for	 androgen	 biosynthesis	 (Wong,	 Ferraldeschi	 et	 al.	 2014).	 The	 AR	 antagonist	
enzalutamide	has	recently	been	FDA-approved	for	treatment	of	mCRPC	after	chemotherapy		








Sipuleucel-T	 is	 an	 autologous	 therapeutic	 vaccine,	 which	 is	 directed	 for	 treatment	 of	
asymptomatic	 or	 low-symptomatic	 CRPC	 and	 involves	 three	 different	 concepts.	 (1)	 The	
Granulocyte-Macrophage	 Colony-Stimulating	 Factor	 (GM-CSF)	 that	 promotes	 immune	
activation.	GM-CSF	 functions	as	an	 immune	growth	and	maturation	 factor	 that	promotes	































Docetaxel	 and	cabazitaxel	 are	 currently	 the	 first-line	 chemotherapy	 treatments	 for	CRPC.	
Both	taxanes	act	by	stabilising	microtubules	and	preventing	depolymerisation,	resulting	in	
cell	cycle	arrest	and	apoptosis	(Yue,	Liu	et	al.	2010,	Alberti	2013).	Taxane	treatment	affects	







Marker	 2013).	 The	 semisynthetic	 cabazitaxel	 is	more	potent	 and	 shows	 some	benefits	 in	
patients	 that	 had	 developed	 resistance	 to	 docetaxel	 (Dayyani,	 Gallick	 et	 al.	 2011,	 Carles,	
Castellano	et	al.	2012).	Recently,	docetaxel	has	been	administered	in	combination	with	ADT	




Despite	 great	 efforts	 developing	 new	 chemotherapy	 alternatives,	 there	 is	 no	 curative	
treatment	for	CRPC	after	docetaxel	failure	(Carles,	Castellano	et	al.	2012).	There	is	therefore	
a	great	need	for	novel	therapies.	
Galeterone	 is	 an	 example	 of	 a	 new,	 under	 development,	 therapy	 for	 mCRPC.	 This	
antiandrogen	 has	 a	 triple	 mode	 of	 action:	 CYP17	 inhibition,	 AR	 antagonism	 and	 AR	
degradation	and	 is	 currently	being	 tested	 in	 a	Phase	 III	 clinical	 trial	 against	 enzalutamine	
(Bastos	 and	 Antonarakis	 2016).	 Safety	 and	 efficacy	 (decreased	 PSA	 levels)	 of	 galeterone	
treatment	 was	 demonstrated	 in	 Phase	 I	 and	 II	 trials	 (Bastos	 and	 Antonarakis	 2016,	
Montgomery,	Eisenberger	et	al.	2016).		
A	different	example	is	the	immune	check	point	inhibitor	Ipilimumab	that	has	been	used	in	
clinical	 trials	 for	 various	 solid	 cancers,	 including	 PCa	 (Silvestri,	 Cattarino	 et	 al.	 2016).	
Ipilimumab	 targets	 the	 cytotoxic	 T-lymphocyte-associated	 protein	 4	 (CTLA-4)	 that	 is	




(Treg).	 The	 role	 of	 immune	 check	 points	 is	 to	maintain	 the	 homeostasis	 in	 the	 immune	
system,	which	is	commonly	achieved	by	down-regulation	of	Treg	activation.	Treg-expressed	
immunosuppressive	 cytokines	 can	alter	 the	 immune	system	 in	 cancer	patients	and	check	
points	can	be	used	by	tumours	to	escape	from	the	immune	system	(Silvestri,	Cattarino	et	al.	












characterised	 by	 its	 non-enveloped	 icosahedral	 protein	 capsid	 (Russell	 2000,	 San	Martin	





some	 adenoviral	 serotypes	 can	 bind	 to	 alternative	 cellular	 receptors	 (Bergelson,	
Cunningham	et	al.	1997,	Marttila,	Persson	et	al.	2005)	(Table	5).	For	example,	some	species	
B	adenoviruses	bind	 to	 the	desmoglein-2	 (DSG-2)	 receptor	 (Wang,	Li	et	al.	2011,	Arnberg	
2012),	 which	 is	 part	 of	 the	 cadherin	 family,	 and	many	 species	 C	 adenovirus	 can	 use,	 in	
addition	 to	hCAR,	alternative,	 sometimes	unknown	 receptors,	which	allow	major	 tropism	
(Uchino,	Curiel	et	al.	2014).	




(Russell	 2009).	 Ad2	 and	 Ad5,	 from	 species	 C	 are	 the	 most	 extensively	 studied	 for	
development	of	oncolytic	agents	(Leopold	and	Crystal	2007).			
Table	5.	Classification	of	adenoviruses	
Species	 Serotype/type	 Receptor(s)	 RGD	
motif	
Tropism	

















E	 4	 CAR	 Yes	 Respiratory,	ocular	
F	 40,	41	 CAR	 No	 Enteric	
G	 52	 Not	determined	 Yes	 Enteric	
Arg-Gly-Asp	 (RGD),	 Coxsackie	 and	 adenovirus	 receptor	 (CAR),	 Cluster	 of	 Differentiation	 (CD),	
Desmoglein-2	 (DSG-2),	 heparan	 sulfate	 proteoglycan	 (HSPG),	major	 histocompatibility	 complex-α2	




























al.	 1994,	 Leopold	 and	 Crystal	 2007).	 These	 interactions	 trigger	 downstream	 PI3K/AKT-
mediated	activation	of	Rho	 family	of	GTPases	and	 results	 in	 virus	 internalization	 through	
clathrin-coated	 vesicles	 and	 endocytosis	 (Russell	 2009).	 Alternatively,	 fiber-mediated	
interaction	 with	 the	 cellular	 surface	 has	 been	 reported	 to	 induce	 immune	 inflammatory	
responses	 such	 as	 activation	 of	 extracellular	 signal-regulated	 kinases	 1	 and	 2	 (ERK1/2),	






































Hearing	 2011).	 Protein	 VII-DNA	 interaction	 plays	 a	 protective	 role	 and	 prevents	 the	
activation	of	the	cellular	DNA	damage	response	(Karen	and	Hearing	2011).	Once	the	virion	
has	dissociated	and	reached	the	nuclear	pore	(Figure	8),	 the	protein	VII	–	DNA	complex	 is	
escorted	 though	 the	 nuclear	 pore	 by	 cellular	 histone	 H1	 (H1),	 while	 the	 remaining	
components	 of	 the	 capsid	 stay	 in	 the	 nuclear	 pore	 and	 are	 finally	 degraded	 (Trotman,	
Mosberger	et	al.	2001)	(Giberson,	Davidson	et	al.	2012).	It	has	been	suggested	that	protein	
VII	must	be	partially	remodelled	or	removed	to	allow	DNA	decondensation	and	enable	the	





Adenovirus	 transcription	 can	 be	 temporally	 divided	 in	 two	 separate	 events:	 early	
transcription	takes	place	before	replication	of	viral	DNA	while	late	transcription	occurs	after	
viral	replication	(Figure	9)	(Russell	2000).	The	early	genes	E1A,	E1B,	E3,	and	E4	modulate	the	
cell	cycle	and	the	cellular	DNA	damage	repair	 responses	to	 facilitate	viral	 replication.	The	
early	genes	also	alter	the	cellular	immune	responses	to	prevent	premature	death	of	the	host	


































(CBP)	 CBP/p300,	 once	 recruited	 CBP/p300	 activates	 transcription	 of	 several	 transcription	















regulate	expression	of	 the	pro-apoptotic	PTEN	resulting	 in	 increased	Akt	phosphorylation	















Figure	 11.	 Schematic	 representation	 of	 E1A-mediated	 regulation	 of	 the	 cell	 cycle.	 A.	 The	 E1A	
adenoviral	 protein	 promotes	 S-phase	 induction	 by	 interacting	 with	 pRB	 and	 p300.	 B.	 The	 E1A	






















































IX	 Protein	IX	 • Structural,	minor	capsid	protein.	It	is	located	in	the	outer	
surface	and	plays	a	role	in	the	initiation	of	the	capsid	
assembly	
IVa2	 IVa2	 • Plays	a	role	in	encapsidation	by	interaction	with	52-55K	
and	in	the	activation	of	the	mayor	late	promoter		



































































The	 replication	 of	 the	 adenoviral	 genome	 takes	 place	 once	 the	 E1A	 gene	 products	 have	
induced	optimal	conditions	for	DNA	replication	in	the	host	cells,	such	as	S-phase	induction,	
and	sufficient	E2	gene	products	have	accumulated	(Shenk	2001).	








two	 cellular	 factors	 form	 a	 pre-initiation	 complex.	 DBP,	 NF1	 and	 Oct-1	 promote	 small	
changes	in	the	origin	structure.	In	addition,	the	DBP	also	binds	to	ssDNA	and	protects	it	from	
nuclease	activity	(Kanellopoulos,	van	der	Zandt	et	al.	1995).		











adenoviral	 genome.	B.	 Schematic	 representation	 of	 initiation	 of	 viral	 DNA	 replication.	 TP	 remains	












control	of	 the	MLP,	encoded	by	 the	 late	 transcription	units	 (L1-L5)	and	are	generated	by	
alternative	RNA	splicing	(Table	6,	Figure	9)	(Shenk	2001,	San	Martin	2012).	The	MLP	is	active	










100K	 prevents	 the	 activation	 of	 the	 elF-4F	 cellular	 factor,	 which	 is	 responsible	 of	 the	
translation	of	cellular	mRNA	(Shenk	2001).	
The	 newly	 synthesised	 adenoviral	 proteins	 are	 translocated	 to	 the	 nucleus	 utilising	 the	




on	 the	L4	100K	viral	protein,	which	acts	as	a	scaffold.	Hexon	assembly	 is	 followed	by	 the	
formation	of	trimeric	fiber	structures	and	the	pentameric	penton	bases	(Shenk	2001).		














to	multiple	adenoviral	proteins	 such	as	 IIIa	and	VII,	which	are	processed	by	 the	protease	
(Mangel	 and	 San	 Martín	 2014),	 the	 ATPase	 IVa2	 (Gustin,	 Lutz	 et	 al.	 1996)	 and	 to	 the	
adenoviral	packaging	signal	(Zhang	and	Imperiale	2000),	but	is	not	found	in	the	mature	virion	








mature	 virions	 indicating	 that	 they	 would	 later	 be	 removed	 from	 that	 position	 to	 allow	
maturation	 (Pérez-Berná,	Marabini	 et	 al.	 2009).	 In	 addition,	 polypeptide	VI	was	 found	 to	
interact	 firmly	 with	 hexon	 in	 immature	 virions	 but	 this	 interaction	 was	 weakened	 after	
protease-mediated	VI	 cleavage	 in	 the	mature	virion.	Protein	VI	 cleavage	might	also	allow	
release	of	protein	VI	during	infection	and	internalization.	Finally,	precursor	proteins	pVII	and	







place	 through	 intermediate	 filaments	 (Shenk	 2001).	 Adenovirus-mediated	 cytolysis	 of	











(cGAS)	 (Anghelina,	 Lam	 et	 al.	 2016).	 The	 E1A	 adenoviral	 protein	 inhibits	 IFN-mediated	
response	 by	 preventing	 transcription	 of	 its	 target	 genes,	 possibly	 by	 competition	 for	
p300/CBP	binding		(Leonard	and	Sen	1996,	Look,	Roswit	et	al.	1998).	p300/CBP	can	bind	to	





et	 al.	 1998).	 Ad12	 E1A	 can	 also	 modulate	 the	 immune	 response	 by	 preventing	 NF-κB	
activation.	E1A	was	reported	to	prevent	protein	kinase	A	catalytic	subunit	(PKAc)	–	mediated	
phosphorylation	of	NF-κB	 resulting	 in	decreased	 transcription	 and	activity	 of	MHC	 class	 I	
(Guan,	Jiao	et	al.	2008).	In	addition,	E4	orf3	has	been	proposed	to	inhibit	IFN	response	by	






the	 host	 immune	 response	 by	 hampering	 antigen	 presentation.	 Expression	 of	 E3gp19K	
blocks	 the	 transport	 of	 MHC	 class	 I	 to	 the	 plasma	 membrane	 to	 prevent	 activation	 of	




reported	 to	 reduce	 the	 recognition	 of	 infected	 cells	 by	 natural	 killer	 cells	 (NK).	 E3gp19K	
mediates	the	intracellular	sequestration	of	MHC-I-related	chain	A	and	B	(MICA/B)	molecules	
in	the	ER,	which	are	ligands	for	the	major	NK	receptor	NKG2D	(McSharry,	Burgert	et	al.	2008).	



















in	 the	past	 two	decades.	Ad5	 is	well	 characterised,	can	be	produced	and	purified	 to	high	
titres,	 is	 relatively	 easy	 to	 engineer,	 presents	 natural	 tropism	 for	 epithelial	 cells	 and	









the	body,	 such	as	 the	 respiratory,	ocular	 renal	and	hepatic	 tissues	 (Arnberg	2012).	When	
engineering	oncolytic	adenoviruses,	it	is	necessary	to	ensure	that	the	mutant	is	designed	to	
have	 its	 infection	 or	 replication	 restricted	 to	 cancer	 cells.	 Replication-selective	 oncolytic	
viruses	are	engineered	 so	 that	 they	would	only	 replicate	 in	 target	 cancer	 cells	but	not	 in	
normal	healthy	 cells.	Replication-selective	adenoviruses	 can	be	engineered	 following	 two	
different	approaches	(Bressy	and	Benihoud	2014).		
In	the	first	approach,	replication-selectivity	in	tumour	cells	is	achieved	by	specific	deletions	











respectively.	 However,	 it	 was	 later	 demonstrated	 that	 E1B55K-deleted	 mutants	 could	
replicate	 independently	 of	 the	 p53	 status	 (Goodrum	 and	 Ornelles	 1998).	 In	 addition,	
decreased	replication	was	also	observed	in	tumours	infected	with	E1B55K-deleted	mutants.	
It	was	later	reported	that	E1B55K,	together	with	E4orf6,	was	also	required	for	nuclear	export	
of	 viral	 mRNAs,	 which	 could	 explain	 reduced	 effectiveness	 of	 these	 mutants	 (O'Shea,	
Johnson	et	al.	2004).	The	mutant	dl1520,	also	known	as	Onyx-015,	and	 the	mutant	H101	
(both	E1B55K-	and	E3B-deleted)	are	examples	of	 replication-selective	viruses	carrying	the	
E1B55K-deletion	 (You,	 Yang	 et	 al.	 2000,	 Lu,	 Zheng	 et	 al.	 2004).	 Due	 to	 the	 attenuated	
replication	 observed	 in	 the	 E1B55K-deleted	 mutants,	 a	 second	 generation	 of	 adenoviral	




































trials	 (Table	7	and	Table	8),	 single	agent	treatment	with	oncolytic	adenoviruses	resulted	 in	
















Anti-metabolites	 can	 alter	 nucleotide	 synthesis	 by	 targeting	 different	 key	 enzymes	
implicated	 in	nucleotide	production	 (Bressy	 and	Benihoud	2014).	 5-fluorouracil	 (5-FU),	 in	
















mice	 with	 SKOV3	 xenograft	 tumours	 (Takakura,	 Nakamura	 et	 al.	 2010).	 In	 addition,	 the	
mutant	 SG511,	 an	 oncolytic	 virus	 with	 Ad5/11	 chimeric	 fibre	 and	 E1B55K	 deletion,	 for	













Onyx-015	 was	 combined	 with	 the	 topoisomerase	 II	 inhibitors	 Vp-16	 (etoposide)	 or	
mitoxantrone.	
We	have	previously	demonstrated	that	the	mutant	dl922-947	(E1ACR2-	and	E3B-	deleted),	
synergistically	 enhanced	mitoxantrone-	 and	docetaxel-induced	 cell	 death	 in	 vitro	 (in	PC3,	
DU145	 and	 LNCaP	 PCa	 cells)	 and	 in	 vivo	 in	 PC3	 and	 DU145	 xenografts	 (Radhakrishnan,	
Miranda	et	al.	2010).	The	combination	of	dl922-947	with	mitoxantrone	or	docetaxel	resulted	









So	 far,	 the	 clinical	 use	 of	 replication-selective	 adenoviruses	 in	 combination	 with	
chemotherapies	for	cancer	treatment	has	only	been	approved	in	China	for	the	replication-




of	 H101	 with	 the	 chemotherapeutic	 treatment	 resulted	 in	 a	 response	 rate	 of	 78.8%	 of	
patients,	compared	to	39.6%	for	single	chemotherapeutic	treatment.	
However,	there	are	several	more	recently	developed	replication-selective	adenoviruses	that	
are	 currently	 being	 tested	 in	 clinical	 trials	 for	 treatment	 of	 different	 cancers,	 including	
prostate	cancer,	some	of	them	in	combination	with	chemotherapy	(Table	7).		
The	Ad5/3-Δ24,	which	carries	a	Δ24	deletion	in	the	E1A	region	and	cannot	bind	to	pRB,	has	
been	 tested	 in	 different	 clinical	 trials.	 In	 the	mutant	 Ad5/3-Δ24	 the	 Ad5	 fiber	 has	 been	
modified	with	 the	 addition	 of	 the	 Ad3	 knob	 and	 showed	 enhanced	 selectivity	 to	 DSG-2-
expressing	 ovarian	 cancer	 cells,	 when	 compared	 to	 hCAR-binding	 Ad5	 virus	 (Kanerva,	





































































































































localised	 PCa	 and	 locally	 recurrent	 PCa	 after	 radiotherapy	 or	 CRPC	 (Table	8	 and	 Table	9).	
Adenovirus	was	first	used	in	PCa	clinical	trials	as	replication-defective	vectors	carrying	suicide	
genes.	 These	 trials	 reported	 low	 toxicity	 of	 the	 treatment	 and	 flu-like	 only	 side	 effects,	
reviewed	in	(Schenk,	Essand	et	al.	2010).	The	mutant	Ad5-CD/TKrep	(E1B55K-deleted),	which	
carries	a	fusion	gene	encoding	for	the	cytosine	deaminase	(CD)	and	the	herpes	simplex	virus	









2001,	 2005).	 Freytag	 and	 colleges	 carried	 out	 several	 clinical	 trials	 using	 Ad5-CD/TKrep	
mutants	 with	 reported	 positive	 responses	 and	 safety	 (Table	 8)	 (Freytag,	 Khil	 et	 al.	 2002,	
Freytag,	Stricker	et	al.	2003,	Freytag,	Movsas	et	al.	2007,	Freytag,	Stricker	et	al.	2007).	In	a	





































































































































































































hIL12	 that	 expresses	 TK,	 together	 with	 IL-12	 (Freytag,	 Zhang	 et	 al.	 2015).	 IL-12	 is	 a	












































































efficacy.	 Administration	 of	 oncolytic	 viruses	 can	 be	 performed	 following	 two	 different	
strategies:	intratumoural	administration	or	systemic	vascular	delivery	(de	Vrij,	Willemsen	et	
al.	2010).	The	intratumoral	delivery	is	the	most	commonly	used	administration	method	for	




physical	 barrier	 that	 hampers	 viral	 transduction	 into	 cancer	 cells	 and	 the	 spread	 of	 viral	
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in	 treatment	 efficacy,	when	 compared	 to	 single	 administration	 (Ayala,	 Satoh	 et	 al.	 2006,	
Freytag,	Movsas	et	al.	2007).		
Systemic	 administration	 would	 enable	 virus	 to	 reach	 metastatic	 lesions,	 however	 this	 is	
currently	 less	 feasible	 with	 adenovirus	 based	 mutants.	 In	 addition	 to	 the	 difficulties	 to	
overcome	the	stromal	barrier	 surrounding	 the	blood	vessels,	oncolytic	adenoviral	vectors	
may	 accumulate	 in	 non-target	 tissues	 that	 express	 hCAR	 and	 integrins,	 such	 as	 the	
respiratory,	ocular	renal	and	hepatic	tissues,	and	be	cleared	from	blood	circulation	(Arnberg	
2012).	Ad5	has	high	hepatic	tropism	and	intravascular	injection	is	rapidly	transduced	into	the	
liver	 (Huard,	 Lochmüller	 et	 al.	 1995).	 Adenoviral	 vectors	 are	 rapidly	 sequestered	 and	






has	 been	 shown	 to	 be	 dependent	 of	 the	 viral	 hexon	 binding	 to	 coagulation	 factor	 X	
(Waddington,	McVey	et	al.	2008).	Factor	X	binding	to	Ad5	brings	the	virus	to	heparan	sulfate	





factor	X	and	decreased	 liver	 sequestration	 (Short,	Rivera	et	al.	2010).	 Interestingly,	 it	has	
been	reported	that	factor	X	can	be	used	by	adenovirus	as	a	receptor	to	infect	hCAR-negative	
adrenal	glands	(Tran,	Ouisse	et	al.	2013).	Pre-existing	humoral	immunity	against	adenovirus	
is	 common	 in	 humans.	 Consequently,	 neutralising	 immunoglobulins	 can	 hamper	 the	
systemic	administration	of	viral	vectors	(Abbink,	Lemckert	et	al.	2007,	de	Vrij,	Willemsen	et	





absence	 of	 antibody	 recognition,	 resulting	 in	 activation	 of	 the	 alternative	 complement	
pathway	(Jiang,	Wang	et	al.	2004).	The	adenoviral	fiber	knob	can	bind	to	the	complemement	
component	 C4-binding	 protein	 resulting	 in	 enhanced	 vhepatocyte	 transduction	
(Shayakhmetov,	Gaggar	et	al.	2005).	The	interaction	of	factor	X	with	the	adenoviral	particle	
results	 in	 liver	 sequestration	 and	 increased	 toxicity	 but	 protects	 the	 viral	 particle	 from	
neutralization	 of	 IgM	 antibodies	 or	 recognition	 by	 the	 complement	 system,	 these	
interactions	 should	be	 considered	 in	 the	desing	of	 new	adenoviral	 vectors	 (Lopez-Gordo,	
Denby	et	al.	2014).	Finally,	adenovirus	shows	high	affinity	for	binding	to	human	erythrocytes	
expressing	hCAR	and	complement	receptor	1	(CR-1)	(Carlisle,	Di	et	al.	2009).	Recently,	Rojas	
and	 colleges	 reported	 that	 erythrocyte-binding	 to	 adenovirus	 did	 not	 reduce	 viral	









include	 modification	 of	 the	 fiber-knob	 or	 incorporation	 of	 fiber	 domains	 from	 different	
adenoviral	serotypes	that	do	not	depend	on	hCAR	binding.	As	an	example,	the	hCAR	binding	
sequence	 in	 the	 Ad5	 fiber	 has	 been	 replaced	 with	 the	 CD46	 binding	 sequence	 of	 Ad35	
(Takagi-Kimura,	Yamano	et	al.	2013).	CD46	 is	highly	expressed	 in	mesothelioma	cells	and	




and	Ad5	Ad5.F37	 (fibers	 from	Ad16,	Ad35	and	Ad37,	 respectively),	which	 tarjet	 the	CD46	
receptor,	resulted	in	enhanced	infection	and	increased	IFN-α	expression,	when	compared	to	







expression	 could	 possibly	 result	 in	 off	 target	 infection	 resulting	 in	 decreased	 treatment	















has	been	modified	to	express	the	tumour	necrosis	 factor	 ligand	(TRAIL).	TRAIL	receptor	 is	
highly	 expressed	 in	 cancer	 cells	 and,	 therefore,	 this	 modification	 resulted	 in	 improved	
targeting,	 reduced	 liver	 tropism	and	 increased	apoptosis	 in	mice	models	 (Wang,	Yu	et	al.	
2016).	



















polymer	 poly-[N-(2-hydroxypropyl)methacrylamide]	 (pHPMA)	 could	 avoid	 neutralization	
(Fisher,	 Stallwood	 et	 al.	 2001).	 In	 this	 study,	 pHRMA	 was	 functionalised	 with	 targeting	
molecules	such	as	the	vascular	endothelialgrowth	factor,	which	facilitated	ligand-mediated	
but	hCAR-independent	viral	internalization	into	the	cells.	More	recently,	pHRMA	was	further	




can	be	 found	 in	 the	hexon	protein,	 such	 as	 a	 sequence	of	 16	 consecutives	 glutamic	 acid	
molecules	(Karlin	and	Brendel	1988).	The	coating	of	the	adenovirus	can	also	be	achieved	by	











coating	 adenovirus	with	 2-aminoethanethiol	 to	 amino-(EO)n/(AGE)m-CYS	 (APC),	 a	 cationic	
PEG	derivate,	 protected	 the	 virus	 from	neutralising	 anti-adenovirus	 antibodies	 in	 vitro	 in	























US	 and	 enhance	molecular	 extravasation	 (Sorace,	Warram	 et	 al.	 2012).	MB-packaging	 of	











Different	 studies	 have	 assessed	 the	 toxicity	 and	 biodistribution	 of	 gold	 nanoparticles.	
Toxicity	 of	 gold	 nanoparticles	 of	 13.5nm	 in	 vivo	 was	 assessed	 by	 Zhang	 and	 colleagues	
(Zhang,	Wu	et	al.	2010).	In	this	study,	no	obvious	effect,	demonstrated	by	no	weight	changes,	
could	be	detected	in	mice	after	the	administration	of	low	concentrations	of	nanoparticles.	In	
contrast,	 a	 trend	 towards	higher	 toxicity	was	detected	after	 the	administration	of	higher	
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concentrations	 (550-2200µg/kg),	 determined	 by	 decreased	 body	 weight,	 blood	 cells	 and	
haematocrit.	The	degree	of	 toxicity	was	also	dependent	on	 the	administration	 route.	Tail	
vein	 injection	 resulted	 in	 the	 lowest	 toxicity	 while	 oral	 or	 intraperitoneal	 administration	
resulted	higher	toxicity.	
Distribution	 of	 gold	 nanoparticles	 in	 vivo	 has	 been	 shown	 to	 be	 size-dependent.	 Small	
nanoparticles	 of	 5-15nm	 were	 more	 extensively	 distributed	 than	 larger	 particles	 of	 50-




to	 be	 functionalization-dependent.	 Galactose-containing	 PEG	 conjugation	 enhanced	
accumulation	of	gold	nanoparticles	 in	 liver	hepatocytes	 (Khlebtsov	and	Dykman	2011).	 In	






to	 prolong	 the	 blood	 circulation	 time.	 PEG-modified	 nanoparticles	 prevented	 binding	 to	
other	molecules	by	steric	effects	and	are	stable	in	biological	environments	(Liu,	Shipton	et	
al.	 2007,	 Sanz,	 Conde	 et	 al.	 2012).	 In	 addition,	 thiolated	 PEG-modified	 nanoparticles	
facilitated	further	functionalization	with	dsRNA	and	short	oligonucleotides	(Sanz,	Conde	et	
al.	 2012).	 Functionalization	 of	 the	 gold	 nanoparticles	 with	 c-myc	 targeting	 siRNA	 was	
reported	 to	 efficiently	 knock-down	 c-myc	protein	 in	 vitro	 in	HeLa	 cells	 and	 in	 vivo	 in	 the	
invertebrate	Hydra	and	in	mouse	(Conde,	Ambrosone	et	al.	2012).	c-myc	siRNA	was	added	
to	 nanoparticles	 via	 either	 ionic	 or	 covalent	 interactions.	 In	 the	 ionic	method,	 negatively	
charged	 siRNA	 would	 attach	 to	 quaternary	 ammonium	 groups	 (R4N+)	 that	 had	 been	
previously	bound	to	PEG-COO-	spacers.	In	the	covalent	method,	PEG-coated	nanoparticles	
were	functionalized	with	thiolated	siRNA	via	thiol	bonds.		
Although	 the	 coating	of	 adenoviral	mutants	with	 gold	nanoparticles	has	not	been	widely	
studied,	some	reports	have	been	published.	A	complex	formed	of	an	adenoviral	vector	and	
gold/iron	 magnetic	 nanoparticles	 has	 been	 reported	 to	 easily	 penetrate	 the	 plasma	
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membrane	 in	 the	 presence	 of	 a	 magnetic	 force	 and	 independently	 of	 cellular	 receptors	
(Kamei,	 Mukai	 et	 al.	 2009).	 In	 addition,	 the	 coating	 of	 adenoviral	 vectors	 with	 gold	
nanoparticles	has	been	studied	 for	 their	use	 in	hyperthermic	 tumour	cell	ablation.	 In	 this	
study,	 an	 adenoviral	 vector	 encoding	 for	 luciferase	 under	 control	 of	 CMV	 promoter	





is	 essential	 for	 preserving	 cell	 homeostasis	 and	 preventing	 tumourigenesis,	 as	 apoptosis	
evasion	is	found	in	most	types	of	cancers	(Hanahan	and	Weinberg	2000,	Zielinski,	Eigl	et	al.	





to	 their	 receptors,	 including	 the	 tumour-necrosis-factor-apoptosis-inducing	 ligand	 (TRAIL)	
receptor	 and	 the	 tumour	 necrosis	 factor	 (TNF)	 receptor	 (Ashkenazi	 2008).	 This	 binding	

















1,	 promoting	 the	 formation	 of	 the	 apoptosome	 and	 induction	 of	 caspase	 9	 mediated	
apoptosis	(Favaloro,	Allocati	et	al.	2012).	The	formation	of	the	mitochondrial	pore	can	be	
prevented	 by	 anti-apoptotic	 Bcl-2	 family	 members,	 such	 as	 Bcl-2	 and	 Bcl-xL.	 Bcl-xL	 can	
compete	with	BAK	for	binding	to	the	BH3	domain	of	tBID,	the	resulting	binding	is	stable	and	
therefore	this	 interaction	prevents	BAK	activation.	Bcl-2	or	Bcl-xL	can	also	directly	bind	to	





(Moll	 and	 Petrenko	 2003,	 Kruse	 and	 Gu	 2009).	 p53	 plays	 a	 key	 role	modulating	 the	 cell	
response	to	multiple	types	of	stress	that	can	result	in	cell	cycle	arrest,	apoptosis,	senescence,	
DNA	repair	or	autophagy	(Kruse	and	Gu	2009).	The	p53	protein	is	unstable	with	a	short	half-


















The	 aim	 of	 most	 cancer	 therapies,	 including	 chemotherapy,	 radiation	 or	 hormone	
deprivation,	 is	 to	 eliminate	 cancer	 cells	 that	 typically	 involve	 the	 initiation	 of	 apoptotic	
signalling	in	response	to	cytotoxic	stress	(Lorenzo,	Arnoldussen	et	al.	2007,	Zielinski,	Eigl	et	
al.	 2013).	 This	 strategy	 can	 be	 hampered	 when	 the	 cancer	 presents	 mutations	 in	 the	
apoptotic	pathway	or	over-expression	of	pro-survival	proteins	(Zielinski,	Eigl	et	al.	2013).	The	





that	 increased	Bcl-xL	expression	may	contribute	 to	PCa	progression	 to	metastatic	disease	
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and/or	 CRPC	 (Sun,	 Tang	 et	 al.	 2008).	 Down-regulation	 of	 antiapoptotic	 Bcl-2	 proteins	
resulted	in	renewed	sensitisation	to	docetaxel	treatment	(Zielinski,	Eigl	et	al.	2013).	Survivin	
is	an	anti-apoptotic	protein	that	can	inhibit	apoptosis	by	blocking	the	caspase	cascade,	over-
expression	 of	 survivin	 has	 been	 found	 in	 primary	 prostate	 tumours	 with	 increasing	










The	 adenoviral	 early	 proteins	 can	 play	 different	 roles	 in	 apoptosis	modulation.	 The	 E1A-
encoded	proteins	promote	apoptosis	by	multiple	mechanisms	while	the	E1B-,	E3-	and	E4-
encoded	proteins	prevent	apoptosis	to	enable	the	viral	life	cycle	to	take	place.	




p14,	 which	 subsequently	 blocks	 MDM2-induced	 p53-degradation	 thereby	 promoting	
apoptosis	 (Putzer,	 Stiewe	 et	 al.	 2000).	 In	 addition,	 E1A	 expression	 has	 been	 reported	 to	





E1A	 also	 sensitises	 cells	 to	 TNFα-induction	of	 apoptosis	 by	 promoting	 TNFα	 activation	of	
procaspase	8.	This	sensitisation	was	reported	to	be	dependent	on	E1A-binding	to	both	pRB	





inhibitor	 (Kreuz,	 Siegmund	 et	 al.	 2001).	 E1A	 has	 been	 reported	 to	 down-regulate	 c-FLIP	
expression	 by	 directly	 inhibiting	 its	 transcription	 or	 promoting	 its	 degradation,	 therefore	
sensitising	 cells	 to	 TNF-α-induced	 apoptosis	 (Perez	 and	White	 2003).	 E1A	 has	 also	 been	
reported	 to	 suppress	 miR-520	 expression.	 miR-520	 down-regulation	 enhances	 PP2A/C	
expression,	which	inhibits	NF-ĸB,	finally	resulting	in	reduced	tumour	invasiveness	(Su,	Chen	
et	al.	2010).	In	addition,	E1A	has	been	reported	to	completely	suppress	myeloid	cell	leukemia	
















binds	 to	 p53	 and	 counteracts	 E1A-induced	 p53	 stabilization	 and	 consequently	 apoptosis	
induction	 (Berk	 2005).	 E1B55K-binding	 to	 p53	 also	 induces	 G1/S	 transition	 (Bressy	 and	
Benihoud	2014).	The	E1B19K	protein	blocks	p53-independent	apoptosis	(Berk	2005).	E1B19K	
is	 a	 homolog	 of	 the	 anti-apoptotic	 Bcl-2	 protein;	 following	 tBID	 activation	 of	 the	 pro-
apoptotic	 Bcl-2	 family	 member	 BAX,	 E1B19K	 recognises	 and	 binds	 a	 BH3	 motif	 of	 BAX	
preventing	 the	 formation	 of	 the	 BAX-BAK	 complex	 and	 therefore	 prevents	 the	







internalization	 and	 degradation	 of	 TRAIL	 receptor	 2	 (Benedict,	 Norris	 et	 al.	 2001,	
Lichtenstein,	 Doronin	 et	 al.	 2004).	 In	 addition,	 as	 previously	 described	 on	 section	 1.3.7,	











E4orf3	 attenuates	 p53	 activity	 by	 inhibitory	methylation	 of	 p53-target	 promoters	 (Soria,	
Estermann	 et	 al.	 2010).	 The	 poly(ADP-ribose)	 polymerase-1	 (PARP-1)	 is	 activated	 as	 a	
response	of	DNA	damage.	PARP-1	activation	can	be	followed	by	apoptosis	 inducing	factor	
(AIF)	translocation	to	the	nucleus.	AIF	nuclear	localization	promotes	PARP-1	–mediated	DNA	












Autophagy	 is	 an	 auto-catabolic	 process	 that	 involves	 the	 sequestration	 of	 cytoplasmic	
components	 inside	 a	 double	membrane	 vesicle	 for	 degradation	 to	 provide	 the	 cell	 with	
energy	 and	 new	building	 blocks	 (Chen	 and	 Karantza	 2011,	 Lozy	 and	 Karantza	 2012).	 The	
autophagy	process	can	be	considered	as	a	cell	survival	mechanism	as	it	acts	by	maintaining	
cell	homeostasis	by	degradation	of	misfolded,	or	no	longer	used,	proteins	and	non-functional	
organelles.	 Autophagy	 promotes	 cell	 survival	 under	 stress	 conditions	 such	 as	 hypoxia,	
nutrient	deprivation	or	cytotoxic	stress	(Glick,	Barth	et	al.	2010,	Chen	and	Karantza	2011).	






















process,	 LC3B	 is	 cleaved	 by	 Atg4	 resulting	 in	 LC3BI,	 which	 is	 now	 conjugated	 to	
phosphatidylethanolamide	 (PE)	 generating	 LC3BII	 in	 a	 reaction	 mediated	 by	 Atg7	 (Glick,	
Barth	 et	 al.	 2010,	 Hoare,	 Young	 et	 al.	 2011).	 (4)	 Upon	 LC3BII	 binding,	 the	 developing	
membrane	may	sequester	the	degradation	targets	in	a	selective	or	random	way,	LC3BII	has	
been	 proposed	 to	 play	 a	 role	 in	 this	 selection	 (Glick,	 Barth	 et	 al.	 2010).	 In	 addition,	
p62/SQSMT1	(p62)	is	responsible	for	the	selection	of	ubiquitinilated	protein	aggregates,	also,	
p62	contains	a	domain	 for	binding	to	LC3B	(Lippai	and	Low	2014).	 (5)	Finally,	 the	already	




Multiple	 signalling	 pathways	 can	 contribute	 to	 autophagy	 modulation.	 The	 mechanistic	
target	of	rapamycin	(mTOR)	is	a	serine/threonine	kinase	and	is	considered	a	master	regulator	
of	autophagy	(Yang	and	Klionsky	2010).	In	the	presence	of	nutrients	or	growth	factors,	the	
PI3K/AKT/mTOR	 signalling	 pathway	 remains	 active,	 which	 allows	 promotion	 of	 cell	
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proliferation	 and	 inhibits	 autophagy	 (Chen	 and	Karantza	 2011).	mTOR	 status	 can	 also	 be	
modulated	 by	 AMP-activated	 protein	 kinase	 (AMPK);	 during	 starvation	 or	 hypoxia	




(m)Atg13,	 FIP200	 (focal	 adhesion	 kinase	 (FAK)	 family	 interacting	 protein	 of	 200	 kD)	 and	
Atg101.	 In	 nutrient	 rich	 conditions,	mTOR	 interacts	with	 the	ULK1	 complex	 (ULK1-Atg13-
FIP200-Atg101)	 inhibiting	 its	 activity.	 During	 starvation,	 mTOR	 dissociates	 enabling	 ULK1	
complex	to	recruit	Atg	proteins	and	promote	autophagosome	formation	(Mizushima	2010).	





autophagy	 (Kang,	 Zeh	et	al.	 2011,	Marquez	and	Xu	2012).	 The	activation	of	 the	Beclin	1-








to	 the	autophagosome	membrane	 (Nakatogawa	2013).	Atg7	 is	an	E1	 type	enzyme	and	 is	
required	 for	 both	 the	 activation	 of	 Atg5	 by	 conjugation	 to	 Atg12	 and	 lipidation	 of	 LC3BI	
(Nakatogawa	2013,	Otomo,	Metlagel	et	al.	2013).	Atg16	interacts	with	Atg5	and	recruits	it	to	
the	forming	autophagosome	membrane.	Alternatively,	Atg12	interacts	with	Atg3,	therefore,	
Atg12-Atg5	 conjugation	 recruits	 Atg3	 to	 the	 forming	membrane	 (Otomo,	Metlagel	 et	 al.	
2013).	Both	Atg7	and	Atg3	are	required	for	LC3B	activation	and	lipidation	(Tanida,	Yamasaki	















Autophagy	 plays	 a	 dual	 role	 in	 cancer.	 Under	 stress	 and	 nutrient	 deficiency	 conditions,	










under	 stress	 conditions	 such	 nutrient	 deficiency	 or	 hypoxia,	 autophagy	 can	 act	 as	 a	 cell	
survival	 mechanism	 providing	 cancer	 cells	 with	 new	 energy	 sources	 during	 later	 stages	
(Ziparo,	Petrungaro	et	al.	2013).		
Beclin	1	has	been	considered	a	tumour	suppressor	gene	after	being	found	monoallelicaly	lost	




The	 PI3K/AKT	 signalling	 pathway	 plays	 an	 important	 role	 in	 cell	 proliferation,	 autophagy	
induction	 and	 apoptosis	 inhibition	 (Toker	 and	 Yoeli-Lerner	 2006,	 Yoeli-Lerner	 and	 Toker	
2006,	Chen	and	Karantza	2011).	Activation	of	AKT	by	phosphorylation	requires	its	association	
with	the	plasma	membrane,	once	active,	it	is	released	and	can	act	on	multiple	substrates.	
Active	 AKT	 has	 been	 reported	 to	 speed	 prostate	 tumour	 growth	 and	 promote	 PCa	
progression	(Graff,	Konicek	et	al.	2000).	PTEN	is	the	main	negative	regulator	of	AKT	activation	
(Song,	Salmena	et	al.	2012),	and	loss	of	PTEN	is	a	frequent	event	in	human	PCa	progression	
as	 it	 allows	 AKT	 activation	 (Majumder	 and	 Sellers	 2005).	 PTEN	 expression	 levels	 can	 be	
correlated	to	the	prostate	cancer	stage;	complete	loss	of	PTEN	commonly	takes	place	when	










up-regulated	autophagy	 in	LNCaP	xenografts	by	 inhibiting	 the	key	regulator	mTOR	(Ming,	
Byrne	 et	 al.	 2013,	 Ziparo,	 Petrungaro	 et	 al.	 2013).	 ADT-promoted	 nutrient	 deficiency	






as	 a	 consequence,	 autophagy	 inhibition	 can	 be	 proposed	 as	 a	 therapeutic	 strategy	 for	
insensitive	PCa.	Moreover,	autophagy	upregulation	has	been	correlated	to	poor	response	to	
radiotherapy	 in	 PCa	 patients	 (Koukourakis,	 Kalamida	 et	 al.	 2015).	 Indeed,	 blocking	 of	
autophagy	with	the	pharmacological	inhibitor	chloroquine	resulted	in	increased	apoptosis	in	





However,	 the	 role	 of	 autophagy	 in	 cancer	 progression	 remains	 controversial.	 Autophagy	
upregulation	has	been	observed	in	apoptosis-defective	cell	lines	as	a	result	of	chemotherapy	
treatment	 and	 has	 been	 associated	with	 increased	 cell	 death.	 Autophagy	 induction	with	












with	 oncolytic	 adenoviruses	 containing	 tumour-specific	 promoters	 (hTERT	 promoter)	 to	
facilitate	 viral	 replication	 or	 engineered	 fiber-knobs	 to	 facilitate	 infection	 resulted	 in	
enhancement	of	 autophagic	 cell	 death	 (Tazawa,	Kagawa	et	 al.	 2013).	 These	observations	
suggested	that	enhancement	of	infection	and	replication	drives	the	autophagy	process	from	


















contrast,	 adenovirus	 has	 been	 reported	 to	 mediate	 phosphorylation	 of	 JNK1	 and	 JNK2,	
therefore	 promoting	 Bcl-2	 phosphorylation	 and	 its	 dissociation	 from	 the	 Beclin	 1-Bcl-2	
complex,	resulting	in	autophagy	induction	(Klein,	Piya	et	al.	2015).	 Interestingly,	the	same	
team	recently	reported	that	active	autophagy	is	required	for	MHC	II-mediated	presentation	
of	 adenoviral	 antigens	 in	 infected	 cells.	 Consequently,	 autophagy	 inhibition	 prevented	
detection	of	viral-encoded	antigens	in	MEF	and	A549	cells	(Figure	16)	(Klein,	Jiang	et	al.	2016).	
Interestingly,	 E1A-mediated	 activation	 of	 E2F1	 through	 pRB-binding	 can	 also	 modulate	





miR-106,	which	 causes	 down-regulation	 of	 p21	 promoting	 autophagic	 and	 apoptotic	 cell	
death	in	H358	and	H460	cell	lines	(Yamasaki,	Tazawa	et	al.	2012,	Tazawa,	Kagawa	et	al.	2013).	
Adenovirus	 infection	 also	 up-regulates	 expression	 of	 miR-15	 and	 miR-16	 which	 down-

























The	 interaction	 of	 Beclin	 1	 with	 the	 antiapoptotic	 Bcl-2	 or	 Bcl-xL	 proteins	 is	 one	 of	 the	
potential	points	for	crosstalk	between	the	apoptotic	and	autophagic	pathways	(Marquez	and	
Xu	2012).	The	formation	of	the	Beclin	1-Bcl-2	complex	prevents	the	formation	of	the	Beclin	
1-Vps34-Vps35	 complex	 and	 impedes	 autophagy	 initiation	 (Gordy	 and	 He	 2012).	 During	
nutrient	deficiency	conditions,	c-Jun	N-terminal	kinase	(JNK)	phosphorylates	Bcl-2	disrupting	
its	interaction	with	Beclin	1	and	allowing	autophagy	induction	(Wei,	Pattingre	et	al.	2008).	
Cellular	 localization	 determines	 the	 outcome	 of	 this	 process	 as	 Bcl-2	 can	 only	 be	
phosphorylated	by	JNK	when	located	close	to	the	endoplasmic	reticulum	(Marquez	and	Xu	





















prevent	 the	 antiapoptotic	 Bcl-xL	 binding	 to	 BAX,	 and	 therefore	 promote	 BAX-induced	
mitochondrial	depolarisation	and	apoptosis.	Similar	 to	 this	mechanism,	Beclin	1	has	been	
shown	to	undergo	caspase	cleavage	during	apoptosis,	cleaved	Beclin	1	is	no	longer	able	to	
initiate	 autophagy,	 so	 this	 cleavage	 results	 in	 autophagy	 inhibition	 (Gordy	 and	He	2012).	
Cleaved	Beclin	1	C-terminus	can	translocate	to	the	mitochondria	membrane	and	promote	
cytochrome-c	release	(Figure	18)		(Wirawan,	Vande	Walle	et	al.	2010).	

















increased	 cell	 volumen,	 disruption	 of	 the	 plasma	membrane,	 and	 swelling	 of	 organelles,	
particularly	 of	 mitocondria	 (Golstein	 and	 Kroemer	 2007,	 Kroemer,	 Galluzzi	 et	 al.	 2009).	
Unlike	apoptosis,	necrotic	 cell	death	 is	associated	with	 local	 inflamation	and	 induction	of	
innate	 immune	 response	 (Festjens,	 Vanden	 Berghe	 et	 al.	 2006).	 Although	 in	 some	 cases	
necrosis	 can	 occur	 in	 an	 accidental	 unprogramed	 way,	 it	 can	 also	 be	 the	 result	 of	 a	
















for	 the	 study	 and	 development	 of	 new	drug	 treatments	 for	 cancer	 therapeutics	 and	 has	
produced	valuable	data	 in	 cancer	biology	 (Sharma,	Haber	et	 al.	 2010).	However,	 findings	
from	2-dimensional	cultures	are	often	different	from	similar	studies	in	vivo	and	in	the	clinic.	
Some	reasons	for	these	differences	are,	for	example,	changes	in	interactions	between	cells,	








used.	 Spheroids	 form	 cellular	 aggregates	 when	 single	 cells	 are	 cultured	 in	 non-adherent	
conditions.	This	classical	technique,	developed	in	the	early	70s	(Sutherland,	McCredie	et	al.	
1971),	 better	 replicates	 solid	 tumours	 in	 many	 aspects,	 including	 cell	 morphology,	 gene	
















addition	 to	 cell-cell	 attachment,	 cells	 grown	 in	 these	 structures	 form	 cell-matrix	
attachments,	better	mimicking	 tissues	 in	 situ	 (Bates,	Edwards	et	al.	2000).	Cells	grown	 in	
collagen	resulted	in	increased	resistance	to	chemotherapy	when	compared	to	the	same	cell	









































myofibroblasts,	 endothelial	 and	 inflammatory	 cells.	 The	 interaction	 between	 all	 these	
components	 can	 determine	 prostate	 cancer	 initiation,	 progression,	 invasion	 and	 also	 the	
response	to	treatment	(Ellem,	De-Juan-Pardo	et	al.	2014).	In	fact,	prostate	cancer	associated	
fibroblast	(CAF)	have	been	shown	to	promote	tumorigenesis	of	benign	epithelia	(Ao,	Franco	
et	 al.	 2007).	 The	 co-culture	 of	 stromal	 and	 epithelial	 PCa	 can	 provide	 significant	 new	
information	about	the	role	of	stroma	in	PCa	progression	and	development	(Ellem,	De-Juan-
Pardo	 et	 al.	 2014).	 In	 addition,	 the	 study	 of	 epithelial	 –	 stroma	 interaction	may	 help	 to	
advance	the	understanding	of	development	of	drug	resistance.		
Fang	et	at	 (Fang,	Sittadjody	et	al.	2013)	developed	a	3-dimensional	model	where	the	PCa	












The	use	of	3-dimensional	co-cultures	 for	 the	pre-clinical	 testing	of	oncolytic	adenoviruses	
has	not	been	widely	studied.	3-dimensional	monocultures	such	as	spheroids	has	been	used	
as	models	for	testing	the	efficacy	of	oncolytic	adenoviruses	and	to	better	study	viral	infection	
and	replication	 in	a	platform	that	would	 resemble	 in	vivo	 tumours	 (Lam,	Hemminki	et	al.	
2007).	The	authors	found	that	viral	infection	and	replication	was	4-fold	greater	in	monolayers	
than	 in	 3-dimensional	 ovarian	 primary	 cancer	 cells	 spheroids	 one	 week	 after	 infection.	
However,	 replication	 levels	were	equal	2	weeks	after	 infection,	 suggesting	 that,	although	
encountering	 initial	 resistance	 due	 to	 the	 decreased	 surface/volume	 ratio,	 the	 virus	 had	
successfully	 replicated	 and	 penetrated	 several	 cell	 layers	 in	 the	 3-dimensional	 spheroid	
culture.	Virus	propagation	was	indirectly	detected	by	expression	of	viral-encoded	luciferase.	
Adenovirus	 has	 also	 been	 shown	 to	 effectively	 deliver	 transgenes	 into	 3-dimensional	
organoids	 (Wang,	 Zhang	 et	 al.	 2014).	 In	 this	 study,	 organoids	 were	 derived	 from	 mice	
intestinal	crypts	and	grown	in	a	matrigel	matrix.	The	addition	of	a	GFP-expressing	adenovirus	





Prof.	 Hemant	 Kocher	 and	 Prof.	 John	 Marshall	 at	 our	 Institute,	 have	 established	 a	 3-
dimensional	model	 for	pancreatic	ductal	adenocarcinoma	(PDAC)	that	allows	the	study	of	
the	 interactions	 between	 cancer	 and	 stromal	 cells.	 The	 pancreatic	 stromal	 cells	 are	







cultures	 were	 later	 generated	 by	 polymerising	 the	 collagen/matrigel	 matrix	 inside	 a	
transwell®	 insert.	 Cancer	 and	 stromal	 cells	were	 seeded	 on	 top	 of	 the	 gel	 and	 fed	 from	
underneath	to	promote	invasion	into	the	gel	(Coleman,	Watt	et	al.	2014).	

































or	 combined	with	 radiotherapy,	 have	 confirmed	 the	 safety	 of	 the	mutants.	 Efficacy	was	















phase	 is	 not	 induced	by	 the	mutant,	which	 prevents	 viral	 replication	 in	 normal	 cells	 and	
consequently,	only	cancer	cells	with	deregulated	cell	cycle	support	AdΔΔ	replication	(Oberg,	
Yanover	 et	 al.	 2010,	 Cherubini,	 Kallin	 et	 al.	 2011).	 The	 absence	 of	 the	 E1B19K	 protein	
prevents	 binding	 to	 the	 proapoptotic	 Bcl-2	 family	members	 BAK	 and	 BAX	 and	 therefore	
promotes	apoptosis,	which	 is	 induced	by	E1A	expression	and	or	cytotoxic	agents	 (Putzer,	




and	promoted	 tumour	 regression	 in	murine	 xenograft	models	of	prostate	 cancer	 (Oberg,	
Yanover	et	al.	2010).	Further	work	showed	that	the	sole	expression	of	the	E1A12S	protein	in	
the	 absence	 of	 viral	 replication	 was	 sufficient	 to	 enhance	mitoxantrone-	 and	 docetaxel-
induced	cell	death	in	prostate	cancer	cell	lines	(Miranda,	Maya	Pineda	et	al.	2012).	Additional	
findings	in	our	team	demonstrated	that	deletion	of	the	E1B19K	protein	only,	generating	the	
replicating	 AdΔE1B19K	 mutant,	 enhanced	 gemcitabine-induced	 apoptotic	 cell	 death	 in	
models	of	pancreatic	cancer	(Leitner,	Sweeney	et	al.	2009,	Pantelidou,	Cherubini	et	al.	2016).	
Furthermore,	our	team	found	that	in	combination	with	gemcitabine,	only	mutants	with	the	
E1B19K	 gene	 deleted	 caused	 enhanced	 apoptotic	 cell	 killing	 (Pantelidou,	 Cherubini	 et	 al.	
2016).	 The	 increased	 apoptosis	 was	 the	 result	 of	 increased	 E1A	 expression	 in	 E1B19K	
mutants	(Ad∆∆	and	Ad∆19K).		Additional,	but	yet	unpublished	work,	demonstrated	that	the	
expression	profiles	of	miRNAs	were	different	in	PC3	prostate	cancer	cells	infected	with	a	non-
replicating	E1A12S-expressing	mutant,	mitoxantrone-treated	and	 in	cells	 treated	with	 the	
combination	 under	 synergistic	 conditions.	 For	 example,	miRNAs	 that	 are	 typically	 down-
regulated	 in	 human	 prostate	 cancer	 had	 increased	 expression	 in	 response	 to	 virus	 and	
mitoxantrone	 including	 members	 of	 the	 miR-15/16	 family	 (Maya	 Pineda	 2013,	 Tazawa,	
Kagawa	 et	 al.	 2013).	 The	 miR-15/16	 family	 regulates	 cell	 cycle,	 apoptosis	 and	 survival	
pathways.	Other	 identified	miRNAs	were	down-regulated	 in	 response	 to	 the	combination	
treatment	e.g.	miR-99	 that	 targets	mTOR	and	consequently	would	promote	autophagy	 in	
prostate	cancer.		Taken	together,	these	findings	led	us	to	investigate	the	role	of	apoptosis	




















A	 major	 objective	 was	 to	 elucidate	 the	 cellular	 mechanism	 by	 which	 Ad∆∆	 modulates	
apoptosis	 and	 autophagy	 in	 mitoxantrone-treated	 PCa	 cells.	 Another	 objective	 was	 to	
explore	whether	autophagy-inhibition	in	Ad∆∆-infected	cells	could	reverse	chemotherapy-
resistance	 and	 enhance	 drug-induced	 cell	 killing	 in	 PCa	 as	 previously	 proposed	 using	




• To	 determine	whether	 Ad∆∆	 attenuates	mitoxantrone-induced	 autophagy	 in	 PCa	
cells	
• To	investigate	whether	Ad∆∆-mediated	autophagy-inhibition	increases	sensitivity	to	


















perchlorate	 (TMRE),	 purchased	 from	 Invitrogen	 (Paisley,	 UK),	 was	 dissolved	 in	 DMSO	 to	
1mg/ml	 and	 kept	 at	 -20°C.	 The	 CellTiter	 96®	 AQeous	 Non-Radioactive	 Cell	 Proliferation	
Assay,	composed	of	MTS	reagent	(3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-
2-(4-sulphophenyl)-2H-tetrazolium)	 (CellTiter	 96®	 AQueous	 MTS	 Reagent	 Powder)	 and	
phenazine	methosulphate	(PMS),	was	purchased	from	Promega	(Southampton,	UK).	1g	of	
MTS	was	dissolved	in	500ml	of	DPBS,	MTS	and	PMS	were	both	stored	at	-20°C.	Penicillin	and	
streptomycin	 (Penicillin	 10000	 units/ml,	 Streptomycin	 10mg/ml),	 and	 Trypsin-EDTA	
solutions	were	purchased	from	Sigma-Aldrich	and	stored	at	4°C.	Bovine	serum	albumin	(BSA)	
was	 purchased	 from	 Sigma-Aldrich	 and	 used	 for	 the	 preparation	 of	 different	 buffers,	 or	
purchased	from	New	England	Biolab	and	used	for	the	preparation	of	a	standard	curve	for	






















foetal	 bovine	 serum	 (FBS;	 Gibco,	 Life	 technologies,	 CA,	 USA)	 and	 1%	 penicillin	 and	
streptomycin	 (Penicillin	 10000	 units/ml,	 Streptomycin	 10mg/ml)	 at	 37°C	 and	 5%	 CO2.	
Infections	with	different	viruses	were	performed	 in	1ml	0%	FBS-DMEM	for	2-3h	 in	6-well	
plates	or	in	100µl	2%	FBS-DMEM	when	cultured	in	96-well	plates.	All	cell	lines	were	obtained	






















































Bcl-2	 +	 +	 Over	expressed	in	PCa	à	
Inhibition	apoptosis		







Integrin	ανβ3	 Low	 Low	 ανβ3	facilitates	Ad	infection	
(internalization	receptor)	



























Virus	 Batch	 vp/ml	 pfu/ml	 vp/pfu	
ratios	
Ad5wt	 270314	 4.12xE10	 4xE10	 1.0	
Ad∆∆	 260109	 2.4xE11	 1.56xE10	 15.4	
Ad∆∆	 050314	 2.82xE11	 1.22xE11	 2.3	
Ad12S	 160912	 2.91xE11	 4.91E+08	 592.7	







h	post-infection,	and	stored	at	 -80°C.	HEK293	were	seeded	 in	16	T175	 flasks	 in	10%	FBS-
DMEM	and	grown	to	80%	confluency.	The	medium	was	then	replaced	with	2%	FBS-DMEM	
and	 flasks	were	 infected	with	250µl/flask	 from	 the	primary	expansion.	Cells	 and	medium	
were	collected	upon	appearance	of	CPE	and	when	cell	detachment	was	observed	(usually	
72h	post-infection).		
Collected	 cells	 and	medium	were	 centrifuged	at	2000rpm	 for	10min	at	4°C,	 the	 resulting	

































(1/5	dilutions)	 in	 TE	buffer	 and	used	 to	 generate	 a	 standard	 curve,	 starting	 at	 500ng/ml.	
100µl	 of	 Pico	 Green	 reagent	 (1/200	 diluted)	 was	 added	 to	 each	 well.	 Absorbance	 was	






































12	 and	 Table	 13).	 Viral	 DNA	 was	 extracted	 using	 a	 QIAmp	 DNA	 Blood	 Mini	 Kit	 (Qiagen,	
Manchester,	 UK)	 according	 to	 the	manufacturer’s	 instructions.	 DNA	was	 eluted	 in	 200μl	
Buffer	AE	(suplied	in	the	kit).	20µl	of	proteinase	K	(Qiagen)	were	added	to	the	purified	DNA	




























































1	 476	 853	 E1A	start	 377	
2	 767	 1029	 E1A-CR2	 262	
3	 1069	 1453	 E1A	end	 384	
4	 1554	 2086	 E1B-19K	 532	
5	 2073	 2440	 E1B-55K	 367	
6	 2383	 3434	 E1B-55K	 1051	
7	 29915	 31038	 E3B	 1123	
8	 28715	 29135	 E3-gp19K	 420	











Assay	 (MTS;	 Promega)	 according	 to	 the	 manufacturer's	 instructions	 3	 to	 5	 days	 after	
treatment	(as	indicated)	using	untreated	cells	(fixed	doses)	and/or	cells	treated	with	viruses	
alone	or	with	the	combination	of	viruses	and	rapamycin	or	chloroquine	(sensitisation	assay)	











Cells	 were	 seeded	 as	 described	 in	 section	 2.4.1.	 On	 the	 day	 of	 treatment,	 medium	was	
decanted	and	replaced	with	90	µl	of	2%	FBS-DMEM.	To	determine	the	effective	dose	that	
killed	 50%	 of	 cells	 (EC50-value),	 dose-response	 curves	 for	 Ad5wt,	 AdΔΔ	 and	 Ad12S	 and	
mitoxantrone	were	generated	treating	the	cells	with	10	µl	of	serial	dilutions	of	viruses	and	
mitoxantrone.	Serial	dilutions	of	virus	were	performed	in	0%	FBS-DMEM	starting	at	100,000	




Cells	 were	 seeded	 as	 described	 in	 section	 2.4.1.	 On	 the	 day	 of	 treatment,	 medium	was	




















µl.	 Dilutions	 of	 the	 treatments	 were	 prepared	 in	 0%	 FBS-DMEM	 and	 10-fold	 more	




























supplemented	 with	 PhosphoSTOP	 phosphatase	 inhibitor	 and	 protease	 inhibitor	 cocktail	
(Roche	 Diagnostics,	 Switzerland).	 Lysis	 was	 allowed	 at	 4°C	 for	 30min	 and	 samples	 were	
stored	at	-80°C.	Before	use,	the	protein	extracts	were	centrifuged	at	10,000rpm	for	15min	at	
4°C,	and	the	cell	pellets	were	discarded.		
Protein	 extracts	 were	 quantified	 using	 the	 Bradford	 assay	 (Bio-Rad).	 5µl	 of	 1/5	 diluted	
protein	 extracts	 were	 added	 to	 195	 µl	 of	 1x	 Bradford	 dye	 reagent	 in	 duplicates.	 Serial	
dilutions	of	BSA	(starting	concentration	1mg/ml)	were	used	to	construct	a	standard	curve.	

















a	 Bio-Rad	 system	 (Bio-Rad)	 in	 the	 presence	 of	 running	 buffer	 containing	 25mM	 Tris-HCl	
pH7.4,	 250mM	 glycine	 and	 0.1%	 SDS.	 After	 separation,	 proteins	 were	 transferred	 to	
polyvinylidene	 fluoride	membranes	 (PVDF;	 Immobilon,	Millipore)	 by	wet	 protein	 transfer	







conjugated	 (HRP)	 secondary	 (Dako)	 antibodies	 and	 chemiluminiscence	 reagent	 (Western	
Lightning	Plus-ECL,	PerkinElmer	Inc.)	followed	by	autoradiography	(Fuji	Medical	X-Ray	film,	








Antibody	 Species	 Dilution	 Type	 Supplier	 Catalogue	
number	
15	–	18		 LC3B	 Rabbit	 1/3000	 Primary	 Abcam	 Ab51520	















35	–	45	 Ad	E1A	 Mouse	 1/2000	 Primary	 Gene	Tex	 GTX23165	
52	 Beclin	1	 Rabbit	 1/1000	 Primary	 Abcam	 ab62557	
55	 Atg5		
(Atg5-Atg12)	




62	 p62	 Mouse	 /	
Rabbit	















Goat	 1/1000	 Primary	 Abcam	 ab36851	





130	 Vinculin	 Mouse	 1/5000	 Primary	 Abcam	 ab18058	
---	 Anti-rabbit-
HRP	
Goat	 1/2000	 Secondary	 Dako	 P0448	
---	 Anti-goat-
HRP	
Rabbit	 1/2000	 Secondary	 Dako	 P0449	
---	 Anti-mouse-
HRP	















Aldrich).	 Cells	 were	 stained	 for	 30	min	 at	 37°C	 in	 the	 dark.	 After	 incubation,	 cells	 were	
washed	 in	PBS	and	resuspended	 in	500µl	of	4’,6-diamidino-2-phenylindole	 (DAPI;	 	Sigma-
Aldrich)	and	diluted	in	PBS	to	the	final	concentration	of	1µg/ml.	
Cells	were	detected	in	a	BD	LSRFortessa™	(Becton	Dickinson,	Oxford,	UK)	gated	with	lasers	

















AdGFP	at	10-1000ppc	 in	0%	FBS-DMEM.	2-3h	after	 treatment,	 the	medium	was	 replaced	
with	10%	FBS-DMEM	with	or	without	drugs.	PrSC	cells	were	 infected	with	AdGFP	at	100-
1000ppc	in	0%	FBS-DMEM.	2-3h	after	treatment,	the	medium	was	replaced	with	10%	FBS-
DMEM.	Cells	were	 collected	48h	after	 treatment	by	 trypsinization,	washed	with	PBS	 and	
detected	on	a	FACS	Calibur	cytometer	(Becton	Dickinson	Immunocytometry	Systems)	and/or	












Cells	 were	 infected	 with	 Ad∆∆	 at	 500ppc	 in	 0%	 FBS-DMEM,	 and/or	 treated	 with	
mitoxantrone	at	450	and	900nM,	in	10%	FBS-DMEM	2-3h	after	infection.	Cells	were	collected	










Figure	23.	Example	of	 assessment	of	 apoptosis	by	Annexin	V	 staining.	 In	 this	 example,	 PC3	 cells	








The	 PrSC	 (200,000	 cells/well)	 cells	 were	 seeded	 24h	 prior	 to	 collection.	 22Rv1	 (400,000	
cells/well)	cells	were	seeded	24h	before	treatment.	All	cell	 lines	were	seeded	 in	2ml	10%	
FBS-DMEM	 in	 6	 well	 plates.	 22Rv1	 cells	 were	 treated	 with	mitoxantrone	 (25nM)	 or	 left	
untreated	as	a	control,	and	collected	48h	after	treatment	by	trypsinisation.	Once	collected,	
all	cell	lines	were	washed	twice	in	2ml	0.1%	BSA	in	DMEM	and	incubated	with	100µl	of	the	




BSA	 in	 DMEM	 and	 detected	 on	 a	 FACS	 Calibur	 cytometer	 (Becton	 Dickinson	
Immunocytometry	Systems,	UK)	and/or	a	BD	LSRFortessa™	cytometer	(Becton	Dickinson,	
Oxford,	UK)	and	analysed	by	the	BD	FACSDiva™	software	(Becton	Dickinson).	10,000	cells	
were	analysed	per	 sample.	Cells	were	gated	 to	exclude	 the	debris	and	analysed	as	 in	
Figure	24.	
	
Figure	 24.	 Example	 of	 assessment	 of	 expression	 of	 surface	 receptors	 by	 antibody	 staining	 and	
detection	by	flow	cytometry.	In	this	example,	PC3M	cells	were	assessed	for	expression	of	CAR	(right)	
using	the	corresponding	antibody.	The	shift	of	the	peak	signal	was	detected	as	positive	for	expression	




Antibody	 Species	 Dilution	 Type	 Supplier	 Catalogue	number	
Anti-Integrin	αVβ3	 Mouse	 1/100	 Primary	 Merk	Millipore	 MAB1976Z	
112	
	
Anti-Integrin	αVβ5	 Mouse	 1/100	 Primary	 Merk	Millipore	 MAB1961Z	
















Figure	 25.	 Example	 of	 autophagy	 assessment	 by	 Lysotracker®.	 In	 this	 example,	 22Rv1	 cells	were	













10μM	 chloroquine	 and/or	 mitoxantrone	 at	 900nM	 and	 25nM	 for	 PC3	 and	 22Rv1,	
respectively;	or	10%	FBS-DMEM	(PrSC	cells).	Medium	and	cells	were	collected	after	24,	48	









DMEM	 in	 6-well	 plates	 24h	 before	 treatment	 and/or	 infection.	 Cells	 were	 infected	 with	
Ad5wt	and	Ad∆∆	at	3000ppc	for	PC3	and	25ppc	for	22Rv1	in	0%	FBS-DMEM	for	2-3h	when	
medium	 was	 replaced	 by	 10%	 FBS-DMEM	 with	 or	 without	 50nM	 rapamycin,	 10μM	
chloroquine	 and/or	 mitoxantrone	 at	 900nM	 for	 PC3	 and	 25nM	 for	 22Rv1.	 Cells	 were	
collected	at	2,	48	and	72h	after	 treatment	by	trypsinisation,	pelleted	and	stored	at	 -80°C	
until	all	time	points	were	collected.	Total	DNA,	including	viral	DNA,	was	purified	using	the	
QIAamp	 DNA	 Blood	 Mini	 Kit	 (QIAGEN,	 Netherlands)	 according	 to	 the	 manufacturer’s	
instructions	(described	on	section	2.3.2.3).	DNA	was	eluted	in	200μl	Buffer	AE.	Purity	and	
concentration	 of	 DNA	 samples	 were	 assessed	 using	 the	 NanoDropTM1000	
Spectrophotometer	(Thermo	Fisher	Scientific)	as	described	above	(section	2.3.2.3).	
Purity	of	 the	 sample	was	determined	 calculating	A260/A280	and	A260/A230	 ratios	 (ratio	

















































































the	 corresponding	 siRNA	 pool	 (Table	 18)	 following	 the	 manufacturers’	 instructions	
(Dharmacon).	
Tube	A	and	B	 (Table	19)	were	 incubated	at	 room	temperature	 for	5	min,	and	 then	mixed	























mitoxantrone	 starting	 at	 40µM,	 and/or	 a	 fixed	 dose	 of	 500ppc	 AdDD.	 Cell	 viability	 was	




When	 checking	 the	 knock-down	efficiency	 in	 cells	 analysed	by	 the	MTS	 assay,	 cells	were	







































medium	 covering	 the	 cells	 was	 replaced	 with	 200	 µl	 of	 0%	 FBS-DMEM	 while	 medium	
underneath	the	transwell	was	replaced	with	350	µl	of	fresh	10%	FBS-DMEM	to	create	an	FBS	














(0%	 FBS-DMEM	 on	 top	 of	 the	 cells,	 10%	 FBS-DMEM	 underneath	 the	 transwells)	 or	 the	























































Antibody	 Species	 Dilution	 Type	 Supplier	 Catalogue	number	
Ad	E1A	 Mouse	 1/500	 Primary	 Gene	Tex	 GTX23165	
LC3B	 Rabbit	 1/500	 Primary	 Abcam	 Ab51520	
α-SMA		
(smooth	muscle	actin)	
Mouse	 1/300	 Primary	 Dako	 M085	
Alexa	Fluor	M488	 Goat	 1/500	 Secondary	 Life	technologies	 A11001	
Alexa	Fluor	M568	 Goat	 1/500	 Secondary	 Life	technologies	 A11004	









Hematoxylin	 and	 Eosin	 stained	 slides	 were	 imaged	 with	 an	 AxioCam	 HRc	 camera	














positive	 for	 the	 indicated	 staining	were	quantified.	 The	 same	magnification	was	used	 for	
















The	 PC3	 (10,000	 cells/well)	 and	 22Rv1	 (20,000	 cells/well)	 cells	 were	 seeded	 24h	 before	
infection	in	100	µl	10%	FBS-DMEM	in	96-well	plates.	
For	the	sensitization	assays,	to	determine	EC50-values,	dose-response	curves	to	AdΔΔ	were	







For	 the	 fixed	dose	 assays,	 PC3	 cells	were	 treated	with	AdΔΔ	 at	 500ppc,	mitoxantrone	 at	
450nM	or	the	combination	of	virus	and	drug,	alone	or	in	the	presence	of	a	fixed	dose	or	NPs	






















































cells	 (p53+,	 AR+	 and	 PTEN+)	 are	 more	 sensitive	 to	 both	 chemotherapy	 treatment	 and	



















were	used	 in	 the	cell	killing	studies	 for	PC3	cells.	AdΔΔ	had	significantly	higher	cell	killing	
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potent	 than	Ad5wt	 in	 certain	 cell	 types,	 including	PC3	 cells	 (Oberg,	 Yanover	et	 al.	 2010).	
Surprisingly,	 the	 PC3M	 cells	 were	 more	 sensitive	 to	 AdΔΔ-induced	 cell	 killing	 than	 the	
parental	PC3	cells	 resulting	 in	the	 lowest	EC50-value	(44.8	±	6.6ppc)	of	all	 tested	cell	 lines	







observed	differences	 in	 viral	 cell	 killing	efficacy	between	 cell	 lines	might	be	explained	by	
differences	 in	 the	expression	 levels	of	hCAR	 in	each	cell	 lines.	Differences	will	be	 studied	
bellow	(section	3.2.4).	
The	cell	killing-efficacy	of	 the	cytotoxic	drug	mitoxantrone	was	also	assessed	 in	 the	three	
prostate	cancer	cell	lines	22Rv1,	PC3	and	PC3M.	22Rv1	cells	were	the	most	sensitive	to	the	







	 22Rv1		 PC3	 PC3M	
Ad5wt	(ppc)	 221.4	±	77.7	 4596	±	630	 Not	generated	
AdΔΔ	(ppc)*	 155.7	±	10.6	 1049	±	91	 44.8	±	6.6	
Ad12S	(ppc)	 846.0	±	104.5	 ˃	30000	 Not	generated	












were	 treated	with	 increasing	 doses	 of	 virus	 (starting	 concentration	 100,000	ppc)	 or	mitoxantrone	
(starting	 concentration	 40µM,	 200µM	 for	 PC3	 cells)	 to	 generate	 dose-response	 curves	 and	 EC50-
values.	Cell	viability	was	measured	3	days	after	treatment	(5	days	for	PC3	cells)	by	MTS	assay,	averages	



















cell	 lines	 (Oberg,	 Yanover	 et	 al.	 2010,	 Miranda,	 Maya	 Pineda	 et	 al.	 2012).	 To	 establish	
129	
	
conditions	 for	enhanced	 cell	 killing	 in	 this	 study,	 sub-optimal	doses	of	Ad5wt,	AdΔΔ,	and	
Ad12S	that	caused	10-20%	of	cell	death	were	selected	from	the	dose-response	data		(Table	
23,	Figure	28)	and	added	to	cells	treated	with	 increasing	doses	of	mitoxantrone	(Figure	30,	




±	 419.8	 for	mitoxantrone	 alone.	 The	 decrease	 in	 EC50-values	was	 significant	 (p<0.01)	 for	
AdΔΔ	and	Ad12S,	when	compared	to	mitoxantrone	alone.	In	contrast,	infection	with	Ad5wt	
at	 1000ppc	 did	 not	 result	 in	 sensitization	 to	 mitoxantrone	 in	 PC3	 cells.	 A	 small	 and	
unsignificant	increase	was	noted	in	mitoxantrone	EC50-values	in	Ad5wt-infected	PC3	cells.	In	
22Rv1	 cells,	 AdΔΔ	 and	 Ad12S,	 but	 not	 Ad5wt,	 decreased	 mitoxantrone	 EC50-values	 at	
selected	doses	that	killed	10-40%	of	cells	alone;	25ppc	for	Ad5wt	and	AdΔΔ,	and	100ppc	for	
Ad12S	 (Figure	 31	A	 and	 B	 and	 Figure	 32).	 At	 these	 doses,	 infection	with	 AdΔΔ	 and	 Ad12S	
decreased	 mitoxantrone	 EC50-values	 2-fold	 and	 2.3-fold	 to	 179.5	 ±	 94.0nM	 and	 157.6	 ±	
91.0nM,	 respectively,	 when	 compared	 to	 365.7	 ±	 63.6nM	 for	 mitoxantrone	 alone.	




batch	 (050314;	 2.3vp/pfu).	 The	 same	 batch	 of	 Ad5wt	 was	 used	 in	 all	 assays	 (270314;	




















Figure	 31.	 Mitoxantrone-induced	 cell	 killing	 is	 significantly	 increased	 only	 in	 combination	 with	
Ad12S	in	22Rv1	cells.	Dose-response	curves	to	mitoxantrone	combined	with	a	fixed	dose	of	virus	that	
killed	10	–	40%	of	cells	alone;	Adwt	or	Ad∆∆	at	25ppc	or	AdE1A12S	at	100ppc.	A.	Representative	dose-
response	 curves	 for	mitoxantrone	 alone	 (black)	 or	 in	 combination	 with	 a	 fixed	 dose	 of	 indicated	
adenovirus	 (blue).	 B.	 EC50-values	 of	 mitoxantrone	 and	 the	 combination	 of	 mitoxantrone	 and	 the	






Figure	 32.	 Ad∆∆	 and	 Ad12S	 sensitise	 PC3	 and	 22Rv1	 cells	 to	 mitoxantrone.	 EC50-values	 were	
calculated	 for	 each	 experiment.	 The	 sensitisation	 ratios	 were	 calculated	 as	 (EC50-value	






To	enable	 further	 investigation	of	 the	enhanced	cell	 killing	and	 to	determine	appropriate	
doses	to	be	used	in	future	mechanistic	studies,	combinations	of	fixed	doses	of	viruses	and	







of	 mitoxantrone	 (225,	 450,	 900nM)	 resulted	 in	 more	 than	 additive	 cell	 death	 that	 was	
significantly	higher	compared	to	mitoxantrone	alone	(p<0.05	for	225nM	and	p<0.001	for	450	
and	900nM).	This	enhancement	of	mitoxantrone-induced	cell	killing	was	emulated	with	the	









mitoxantrone	 (225,	 450	 and	900nM)	 resulted	 in	 a	 trend	 towards	more	 than	 additive	 cell	
killing,	statistical	analysis	could	not	be	performed	due	to	insufficient	number	of	repeats	(n=2)	
(Figure	33B).	Analysis	of	cell	viability	in	PC3M	cells	resulted	in	similar	results	to	those	observed	
in	PC3	cells	 (Figure	34).	 In	 these	cells,	 the	 combined	 treatment	of	AdΔΔ	at	20ppc	with	all	
tested	 doses	 of	 mitoxantrone	 (450,	 900nM)	 resulted	 in	 enhancement	 of	 mitoxantrone-
induced	cell	death	determined	by	the	MTS	viability	assay.	Statistical	analysis	could	not	be	




mitoxantrone	 appeared	 to	 inhibit	 cell	 killing	when	 compared	 to	 the	 expected	 theoretical	
additive	effect	in	22Rv1	cells	(Figure	35).	Due	to	the	high	sensitivity	of	22Rv1	cells	to	virus	and	




















































decreases	 in	 mitoxantrone	 EC50-values	 in	 PC3	 cells	 infected	 with	 Ad∆∆	 and	 Ad12S,	
respectively,	compared	to	2-fold	and	2.3-fold	decreases	in	22Rv1	cells		(Figure	30	and	Figure	
32).	 PC3	 cells	were	 highly	 insensitive	 to	 single	 agent	 treatment	with	 both	 virus	 and	drug	
compared	to	22Rv1	cells,	and	required	treatment	with	higher	doses	(Table	23).	Decreased	


















3.1.5 The	 E1B19K-deleted	 mutants	 AdΔΔ	 and	 Ad12S	 counteract	 mitoxantrone-induced	
autophagy	initiation	in	PC3,	22Rv1	and	PC3M	cells.	
	
It	has	previously	been	 reported	 that	both	androgen	withdrawal	 (Ming,	Byrne	et	al.	2013,	
Ziparo,	 Petrungaro	 et	 al.	 2013)	 and	 chemotherapy	 treatment	 	 (Farrow,	 Yang	 et	 al.	 2014)	
promote	 autophagy	 in	 in	 vitro	 and	 in	 vivo	 in	 various	 cancer	models.	 Treatment	with	 the	
antiandrogen	 bicalutamide	 caused	 hypoxia	 and	 therefore	 autophagy	 induction	 in	 LNCaP	
xenografts	 by	 inhibiting	 the	 key	 regulator	 mTOR	 (Ming,	 Byrne	 et	 al.	 2013).	 In	 addition,	





and	22Rv1	 cells	 (Maya	Pineda	2013).	 Therefore,	we	hypothesised	 that	 the	 enhanced	 cell	
killing	in	response	to	Ad∆∆	may	involve	inhibition	of	autophagy	and	could	be	developed	as	a	
therapeutic	strategy	for	chemotherapy-resistant	PCa.	
In	 order	 to	 elucidate	 the	 effects	 of	 Ad∆∆	 on	 drug-mediated	 autophagy	 and	 whether	 its	
inhibition	contributed	to	the	synergistic	cell	killing	 in	combination	with	mitoxantrone,	the	
role	 of	 early	 and	 late	 phases	 of	 autophagy	 was	 explored.	 Induction	 and	 completion	 of	
autophagy	was	determined	by	increased	LC3BI	conversion	to	LC3BII	and	degradation	of	p62,	









uninfected	cells	 (Figure	36A	and	B).	 Infection	with	Ad12S	even	resulted	 in	a	trend	towards	
reduction	of	basal	autophagy	levels	detected	as	a	lower	LC3BII/I	ratio	by	approximately	50%.	
As	 expected,	 autophagy	 initiation	was	 induced	 in	 PC3	 cells	 in	 response	 to	mitoxantrone	
treatment	 at	 225,	 450	 and	 900nM.	 	 This	 induction	was	 seen	 as	 1.5	 –	 2-fold	 increases	 in	
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LC3BII/I	 ratios	 compared	 to	 untreated	 cells	 and	 was	 dose-dependent.	 Interestingly,	
expression	of	p62	increased	3	–	4-fold	in	PC3	cells	treated	with	the	low	doses	of	mitoxantrone	
at	 225	 and	 450nM.	 In	 contrast,	 p62	 expression	 did	 not	 change	 in	 PC3	 cells	 treated	with	
900nM	mitoxantrone	 when	 compared	 to	 untreated	 cells	 (Figure	 36A	 and	 C).	 In	 PC3	 cells	
treated	with	low	doses	of	mitoxantrone	at	225	and	450nM,	infection	with	AdΔΔ	and	Ad12S	




counteract.	 Importantly,	 no	 further	 increases	 in	 LC3II/I	 ratios	 were	 observed	 in	 the	
combination	treated	cells	(Figure	36A	and	B).	The	combined	treatment	of	AdΔΔ	or	Ad12S	with	
mitoxantrone	 resulted	 in	 decreased	 expression	 of	 p62	 compared	 to	mitoxantrone	 alone	
(Figure	 36A	 and	 C).	 More	 specifically,	 the	 combination	 of	 AdΔΔ	 with	 450	 and	 900nM	
mitoxantrone	resulted	in	an	approximately	50%	decrease	in	p62	levels	when	compared	to	
mitoxantrone-only	 treated	 cells.	 The	 combination	 of	 Ad12S	 and	 450nM	 mitoxantrone	
resulted	in	a	4-fold	decrease	in	p62	expression	when	compared	to	mitoxantrone	only	and	
was	even	lower	than	basal	levels.	The	p62	expression	was	barely	detectable	in	cells	treated	
with	 Ad12S	 in	 combination	 with	 900nM	mitoxantrone	 (Figure	 36A	 and	 C).	 The	 combined	
treatment	of	Ad5wt	and	all	tested	doses	of	mitoxantrone	(225,	450	and	900nM)	caused	no	
changes	in	p62	expression	or	LC3BII/I	ratios	when	compared	to	mitoxantrone-only	treated	
cells	 (Figure	 36).	 Unfortunately,	 monitoring	 of	 p62	 expression	 proved	 problematic	 as	
experimental	replicas	were	quite	variable	and	p62	expression	was	often	difficult	to	detect,	
possibly	 because	 of	 antibody	 instability.	 In	 contrast,	 LC3II/I	 expression	 was	 highly	













increase	 in	 the	 signal	 can	 indicate	 autophagy	 completition.	 Alternatively,	 increased	
Lysotracker	 staining	 may	 also	 indicate	 an	 overall	 increase	 in	 the	 number	 of	 lysosomes.	
Stained	 cells	 were	 detected	 by	 flow	 cytometry.	 Treatment	 with	 the	 autophagy-inducer	
rapamycin	was	used	as	a	positive	control.	Rapamycin-treatment	 increased	the	number	of	
acidic	 vesicles,	 when	 compared	 to	 untreated	 cells	 (Figure	 37).	 In	 agreement	 with	 the	
increased	mitoxantrone-dependent	LC3BII/I	ratios	(Figure	36A	and	B),	PC3	cells	treated	with	
450nM	mitoxantrone	increased	the	number	of	cells	with	positive	vesicles	to	11.5	±	3.4	%.	
The	 combined	 treatment	 of	 mitoxantrone	 and	 AdΔΔ	 at	 500ppc	 reduced	 the	 number	 of	
positive	 cells	 to	 5.0	 ±	 0.6	 %.	 The	 difference	 between	 mitoxantrone	 and	 the	 combined	
treatment	was	 significant	 (p<0.01).	 Infection	with	AdΔΔ	alone	even	 reduced	 the	 levels	of	
acidic	vesicles	when	compared	to	untreated	cells	suggesting	a	decrease	in	basal	autophagy	






Figure	 36.	Mitoxantrone	 promotes	 autophagy	 initiation	 that	 is	 counteracted	 by	 AdΔΔ	 or	 Ad12S	
adenoviral	mutants	in	PC3	cells.	A.	Immunoblotting	for	p62	and	LC3BII/I	proteins	in	PC3	cells	treated	
with	mitoxantrone	 at	 225,	 450,	 900nM	 and/or	 Adwt	 or	 AdΔΔ	 at	 500ppc	 and	 Ad12S	 at	 5000ppc.	
Representative	images	of	3	to	6	immunoblots.	B.	Densitometry	quantification	of	LC3BII/I	expression.	
LC3BII/I	ratio	is	expressed	as	LC3II	(lower	band)	divided	by	LC3I	(higher	band),	averages	±SD,	n=6.	C.	
Densitometry	 quantification	 of	 p62	 expression,	 averages	 ±SD,	 n=3.	 All	 densitometry	 values	 were	
normalised	to	the	loading	control	before	calculating	ratios.	B	and	C.	One-way	Anova	with	Bonferroni	








































20ppc	 reduced	 the	 number	 of	 cells	 that	 were	 positive	 for	 acidic	 vesicles	 by	 50%,	 when	
compared	 to	 10nM	 mitoxantrone	 only.	 This	 reduction	 in	 acidic	 vesicles	 was	 significant	
(p<0.01).	Single	treatment	with	AdΔΔ	only	slightly	increased	the	number	of	positive	cells	to	













loading	 control	 before	 calculating	 ratios.	B	 and	 C.	 One-way	 Anova	with	 Bonferroni	 post-test	 was	
























trend	towards	reduction	of	mitoxantrone-dependent	 increases	 in	LC3BII/I	 ratios	by	2-fold	
(Figure	 40A	 and	 C).	 No	 significant	 changes	 in	 p62	 expression	 levels	 in	 response	 to	 the	

















±SD,	 n=2.	 C.	 Densitometry	 quantification	 of	 p62	 expression,	 averages	 ±SD,	 n=2.	 All	 densitometry	





non-replicating	 E1A-expressing	 Ad12S	 virus	 resulted	 in	 similar	 effects	 as	 seen	 for	 AdΔΔ	
infection,	which	suggested	that	the	attenuation	was	mainly	due	to	the	expression	of	the	E1A	
protein,	 as	 this	 is	 only	 protein	 expressed	 by	 Ad12S.	 In	 contrast	 to	 the	 LC3BII/I	 results,	
infection	with	AdΔΔ	or	Ad12S	did	not	prevent	p62	degradation	and	under	some	conditions,	
promoted	 p62-degradation.	 However,	 these	 data	might	 also	 indicate	 that	 infection	 with	
AdΔΔ	 or	 Ad12S	 only	 affected	 initial	 steps	 in	 the	 autophagy	 pathway.	 The	 findings	 were	











The	 E1A-encoded	 viral	 proteins	 are	 well	 stablished	 to	 promote	 apoptosis	 by	 multiple	
mechanisms	while	the	E1B-,	E3-	and	E4-encoded	proteins	prevent	premature	apoptosis	to	
enable	 completion	of	 the	viral	 life-cycle	 (see	 section	1.5.2).	Previous	 findings	 in	my	 team	
demonstrated	 that	 the	 replicating	 AdΔE1B19K	 mutant	 (E1B19K-deleted),	 enhanced	
gemcitabine-induced	apoptotic	cell	death	in	models	of	pancreatic	cancer	(Leitner,	Sweeney	
et	 al.	 2009,	Pantelidou,	Cherubini	 et	 al.	 2016).	 The	 increased	apoptosis	was	 the	 result	of	
increased	E1A	expression	in	E1B19K	mutants	(Ad∆∆	and	Ad∆19K).	
In	order	 to	 investigate	whether	 the	AdΔΔ-mediated	attenuation	of	mitoxantrone-induced	
autophagy	 was	 paralleled	 by	 increased	 apoptosis,	 changes	 in	 apoptosis	 markers	 were	
investigated	 in	the	PC3,	22Rv1	and	PC3M	cells.	Cells	were	treated	with	Ad5wt,	AdΔΔ	and	
Ad12S	 and	 mitoxantrone	 at	 doses	 determined	 in	 sections	 3.1.3	 and	 3.1.5	 that,	 when	
combined,	resulted	in	more	than	additive	cell	killing	in	PC3	and	PC3M	cells	and	additive	cell	
killing	in	22Rv1	cells	(Figure	33,	Figure	34	and	Figure	35).	
PC3	 cells	 were	 treated	 with	 Ad5wt,	 AdΔΔ	 at	 500ppc	 or	 Ad12S	 at	 5000ppc	 alone	 or	 in	
combination	with	225,	450	or	900nM	mitoxantrone	and	cleavage	of	PARP	and	pro-caspase	3	
were	assessed	by	immunoblotting	(Figure	41).	Treatment	with	low	doses	of	mitoxantrone	at	
225	 and	 450nM	 resulted	 in	 non-significant	 increased	 PARP	 cleavage	 (Figure	 41A	 and	 B;	





5-fold	and	4	 fold	compared	 to	basal	 levels,	 respectively	 (Figure	41A	and	B).	The	combined	
treatment	 of	 AdΔΔ	with	 225	 and	 450nM	mitoxantrone	 induced	 5-fold	 increases	 in	 PARP	
ratios,	when	compared	to	untreated	cells.	This	increase	was	similar	to	AdΔΔ-only	infected	
cells.	The	combined	treatment	of	Ad12S	and	all	tested	doses	of	mitoxantrone	(225,	450	and	
900nM)	 resulted	 in	 a	 strong	 trend	 towards	 increased	 PARP	 cleavage	when	 compared	 to	
single	agent	treatments.	The	combination	of	Ad12S	and	900nM	mitoxantrone	resulted	in	a	
6-fold	 increase	 in	 the	 PARP	 ratio	 when	 compared	 to	 untreated	 cells.	 The	 combined	
treatment	of	Ad5wt	with	all	tested	doses	of	mitoxantrone	(225,	450,	900nM)	resulted	in	4-
fold	 increases	 in	 PARP	 ratios,	 when	 compared	 to	 untreated	 cells.	 These	 results	 were	
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surprising	 since	 infection	with	 Ad5wt	 alone	 induced	 a	 6-fold	 increase	 in	 the	 PARP	 ratio,	
implying	that	the	combination-treatments	with	Ad5wt	caused	less	apoptotic	death	than	virus	
alone	but	more	 than	mitoxantrone	alone	 (Figure	41A	and	B).	No	changes	 in	pro-caspase	3	





48	 –	 120h	 after	 treatment.	 Cells	 treated	 with	 900nM	 of	 mitoxantrone	 promoted	
depolarization	of	the	mitochondrial	membrane	in	14.1	±	0.7%	of	cells	at	72h,	this	percentage	
gradually	 increased	 over	 time	 up	 to	 34.5	 ±	 3.1%	 at	 120h.	 Treatment	 with	 450nM	
mitoxantrone	slightly	promoted	apoptosis	in	12.5	±	2.7%	of	cells	only	120h	after	treatment	
(Figure	41C).	Single	agent	treatment	with	AdΔΔ	at	500ppc	did	not	 induce	apoptosis	 in	PC3	
cells	 at	 any	 time-point	 (48	 –	 120h).	 In	 order	 to	 investigate	 the	 effects	 of	 the	 combined	
treatments	of	AdΔΔ	and	mitoxantrone	on	the	mitochondrial	depolarization,	PC3	cells	were	
treated	 with	 AdΔΔ	 in	 combination	 with	 450	 and	 900nM	 mitoxantrone.	 The	 combined	
treatment	 of	 AdΔΔ	 and	 450nM	 mitoxantrone	 promoted	 mitochondrial	 membrane	
depolarization	 in	 21.3	 ±	 2.0%	 of	 cells,	 this	 percentage	 was	 higher	 when	 compared	 with	
mitoxantrone-only	 treated	 cells.	 The	 combination	 of	 AdΔΔ	 with	 900nM	 mitoxantrone	






surface	 of	 the	 cellular	 membrane,	 which	 enables	 binding	 of	 Annexin	 V	 thus	 indicating	
apoptotic	 cell	 death.	Mitoxantrone	 treatment	with	 450	 and	 900nM	 increased	 Annexin	 V	
positive	cells	in	a	dose-dependent	manner	reaching	7.6	±	0.5%	and	27.2	±	8.2	%	for	450	and	















averages	 ±SD,	 n=3.	 C.	 PC3	 cells	 were	 treated	 with	 AdΔΔ	 at	 500ppc	 and/or	 indicated	 doses	 of	
mitoxantrone	at	450	or	900	nM	and	collected	at	indicated	time	points.	Mitochondrial	depolarization	
was	measured	 as	 an	 indication	 of	 apoptosis	 by	 loss	 of	 TMRE	 staining	 (Q3),	 n=2.	 TMRE	 and	 DAPI	








Similar	 studies	 were	 performed	 in	 22Rv1	 cells,	 treated	 with	 increasing	 doses	 of	
mitoxantrone.	Non-significant	 increased	PARP-cleavage	was	seen	with	3,	10	and	25nM	of	
drug	 (indicated	with	 black	 arrow)	 in	 a	 dose-dependent	manner	 by	 2-3-fold	 compared	 to	
untreated	cells	(Figure	42A	and	B).	In	addition,	treatment	with	3,	10	and	25nM	mitoxantrone	
resulted	 in	 a	 dose-dependent	 decrease	 in	 pro-caspase	 3	 indicating	 increased	 apoptosis	
(Figure	42A).	Single	treatment	with	AdΔΔ	and	Ad12S	promoted	5-fold	 increases	 in	cleaved	
PARP/proPARP	ratios.	The	combined	treatment	of	either	AdΔΔ	or	Ad12S	with	all	tested	doses	
of	mitoxantrone	 (3,	 10	 and	 25nM)	 resulted	 in	 a	 strong	 trend	 towards	 increased	 cleaved	
PARP/proPARP	 ratios,	 compared	 to	 single	 agent	 treatment	 with	 mitoxantrone.	 The	
combined	treatment	of	AdΔΔ	with	all	tested	doses	of	mitoxantrone	(3,	10	and	25nM)	further	


































extent	 than	Adwt.	 A.	 Expression	of	 PARP	and	pro-caspase	3	by	 immunoblotting	 (cleaved	PARP	 is	
indicated	with	black	arrow).	22Rv1	cells	were	treated	with	Adwt	or	Ad∆∆	at	15ppc	or	Ad12S	at	50ppc	
and/or	 indicated	doses	of	mitoxantrone	at	3,	10	or	25	nM	and	collected	48h	after	treatment.	One	
representative	 immunoblot	of	3.	B.	Densitometry	 values	of	 cleaved	PARP	 (lower	band)	divided	by	
proPARP	 (higher	 band).	 All	 densitometry	 values	 were	 normalised	 to	 the	 loading	 control	 before	
calculating	 ratios.	 One-way	 Annova	 with	 Bonferroni	 post-test	 was	 performed	 but	 resulted	 in	 no	
significant	differences,	averages	±SD,	n=3.	C.	22Rv1	cells	were	treated	with	AdΔΔ	at	20ppc	and/or	
indicated	doses	of	mitoxantrone	at	10	or	25	nM	and	collected	at	indicated	time	points,	averages	±SD,	
n=2.	 Mitochondrial	 depolarization	 was	 measured	 as	 an	 indication	 of	 apoptosis	 by	 loss	 of	 TMRE	








in	 increased	 mitochondrial	 depolarization,	 however	 these	 increases	 were	 not	 dose-
dependent.	Treatment	with	450nM	mitoxantrone	resulted	in	the	highest	increase	with	48.7	
±	3.5%	of	cells	undergoing	depolarization	of	the	mitochondrial	membranes.	Treatment	with	
900nM	 mitoxantrone	 only,	 resulted	 in	 41.4	 ±	 4.1%	 of	 apoptotic	 cells	 (Figure	 43).	
Mitochondrial	 depolarization	 appeared	 earlier	 in	 PC3M	 cells	 than	 in	 PC3	 cells;	 72h	 after	
treatment	versus	120h	in	PC3	cells	with	a	maximum	of	34.5%	of	cells	(Figure	41D	and	Figure	
43).	At	120h	after	treatment	all	PC3M	cells	were	dead	and	data	could	not	be	generated	at	
this	 time-point.	 Treatment	 with	 Ad5wt	 or	 AdΔΔ	 at	 20ppc	 induced	 mitochondrial	
depolarization	 in	 15.8	 ±	 9.5%	 and	 25.7	 ±	 17.5%	 of	 cells,	 respectively	 (Figure	 43A).	 The	
combined	 treatment	 of	 AdΔΔ	 with	 450	 and	 900nM	 mitoxantrone	 increased	 the	
mitochondrial	depolarization	over	that	of	mitoxantrone	alone.	This	increase	was	significant	
(p<0.001	and	p<0.0001	for	450	and	900nM,	respectively).	The	percentage	of	cells	undergoing	












582/15	 and	 V	 450/50,	 respectively.	 One-way	 Anova	 with	 Bonferroni	 post-test	 ***p<0.001,	
****p<0.0001,	averages	±SD,	n=3.	B.	Representative	selected	images	from	FACS	analysis	in	A.	Data	






increased	 by	 co-treatment	 with	 AdΔΔ.	 Finally,	 both	 AdΔΔ	 and	 Ad12S	 enhanced	
mitoxantrone-induced	 PARP-cleavage	 in	 PC3	 and	 22Rv1	 cells,	 suggesting	 that	 this	
enhancement	was	due	to	the	expression	of	the	E1A	adenoviral	protein.	The	TMRE,	Annexin	












Aiming	 to	 establish	 a	 possible	 relationship	 of	 the	 attenuation	 of	 mitoxantrone-induced	
autophagy-initiation	and	the	enhancement	in	mitoxantrone-induced	apoptosis	in	PC3,	22Rv1	
and	PC3M	cells,	the	data	were	further	processed.	LC3BII/I	ratios	were	directly	compared	with	




of	 the	 drug,	 attenuated	 mitoxantrone-induced	 increase	 in	 LC3II/I	 ratios	 (filled	 red	 bars)	
(Figure	 44A).	 A	 similar	 effect	 was	 also	 seen	 with	 the	 Lysotracker	 staining	 (Figure	 37).	
Mitoxantrone	 treatment	 at	 450	 and	 900nM	 promoted	 apoptotic	 cell	 death	 in	 PC3	 cells	
showed	by	TMRE	and	Annexin	V	assays	(Figure	44A;	open	blue	bars).	Apoptosis	was	further	
promoted	when	PC3	cells	were	treated	with	450nM	mitoxantrone	in	combination	with	AdΔΔ	





cells	 mitoxantrone	 also	 promoted	 apoptosis,	 determined	 by	 TMRE	 and	 increased	 PARP	































and	 promoted	 mitoxantrone-induced	 apoptosis.	 AdΔΔ-mediated	 attenuation	 of	
mitoxantrone-induced	 autophagy	 could	 be	 detected	 at	 early	 stages	 in	 the	 autophagic	











3.2 INHIBITION	OF	 AUTOPHAGY	 ENHANCES	MITOXANTRONE-INDUCED	CELL	 KILLING	 BY	
PROMOTING	APOPTOSIS	 IN	PC3	AND	22RV1	CELLS,	BOTH	 IN	THE	PRESENCE	AND	
ABSENCE	OF	ADENOVIRUS.		
3.2.1 The	 autophagy-inhibitor	 chloroquine	 increases	 AdΔΔ	 and	 Ad12S-mediated	
sensitization	 to	mitoxantrone	 in	 PC3	 and	22Rv1	 cells	while	 the	 autophagy-inducer	
rapamycin	prevents	Ad-mediated	sensitization	in	PC3	cells.	
	
In	 order	 to	 further	 investigate	 the	 effect	 of	 autophagy-modulation	 in	 AdΔΔ-mediated	
enhancement	 of	mitoxantrone-induced	 cell	 death,	 the	 autophagy-inducer	 rapamycin	 and	
the	late-stage	autophagy-inhibitor	chloroquine	were	added	to	PC3	and	22Rv1	cells	treated	
with	 Ad5wt,	 AdΔΔ,	 Ad12S	 and	 mitoxantrone,	 followed	 by	 assessment	 of	 cell	 viability.	








accumulation	while	 rapamycin-treatment	 increased	 LC3BII	 conversion	 and	promoted	p62	
degradation	in	PC3	and	22Rv1	cells	(Figure	45A	and	B).	In	clinical	trials,	both	rapamycin	and	
chloroquine	are	given	daily	at	doses	of	2	–	6mg	and	600mg,	respectively,	in	combination	with	





Figure	 45.	 Rapamycin	 promotes	 and	 chloroquine	 blocks	 autophagy	 in	 PC3	 and	 22Rv1	 cells.	 A.	
Expression	 of	 p62	 and	 LC3BII/I	 in	 representative	 immunoblots	 (n=2)	 of	 PC3	 cells	 treated	 with	
chloroquine	(CQ)	or	rapamycin	(R)	at	indicated	doses	and	collected	at	indicated	time	points	(24	–	72h).	
B.	Expression	of	p62	and	LC3BII/I	 in	 representative	 immunoblots	 (n=2)	of	22Rv1	cells	 treated	with	
chloroquine	(CQ)	or	rapamycin	(R)	at	indicated	doses	and	collected	at	indicated	time	points	(24	–	72h).		
Selected	doses	of	chloroquine	at	10µM	or	rapamycin	at	50nM	that	had	been	verified	to	block	
and	 induce	 autophagy	 (Figure	 45A),	 respectively,	 were	 added	 to	 PC3	 cells	 treated	 with	
increasing	doses	of	mitoxantrone,	alone	or	in	combination	with	previously	selected	doses	of	
Ad5wt	 or	 AdΔΔ	 at	 500ppc,	 or	 Ad12S	 at	 5000ppc.	 These	 doses	 of	 AdΔΔ	 and	 Ad12S	 had	
previously	 been	 shown	 to	 sensitise	 cells	 to	mitoxantrone	 (section	 3.1.2).	 The	 addition	 of	
chloroquine	 to	 mitoxantrone-treated	 cells	 sensitised	 cells	 to	 mitoxantrone-induced	 cell	
death	and	resulted	in	an	approximate	70%	decrease	in	EC50-value	(Figure	46A,	Figure	47,	Table	
24).	In	contrast,	treatment	with	rapamycin	resulted	in	a	clear	de-sensitization	and	increased	
the	 EC50-value	 to	 mitoxantrone	 2-fold,	 this	 increase	 was	 significant	 (p<0.05)	 (Figure	 46A,	
Figure	47,	Table	24).	The	combined	treatment	of	chloroquine	with	Ad5wt,	AdΔΔ	or	Ad12S,	
maintained	and	even	increased	sensitization	to	mitoxantrone,	decreasing	the	EC50-values	by	











Changes	 in	 sensitization	 to	mitoxantrone	 as	 a	 result	 of	 autophagy	modulation	were	 also	
assayed	in	22Rv1	cells.	Selected	doses	of	chloroquine	at	10µM	or	rapamycin	at	25nM	that	
had	been	verified	to	block	and	induce	autophagy	(Figure	45B),	respectively,	were	added	to	




to	mitoxantrone-induced	 cell	 death	and	 resulted	 in	 a	decreased	EC50-value	by	40%	when	
compared	 to	 mitoxantrone	 alone	 (Figure	 46B,	 Figure	 48,	 Table	 24).	 This	 decrease	 was	
significant	 (p<0.05).	 Surprisingly,	 rapamycin	 treatment	 did	 not	 cause	 any	 changes	 in	
mitoxantrone	EC50-values	in	this	cell	line.	The	combined	treatment	of	chloroquine	with	AdΔΔ	
or	 Ad12S,	 maintained	 and	 even	 slightly	 increased	 sensitization	 to	 mitoxantrone	 by	





treatment	 of	 rapamycin	 and	 AdΔΔ	 slightly	 increased	 mitoxantrone	 EC50-values	 when	
compared	to	cells	treated	with	AdΔΔ	and	mitoxantrone	only,	although	this	increase	was	not	
significant	(Figure	46B,	Figure	48,	Table	24).	








and	PC3M	cells.	 In	 combination	with	 the	 findings	 from	 the	 studies	with	 chloroquine	 and	






















































The	 results	 presented	 in	 sections	 3.1.5	 and	3.1.6	demonstrated	 that	AdΔΔ	enhanced	 cell	
killing	by	attenuating	mitoxantrone-induced	autophagy	and	promoting	apoptosis	 in	22Rv1	
and	PC3	cells.	To	further	investigate	the	role	of	autophagy-inhibition	in	the	enhancement	of	
cell	killing,	apoptosis	was	determined	 in	cells	 treated	with	AdΔΔ	and	mitoxantrone	 in	 the	
presence	of	the	autophagy-inhibitor	chloroquine	or	the	-inducer	rapamycin.	Mitochondrial	
depolarization	was	assessed	 in	PC3	cells	120h	after	 treatment,	 since	 the	previous	studies	
proved	 maximum	 apoptosis-induction	 at	 this	 time	 point	 (Figure	 41).	 Treatment	 with	 the	
apoptosis-inducer	 staurosporine	 at	 1µM	 for	 15h	 was	 used	 as	 a	 positive	 control.	 The	
combined	 treatment	 of	 AdΔΔ	 at	 750ppc	 and	 450nM	mitoxantrone	 resulted	 in	 increased	
number	 of	 cells	 undergoing	 mitochondrial	 depolarization	 compared	 to	 single	 agent	
treatments	(24.0	±	9.5%	for	combined	treatment	and	18.3	±	10.2%	for	mitoxantrone	alone)	
(Figure	49).	 As	 previously	 shown	 (section	 3.1.6),	 the	 higher	 dose	 of	 900nM	mitoxantrone	
greatly	 induced	 mitochondrial	 depolarization	 in	 39.7	 ±	 17.7%	 of	 cells.	 However,	 this	








were	 not	 significant.	 Similarly,	 the	 addition	 of	 rapamycin	 to	 cells	 treated	 with	 900nM	
reduced	depolarization	to	19.8	±	7.9%.	The	addition	of	rapamycin	to	cells	treated	with	the	
combination	 of	 AdΔΔ	 and	 900nM	mitoxantrone	 reduced	mitochondrial	 depolarization	 to	
16.9	 ±	 7.3%.	 This	 decrease	 was	 significant	 (p<0.01)	 in	 cells	 treated	 with	 rapamycin	 and	






This	 increase	 was	 significant	 (p<0.01)	 in	 both	 conditions.	 Chloroquine	 did	 not	 further	




















mitoxantrone	 and	 AdΔΔ	 at	 20ppc	 enhanced	 mitoxantrone-induced	 mitochondrial	
depolarization	 resulting	 in	 41.5	 ±	 12.5%	 of	 cells.	 The	 addition	 of	 rapamycin	 did	 not	
significantly	affect	apoptosis	 in	22Rv1	cells.	These	data	are	 in	agreement	with	 the	 lack	of	
effect	on	the	EC50-values	of	mitoxantrone	in	response	to	rapamycin-treatment,	shown	in	the	
MTS	 data	 (section	 3.2.1;	 Table	 24).	 In	 contrast,	 chloroquine	 treatment	 further	 promoted	
mitochondrial	depolarization	in	22Rv1	cells	treated	with	10	and	25nM	mitoxantrone	alone	




combination	 with	 AdΔΔ.	 Chloroquine	 treatment	 resulted	 in	 a	 non-significant	 increase	 in	
depolarization	in	cells	treated	with	25nM	mitoxantrone,	alone	or	in	combination	with	AdΔΔ.	





Figure	 50.	 Chloroquine	 further	 promotes	 apoptosis	 in	 22Rv1	 cells	 treated	 with	 the	 combined	







These	 data	 demonstrated	 that	 chloroquine-treatment	 promoted	 mitoxantrone-induced	
apoptosis	in	the	presence	and	absence	of	AdΔΔ,	in	both	PC3	and	22Rv1	cells.	However,	Ad∆∆	















The	 results	 presented	 in	 section	 3.2.2	 demonstrated	 that	 the	 autophagy	 inhibitor	
chloroquine	 enhanced	 mitoxantrone-induced	 depolarization	 of	 the	 mitochondrial	









rapamycin	 with	 mitoxantrone	 resulted	 in	 a	 3.5-fold	 increase	 in	 LC3BII/I	 ratio	 and	
accumulation	of	p62.	In	cells	infected	with	Ad5wt	or	AdΔΔ	and	treated	with	mitoxantrone	
and	 rapamycin,	 LC3BII/I	 ratios	were	maintained	and	even	 slightly	 increased	 compared	 to	










Figure	 51.	 The	 combined	 treatment	 of	 mitoxantrone	 and	 rapamycin	 promotes	 LC3I	 to	 LC3II	
conversion,	which	is	not	counteracted	by	adenovirus.	A.	PC3	cells	were	infected	with	Adwt	or	AdΔΔ	
at	500ppc	or	Ad12S	at	5000ppc	and/or	treated	with	mitoxantrone	at	450	nM	and/or	rapamycin	at	
50nM	 and	 collected	 at	 48h.	 Representative	 immunoblots,	 n=2.	B.	 Densitometry	 quantification	 of	
LC3BII/I	expression.	LC3BII/I	ratios	are	expressed	as	LC3II	(lower	band)	divided	by	LC3I	(higher	band).	
C.	Densitometry	quantification	of	p62	expression.	All	densitometry	values	were	normalised	 to	 the	





of	 chloroquine	 and	mitoxantrone	 resulted	 in	 a	 small	 non-sifnificant	 decrease	 in	 LC3BII/I	
ratios,	 which	 may	 suggest	 that	 mitoxantrone	 released	 chloroquine-induced	 blockage.	
Infection	 with	 AdΔΔ	 or	 Ad12S	 in	 PC3	 cells	 treated	 with	 chloroquine	 and	 mitoxantrone	









Figure	 52.	 Chloroquine	 treatment	 results	 in	 autophagy	 blockage	 in	 PC3	 cells.	A.	 PC3	 cells	 were	
infected	with	Ad5wt	or	AdΔΔ	at	500ppc	or	Ad12S	at	5000ppc	and/or	treated	with	mitoxantrone	at	
450nM	 and/or	 Chloroquine	 at	 10uM	 and	 collected	 at	 48h.	 Representative	 immunoblots,	 n=2.	 B.	
Densitometry	quantification	of	LC3BII/I	expression.	LC3BII/I	ratios	are	expressed	as	LC3II	(lower	band)	
divided	 by	 LC3I	 (higher	 band).	C.	 Densitometry	 quantification	 of	 p62	 expression.	 All	 densitometry	




2-fold	 increase	 in	 LC3BII/I	 ratio	 and	 degradation	 of	 p62	 (Figure	 53).	 This	 induction	 was	
maintained	 when	 rapamycin	 was	 combined	 with	 mitoxantrone	 at	 10nM.	 Infection	 with	
Ad5wt	 and	 AdΔΔ	 at	 20ppc,	 counteracted	 rapamycin-induced	 LC3BII/I	 conversion	 and	
restored	 basal	 LC3II/I	 levels.	 However,	 the	 combination	 of	 either	 Ad5wt	 or	 AdΔΔ	 with	
rapamycin	did	not	attenuate	rapamycin-induced	p62	degradation.	Infection	with	Ad5wt	and	




blocked	 late-stage	 autophagy	 demonstrated	 by	 accumulation	 of	 LC3BII	 shown	 by	 2-fold	
increases	 in	 LC3BII/I	 ratios	 but	 no	 degradation	 of	 p62.	 The	 combined	 treatment	 of	
chloroquine	and	mitoxantrone	resulted	in	a	small	non-significant	decrease	LC3BII/I	ratio	and	
degradation	 of	 p62	 when	 compared	 to	 chloroquine	 alone.	 These	 results	 suggested	 that	
mitoxantrone	attenuated	chloroquine-induced	blockage.	Infection	with	Ad5wt	and	AdΔΔ,	in	





Figure	 53.	 Adenovirus	 attenuates	 mitoxantrone-	 or	 rapamycin-induced	 LC3II	 conversion.	
Adenovirus	 slightly	 attenuates	 chloroquine-induced	 autophagy	 blockage	 in	 the	 absence	 of	
mitoxantrone.	 	 A.	 22Rv1	 cells	 were	 infected	 with	 Ad5wt	 or	 AdΔΔ	 at	 20ppc	 and/or	 treated	 with	









The	 aim	 of	 these	 studies	 was	 to	 assess	 the	 effects	 of	 an	 autophagy	 inhibitor	 and	 an	




higher	quality	 immunoblots.	Data	 shown	 in	 this	 section	 (3.2.3)	 suggested	 that	 rapamycin	








that	 rapamycin	 and	 chloroquine	 caused	 autophagy	 induction	 and	 blockage,	 respectively.	
However,	 these	 data	 did	 not	 provide	 reliable	 information	 of	 the	 effect	 of	 chemical	
modulation	of	autophagy	in	cells	treated	with	the	combination	of	mitoxantrone	and	AdΔΔ.	
	
3.2.4 Mitoxantrone	with	or	without	 the	 addition	of	 rapamycin	or	 chloroquine	enhances	
adenoviral	infection	in	PC3	and	22Rv1	cells.	
	



























22Rv1	 cells	 and	was	 significant	 (p<0.001)	when	 compared	 to	 infection	with	AdGFP	alone	
(Figure	54D).	In	22Rv1	cells,	infection	with	AdGFP	at	10	and	100ppc	caused	dose-dependent	
GFP-expression	of	26.2	±	6.3%	and	78.9	±	5.7%,	respectively	(Figure	54B).	Neither	treatment	















integrin	and	hCAR	was	 increased	 to	27.7	±	1.0%	and	28.1	±	1.7%	of	cells,	 respectively,	 in	
175	
	
mitoxantrone-treated	 cells,	 when	 compared	 to	 non-treated	 cells.	 Statistics	 could	 not	 be	
performed	due	 to	 insufficient	number	of	 repeats.	22Rv1	cells	 showed	 low	 levels	of	αvβ3-
integrin,	which	was	not	increased	after	mitoxantrone	treatment	(Figure	54E).	











indicated	 doses.	 Averages	 ±	 SD,	 n=3,	 unpaired	 T-test	 *p<0.05.	 B.	 22Rv1	 cells	 were	 treated	 with	
chloroquine	at	10µM	or	 rapamycin	at	50nM	and	 simultaneously	 infected	with	AdGFP	at	 indicated	
doses.	Averages	±	SD,	n=2.	C.	PC3	cells	were	treated	with	mitoxantrone	at	900nM	and/or	chloroquine	
at	10µM,	or	rapamycin	at	50nM	for	24h;	the	treatment	was	then	replaced	with	AdGFP	infection	at	






were	analysed	48	h	after	 infection,	GFP	signal	was	measured	as	an	 indication	of	 infection	by	 flow	
cytometry.	 	 E.	 22Rv1	 cells	 were	 treated	 with	 mitoxantrone	 at	 25nM.	 Expression	 of	 cell	 surface	
receptors	was	measured	by	flow	cytometry,	n=2.	
	
3.2.5 Mitoxantrone	with	or	without	 the	addition	of	 rapamycin	or	chloroquine	decreases	
adenoviral	replication	in	PC3	and	22Rv1	cells.	
	






previously	observed	 low	 infectivity	 in	PC3	cells	 (Figure	54).	Ad5wt	and	AdΔΔ	replicated	 to	
similar	 levels	 in	 PC3	 cells.	 Ad5wt-replication	was	 4.9x106	 ±	 4.6x106	 pfu/ml	 and	 7.8x106	 ±	
4.3x106	pfu/ml	at	48	and	72h	post	infection,	respectively,	while	AdΔΔ-replication	was	4.8x106	
±	 1.0x106	 pfu/ml	 and	 6.01x106	 ±	 2.7x106	 pfu/ml	 (Figure	 55A).	 The	 combination	 or	 either	









for	 AdΔΔ	 (Figure	 55B).	 Mitoxantrone-mediated	 attenuation	 of	 viral	 replication	 was	
maintained	 in	 the	 presence	 of	 rapamycin	 and	 chloroquine.	 The	 combined	 treatment	 of	







Because	 of	 the	 inconclusive	 results	 from	 the	 replication	 assays	 regarding	 the	 effects	 of	
chloroquine	 on	 viral	 replication	 (decreased	 replication	 Figure	 55A;	 no	 change	 Figure	 55B),	
changes	 in	 viral	 genome	amplification	were	examined	 (qPCR	 Figure	55C).	 Amplification	of	
AdΔΔ	 at	 3000ppc	 was	 time-dependent	 in	 PC3	 cells.	 Mitoxantrone	 treatment	 at	 900nM	
attenuated	 viral	 amplification,	 which	 was	 decreased	 by	 96%	 and	 87%	 for	 48	 and	 78h,	
respectively.	 These	 mitoxantrone-mediated	 decreases	 in	 viral	 genome	 copies	 were	 also	




(Figure	 55C).	 Ad∆∆	 dose	 was	 increased	 in	 this	 assay	 a	 different	 bacth	 was	 used	 (batch	
050314),	 which	 had	 a	 higher	 vp/pfu	 ratio	 (15.3vp/pfu),	 compared	 to	 the	 newer	 batch	
(050314;	2.3vp/pfu).	
Finally,	expression	of	the	early	and	late	viral	genes,	E1A	and	hexon,	were	assessed	in	PC3	
cells	 treated	 with	 900nM	 mitoxantrone	 in	 combination	 with	 50nM	 rapamycin	 or	 10µM	
chloroquine.	Expression	of	E1A	and	hexon	was	detected	in	PC3	cells	infected	with	Ad5wt	or	
AdΔΔ	 at	 500ppc	 and	 was	 not	 affected	 by	 rapamycin	 or	 chloroquine.	 Treatment	 with	
mitoxantrone	 attenuated	 E1A	 expression	 in	 Ad5wt-infected	 cells,	 which	 was	maintained	
when	cells	were	treated	with	the	combination	of	mitoxantrone	and	rapamycin	(Figure	55D).	
E1A	 expression	 was	 barely	 detectable	 in	 the	 presence	 of	 the	 combined	 treatment	 of	
mitoxantrone	 and	 chloroquine	 in	 Ad5wt-infected	 cells.	 Expression	 of	 hexon	 was	 hardly	
detectable	 in	 Ad5wt-infected	 PC3	 cells	 when	 treated	 with	 mitoxantrone,	 alone	 or	 in	
combination	with	either	rapamycin	or	chloroquine,	confirming	that	mitoxantrone	treatment	
interferes	with	viral	replication	(Figure	55D).	Mitoxantrone	treatment	did	not	strongly	affect	
E1A	expression	 in	AdΔΔ-infected	 cells.	On	 the	other	hand,	 the	 combination	of	AdΔΔ	and	
mitoxantrone	decreased	hexon	expression,	indicating	attenuation	of	viral	replication.	Similar	
effects	 were	 seen	when	mitoxantrone	was	 combined	with	 rapamycin.	 Similar	 to	 Ad5wt-

















or	 AdΔΔ	 at	 500ppc	 and/or	 treated	 with	 mitoxantrone	 at	 450	 nM	 and/or	 Rapamycin	 at	 50nM,	
180	
	




































chloroquine.	 22Rv1	 cells	 were	 infected	 with	 Ad5wt	 or	 AdΔΔ	 at	 20ppc.	 Surprisingly,	 E1A	





hexon	 data,	 decreased	AdΔΔ-replication	 compared	 to	 Ad5wt	was	 observed	 in	 the	 TCID50	
replication-assays	 (Figure	 56A	and	B).	 Surprisingly,	 expression	of	 both	 E1A	 and	hexon	was	
increased	 in	 AdΔΔ-infected	 cells	 treated	 with	 the	 combination	 of	 mitoxantrone	 and	
rapamycin	 or	 mitoxantrone	 and	 chloroquine	 (Figure	 56D).	 Increased	 E1A	 and	 hexon	

























These	 findings	 demonstrated	 that	 late-stage	 autophagy	 inhibition	 with	 chloroquine	
sensitised	both	PC3	and	22Rv1	cells	to	mitoxantrone-induced	cell	death.	Chloroquine	also	
sensitised	the	cells	to	mitoxantrone	in	the	presence	of	Ad5wt,	AdΔΔ	and	Ad12S	in	PC3	and	
AdΔΔ	 and	 Ad12S	 in	 22Rv1	 cells.	 Autophagy-induction	 with	 rapamycin-treatment	
desensitised	PC3	cells	 to	mitoxantrone	and	 reversed	Ad5wt-,	AdΔΔ-	and	Ad12S-mediated	
sensitization.	 Chloroquine-treatment	 induced	 depolarization	 of	 the	 mitochondrial	
membrane	in	PC3	and	22Rv1	cells	treated	with	mitoxantrone	alone	or	in	combination	with	
Ad∆∆.	 In	 contrast,	 rapamycin-treatment	 attenuated	 depolarization	 of	 the	 mitochondrial	
membrane	in	PC3	cells	treated	with	mitoxantrone	alone	or	in	combination	with	Ad∆∆.		




levels	 in	 22Rv1	 cells	 (15.6	 ±	 5.5%	 and	 13.8	 ±	 0.7%	 of	 cells,	 for	 αvβ5-integrin	 and	 hCAR,	



















that	 caused	 increased	apoptotic	 cell	death	 (sections	3.2.1	and	3.2.2),	 resulted	 in	 strongly	
attenuated	viral	replication	in	PC3	cells	and	a	similar	trend	in	the	22Rv1	cells.	These	findings	
indicated	that	the	observed	increases	in	cell	death	were	not	due	to	increased	viral	replication	
























was	 prevented,	 Atg5	 and	 Atg7	 were	 targeted	 for	 knock-down.	 Both	 Atg5	 and	 Atg7	 are	
essential	 for	 inititation	 of	 autophagy	 and	 are	 key	 factors	 in	 the	 formation	 of	 the	
autophagosome	membrane	formation	(Tanida,	Yamasaki	et	al.	2012,	Nakatogawa	2013).	To	






siRNA	 (siNT)	 pool	 and	 siRNA	 pools	 targeting	 Atg5	 (siAtg5)	 or	 Atg7	 (siAtg7).	 Dharmafect	
transfection	reagent	was	added	to	PC3	cells	 to	 facilitate	siRNA	transfection,	 including	the	
non-transfected	 cells.	 Transfection	efficiency	 for	 siAtg5	was	monitored	over	 time	at	 24	–	
144h.	 Transfection	 with	 siAtg5	 at	 50	 and	 100nM	 resulted	 in	 potent	 knock-down	 of	 the	
















Transfection	 efficiency	 for	 siAtg7	was	 also	monitored	 over	 time	 at	 24	 –	 144h.	 Based	 on	
findings	with	Atg5	(Figure	57)	that	demonstrated	50nM	siAtg5	to	be	sufficient	for	efficient	
knock-down,	transfection	was	performed	with	siNT	and	siAtg7	at	50nM	only.	Transfection	
























50%	 decrease	 in	 LC3BI	 to	 LC3BII	 conversion	 compared	 to	 siNT	 treated	 cells	 with	 LC3BII	
expressed	 lower	than	basal	 levels,	and	no	degadation	of	p62	(Figure	59A-C).	 In	addition,	a	
trend	towards	p62	accumulation	was	noted	when	compared	to	siNT-transfected	cells	with	a	
1.5	–	2-fold	increase	in	p62	levels	(Figure	59C).	However,	those	effects	were	not	statistically	




and	 mitoxantrone-treated	 (450nM)	 PC3	 cells	 (Figure	 60).	 More	 specifically,	 siAtg7	
transfection	caused	an	approximately	50%	decrease	 in	LC3BII/I	 ratios,	when	compared	to	
siNT	cells	and	an	accumulation	of	LC3BI.	Treatment	with	450nM	mitoxantrone	did	not	induce	




















transfection.	 Cells	were	 transfected	with	 a	 non-targeting	 siRNA	 (siNT),	 Atg7	 siRNA	 (siAtg7)	 or	 the	
transfection	reagent	alone	(Dharmafect).	Samples	were	collected	48h	after	treatment.	Representative	
immunoblots,	n=3.	B.	Densitometry	quantification	of	LC3	expression	from	A.	LC3B	ratios	are	expressed	
as	 LC3BII	 (lower	 band)	 divided	 by	 LC3BI	 (higher	 band).	 Each	 band	was	 normalised	 to	 the	 loading	
control.	Averages	±	SD,	n=3.	C.	Densitometry	quantification	of	p62	expression	from	A.	p62	was	divided	
by	 loading	 control.	 Averages	 ±	 SD,	 n=3.	 B	 and	 C.	 One-way	 Anova	 with	 Bonferroni	 post-test	 was	





were	 transfected	with	 the	 siAtg7	 or	 siNT	 pools	 followed	by	 assessment	 of	mitochondrial	




2.9	 (Figure	27).	A	 slightly	 lower	dose	of	mitoxantrone	was	 selected	compared	 to	previous	
experiments,	 due	 to	 an	 observed	 overall	 increase	 in	 sensitivity	 to	 mitoxantrone	 in	
transfected	cells,	which	will	be	discussed	below	(section	3.3.3).		
I	 previously	 showed	 that	 AdΔΔ-infection	 enhanced	 mitoxantrone-induced	 mitochondrial	
depolarization	 in	 non-transfected	 cells	 (section	 3.1.6).	 In	 agreement	 with	 these	 findings,	
mitoxantrone-treatment	 induced	 mitochondrial	 depolarization	 in	 siNT-transfected	 cells,	
which	was	enhanced	in	the	presence	of	AdΔΔ	(Figure	61).	Transfection	with	siAtg7	further	
promoted	 mitochondrial	 depolarization	 in	 cells	 treated	 with	 this	 low	 dose	 of	 100nM	





siAtg7	 transfected	 cells	 treated	with	mitoxantrone	 and	Ad∆∆	 compared	 to	mitoxantrone	
















siRNAs.	 Autophagy-inhibition	 in	 siAtg5	 and	 siAtg7	 transfected	 cells	was	 demonstrated	by	
greatly	 decreased	 LC3BII	 conversion	 and	 no	 p62	 degradation.	 Interestingly,	 autophagy-
inhibition	was	associated	with	increased	mitochondrial	depolarization	in	siAtg7	cells	treated	
with	mitoxantrone	 alone	 and	 in	 combination	 with	 AdΔΔ,	 indicating	 increased	 apoptosis.	
These	data	indicated	that	autophagy	inhibition	promoted	apoptosis	in	mitoxantrone-treated	
cells.	These	findings	agreed	with	chloroquine-mediated	promotion	of	mitoxantrone-induced	






3.3.3 Atg5	 or	 Atg7	 knock-down	 does	 not	 affect	 AdΔΔ-mediated	 sensitization	 to	
mitoxantrone.	
	
I	 demonstrated	 (section	 3.3.2)	 that	 siAtg7-mediated	 autophagy-inhibition	 promoted	
mitoxantrone-induced	apoptosis.	 In	order	 to	assess	whether	 the	 increased	apoptosis	was	
paralleled	 by	 increased	 sensitisation	 to	 AdΔΔ	 in	 mitoxantrone-treated	 cells,	 cell	 viability	




siNT	 and	non-transfected	 cells,	 demonstrated	by	 decreased	 EC50-values	 for	mitoxantrone	
(Figure	62A	and	B,	Figure	64,	Table	25).	Co-infection	with	AdΔΔ	reduced	mitoxantrone	EC50-
values	by	73%,	 77%	and	78%	 for	 non-transfected	 cells	 and	 cells	 transfected	with	 siNT	or	
siAtg7,	respectively.	Data	were	processed	to	generate	sensitization	ratios	(Figure	62B).	The	
differences	 in	 EC50-ratios	 for	 mitoxantrone	 alone	 or	 in	 combination	 with	 AdΔΔ	 were	
significant	 for	 all	 tested	 conditions	 (p<0.01	 for	 non-transfected	 and	 siAtg7	 cells,	 and	
p<0.0001	for	siNT	cells)	(Figure	62B).	The	EC50-values	to	mitoxantrone	as	a	single	agent	were	
116.1	±	51.6	nM,	101.2	±	18.3	nM	and	248.3	±	101.4	nM	for	non-transfected	cells,	siNT	cells	
or	 siAtg7	 cells,	 respectively.	 Importantly,	 these	 EC50-values	 for	mitoxantrone	were	 lower	
compared	 to	 previous	 studies	 in	 PC3	 cells	 grown	 under	 regular	 conditions	 (without	
transfection	 reagent)	 where	 the	 EC50-value	 was	 2276.5	 ±	 419.8	 nM	 (Table	 23).	 This	 fact	
suggested	that	cells	became	more	sensitive	to	chemotherapy-treatment	in	the	presence	of	




resulted	 in	 20	 –	 40%	 cell	 death.	 Results	 from	 the	 cell	 death	 assays	were	 reanalysed	 and	
normalised	 to	 untreated	 non-transfected	 cells	 (Dharmafect	 control)	 (Figure	 62C).	











mitoxantrone.	 A.	 A	 fixed	 dose	 of	 AdΔΔ	 at	 500ppc	 that	 killed	 10-30%	 of	 cells	 was	 added	 to	
mitoxantrone-treated	 cells.	 EC50-values	 generated	 with	 dose-response	 curves	 of	 mitoxantrone	 in	
combination	with	fixed	doses	of	AdΔΔ	at	500ppc.	PC3	cells	were	previously	transfected	with	a	non-














(Figure	 63)	 to	 further	 investigate	 the	 role	 of	 inhibition	 of	 autophagy-initiation	 on	 drug-
dependent	cell	death.	
Infection	 with	 AdΔΔ	 resulted	 in	 potent	 sensitization	 to	 mitoxantrone	 in	 all	 cells;	 non-
transfected	cells	and	cells	transfected	with	siNT	or	siAtg5	(Figure	63A	and	B,	Figure	64,	Table	
25).	The	data	were	processed	to	generate	sensitization	ratios	(Figure	63B),	demonstrating	that	
the	differences	 in	EC50-ratios	 for	mitoxantrone	alone	and	 in	combination	with	AdΔΔ	were	
significant	for	all	 tested	conditions	(p<0.0001	for	non-transfected	cells	and	siNT	cells,	and	
p<0.001	for	siAtg5	cells)	(Figure	63B).	Fixed	doses	were	selected	from	the	dose-response	data	









mitoxantrone.	 A.	 A	 fixed	 dose	 of	 AdΔΔ	 at	 500ppc	 that	 killed	 10-30%	 of	 cells	 was	 added	 to	
mitoxantrone-treated	cells.	EC50-values	were	generated	with	dose-response	curves	to	mitoxantrone	
in	combination	with	fixed	doses	of	AdΔΔ	at	500ppc.	PC3	cells	were	previously	transfected	with	a	non-
targeting	 (NT)	 siRNA,	Atg5	 siRNA	or	 the	 transfection	 reagent	 alone.	Averages	 ±	 SD,	 n=4.	One-way	
Anova	with	Bonferroni	post-test.	B.	Ratio	of	EC50-values	in	A	expressed	as	(EC50	combined	treatment)	
/	 (EC50	mitoxantrone).	Averages	±	SD,	n=4,	Unpaired	t-test,	***p<0.001	****p<0.0001.	C.	Selected	

































mitoxantrone.	 Early	 stage	 autophagy-inhibition	with	 siAtg5	 or	 siAtg7	 did	 not	 significantly	
sensitise	 cells	 to	 either	 mitoxantrone-treatment	 or	 Ad∆∆-infection.	 However,	 a	 trend	
towards	 increased	EC50-values	 to	mitoxantrone	was	noted	 in	 siAtg5	or	 siAtg7	 transfected	
cells.	 Inhibition	of	autophagy-initiation	with	siAtg5	or	siAtg7	did	not	affect	cell	killing	and	
contrasted	with	 the	 findings	 using	 the	 late	 stage	 autophagy-inhibitor	 chloroquine,	which	
further	enhanced	both	cell	killing	and	apoptosis	under	similar	conditions.		
3.3.4 Atg7	 and	 Atg5	 knock-down	 does	 not	 significantly	 affect	 viral	 gene	 expression	 or	
replication	in	PC3	cells.	
	
In	 order	 to	 investigate	 whether	 the	 different	 responses	 to	 siAtg5	 and	 siAtg7	 versus	







changes	 in	E1A	expression	 in	 cells	 transfected	with	 siAt5	or	 siAtg7	 compared	 to	 the	 siNT	
transfected	cells	or	non-transfected	cells.	Hexon	expression	was	monitored	as	an	indication	
of	viral	late	gene	expression	and	replication.	In	agreement	with	the	E1A	data,	no	changes	in	















48h	after	 treatment.	Representative	 immunoblots,	 n=3.	 B.	Fixed	doses	of	AdΔΔ	at	 500ppc	and/or	














and	 in	AdΔΔ	co-infected	cells.	The	enhancement	of	apoptosis	was	 in	agreement	with	 the	











3.4 BCL-2	 KNOCK-DOWN	 PREVENTS	 ADΔΔ-MEDIATED	 SENSITIZATION	 TO	
MITOXANTRONE	AND	PROMOTES	AUTOPHAGY	IN	PC3	CELLS.	
	
It	 has	been	established	 that	 the	Bcl-2	protein	plays	a	main	 role	 in	 the	 crosstalk	between	
apoptosis	and	autophagy	regulation	(Marquez	and	Xu	2012).	While	Bcl-2	is	an	important	anti-






2	 from	 the	Beclin	1	 complex	and	 induce	autophagy	 (Piya,	White	et	 al.	 2011).	 In	order	 to	
determine	whether	Ad∆∆	(deleted	in	E1B19K)	was	dependent	on	a	functional	Bcl2-Beclin1	












expression	 levels	 in	 all	 tested	 conditions	 (siNT,	 siBcl-2	 and	 non-transfected	 cells).	 siBcl-2	






were	 treated	with	mitoxantrone	 at	 450nM,	 AdΔΔ	 at	 500ppc	 or	 the	 combination	 of	 both	
201	
	
treatments	 96h	 post-transfection	 (as	 explained	 in	 Figure	 27),	 followed	 by	 assessment	 of	
expression	of	Bcl-2	and	the	autophagy	markers	LC3B	and	p62.		
Transfection	of	PC3	cells	with	siRNA	to	Bcl-2	efficiently	knocked-down	the	protein	that	was	
























in	 siNT	 and	 siBcl-2	 cells.	 Infection	 with	 AdΔΔ	 resulted	 in	 a	 trend	 towards	 increased	
mitochondrial	depolarization	in	mitoxantrone-treated	siNT	and	siBcl-2	cells,	when	compared	
to	mitoxantrone-only	 treated	cells.	No	 significant	differences	were	observed	 in	apoptosis	
induction	 in	 cells	 transfected	with	 siBcl-2	 and	 siNT	 cells	 at	 any	 of	 the	 tested	 treatments	
(mitoxantrone,	 AdΔΔ	 or	 the	 combined	 treatment)	 (Figure	 67).	 Although	 a	 trend	 towards	
increased	apoptosis	with	Ad∆∆	in	siBcl-2	cells	was	noted.		
















In	 order	 to	 assess	 the	 effects	 of	 Bcl-2	 knock-down	 on	 AdΔΔ-mediated	 sensitization	 to	
mitoxantrone,	a	 fixed	dose	of	AdΔΔ	at	500ppc	was	added	 in	combination	with	 increasing	
doses	of	mitoxantrone	to	cells	that	had	previously	been	transfected	with	a	siNT	or	siBcl-2.	








with	AdΔΔ	were	significant	 for	non-transfected	and	siNT	cells	 (p<0.0001).	Unpaired	 t-test	













mitoxantrone	alone,	AdΔΔ	at	500ppc	or	 the	combination	of	both	 treatments	 (Figure	68C).	
Transfection	with	siBcl-2	resulted	in	an	overall	increase	in	cell	death	when	compared	to	siNT	
cells	 (Figure	 68C).	 This	 increase	 was	 highly	 significant	 (p<0.0001)	 in	 non-treated	 siBcl-2	
transfected	cells	when	compared	to	siNT	transfected	cells.	AdΔΔ	infection	at	500ppc	or	60nM	







In	 summary,	 AdΔΔ-mediated	 sensitization	 to	 mitoxantrone	 was	 prevented	 in	 siBcl-2	
transfected	 PC3	 cells.	 These	 data	 indicated	 that	 expression	 of	 Bcl-2	 was	 required	 for	



















transfected	 with	 a	 non-targeting	 siRNA	 (NT),	 Bcl-2	 siRNA	 or	 the	 transfection	 reagent	 alone	
(Dharmafect).	Averages	±	SEM,	n=4.	One-way	Anova	with	Bonferroni	post-test,	*p<0.05,	**p<0.01,	
























3.4.4 Bcl-2	 knock-down	 might	 decrease	 expression	 levels	 of	 adenoviral	 proteins	 in	
mitoxantrone-treated	PC3	cells.	
	







transfected	 or	 the	 non-transfected	 cells.	 These	 data	 suggested	 that	 expression	 of	 early	
adenoviral	proteins	and	AdΔΔ	replication	were	slightly	attenuated	by	mitoxantrone	in	siBcl-
2	 transfected	 PC3	 cells.	 However,	 different	 replicas	 showed	 some	 variability	 in	 E1A	 and	







Figure	 70.	 Bcl-2	 knock-down	 interferes	 with	 the	 expression	 of	 viral	 early	 and	 late	 proteins	 in	
mitoxantrone-treated	PC3	cells.	Fixed	doses	of	AdΔΔ	at	500ppc	and/or	mitoxantrone	at	450nM	were	
added	to	PC3	cells	4	days	after	transfection.	Cells	were	previously	transfected	with	a	non-targeting	
siRNA	 (siNT),	 Bcl-2	 siRNA	 (siBcl-2)	 or	 the	 transfection	 reagent	 alone	 (Dharmafect).	 Samples	 were	

















to	 0.3-fold	 at	 12h	 post-treatment	when	 compared	 to	 untreated	 cells.	 This	 decrease	was	
maintained	in	the	presence	of	Ad5wt	and	AdΔΔ.	





mitoxantrone	 (225,	 450	 and	 900nM)	 resulted	 in	 a	 dose-dependent	 decrease	 in	 Bcl-2	
expression	(Figure	71B).	Single	infection	with	Ad5wt,	AdΔΔ	or	Ad12S	slightly	increased	Bcl-2	
expression	 levels	 when	 compared	 to	 the	 untreated	 control.	 Interestingly,	 the	 combined	
treatment	of	AdΔΔ	or	Ad12S	with	mitoxantrone	resulted	in	a	trend	towards	increased	Bcl-2	
expression	 when	 compared	 to	 mitoxantrone-only	 treated	 cells.	 More	 specifically,	 the	
combination	of	AdΔΔ	with	225nM	mitoxantrone	resulted	in	increased	Bcl-2	expression	when	
compared	 to	 mitoxantrone	 only.	 The	 combination	 of	 Ad12S	 with	 all	 tested	 doses	 of	
mitoxantrone	(225,	450	and	900nM)	resulted	in	potent	increases	in	Bcl-2	expression,	when	

























major	anti-apoptotic	 factor,	 knock-down	alone	caused	more	cell	death	compared	 to	 siNT	
transfected	 cells.	 In	 addition,	 siBcl-2	 promoted	 autophagy	 initiation,	 demonstrated	 by	
increased	LCB3II/I	ratio,	which	was	not	counteracted	by	AdΔΔ	infection.	Furthermore,	knock-
down	of	 Bcl-2	 resulted	 in	 a	 trend	 towards	 attenuated	 expression	 of	 viral	 proteins	 in	 the	
presence	of	mitoxantrone.	The	decreased	expression	of	viral	proteins	may	contribute	to	the	
absence	 of	 AdΔΔ-mediated	 sensitization	 to	 mitoxantrone	 in	 siBcl-2	 cells.	 In	 addition,	













In	 order	 to	 investigate	 whether	 the	 increased	 cell	 killing	 and	 decreased	 activation	 of	












and	 2276.6	 ±	 419.8nM	 for	 Ad∆∆	 and	mitoxantrone,	 respectively;	 Figure	28,	 Table	23)	 but	

































levels	 than	 AdΔΔ	 and	 replication	was	 time	 dependent.	 At	 24,	 48	 and	 72h	 post-infection	
Ad5wt	replication	was	1.6x108	±	2.4x107,	2.8x109	±	2.5x109	and	5.3x1010	±	2.3x1010	pfu/ml,	
respectively,	while	 AdΔΔ	was	 1.3x106	 ±	 3.8x105,	 3.7x107	 ±	 2.6x107	 and	 4.5x108	 ±	 5.1x108	
pfu/ml,	respectively	(Figure	73E).	
In	conclusion,	PrSC	cells	were	moderately	resistant	to	adenoviral	 infection,	which	may	be	
explained	 by	 low	 expression	 levels	 of	 hCAR.	 The	 expression	 of	 αvβ3-	 and	 αvβ5-integrins	
appeared	not	to	sufficiently	facilitate	infection	in	the	absence	of	hCAR	in	PrSC	cells	similar	to	
the	 findings	 in	PC3	 cells.	 In	 addition,	AdΔΔ	 replicated	poorly	 in	PrSC	 compared	 to	Ad5wt	
confirming	the	AdΔΔ-selectivity	for	cancer	cells,	as	previously	demonstrated	(Oberg,	Yanover	









cytometry	 48h	 after	 infection,	 n=2.	 The	 GFP	 signal	 was	 detected	 with	 laser	 B	 530/30.	 	 B.	
Representative	FACS	 images	 from	A.	 C.	Expression	of	 indicated	cell	 surface	 receptors	 in	PrSC	 cells	
measured	by	flow	cytometry,	n=2.	Alexa	Fluor	488-labelled	antibody	signal	was	detected	with	laser	B	
530/30.	D.	Representative	FACS	 images	 from	C.	E.	PrSC	were	were	 infected	with	Adwt	or	AdΔΔ	at	
100ppc	and	collected	at	indicated	time	points	after	infection	(24,	48	and	72h),		n=2.	Viral	bursts	were	











was	 observed	 in	 preliminary	 studies	 (Figure	 74).	 22Rv1	 cells	 seeded	 alone	 on	 top	 of	 the	
collagen/matrigel	matrix	were	viable	and	grew	to	form	5	–	8	cell	layers	but	did	not	invade	
into	 the	 gel	 (Figure	 74A).	 In	 contrast,	 the	 co-cultures	 of	 PrSC	 and	 22Rv1	 cells	 resulted	 in	
increased	 growth	 and	 thickness	 of	 the	 cell	 layer	 and	 invasion	 into	 the	 gel	 (indicated	 by	
double-head	arrows)	(Figure	74B).	PC3	cells	seeded	alone	on	collagen/matrigel	matrix	did	not	
appear	 to	 proliferate	 and	 formed	only	 a	 viable	monolayer	 on	 top	of	 the	 gel	 (Figure	 74C).	




















To	 determine	 the	 efficacy	 of	 AdΔΔ-mediated	 enhancement	 of	mitoxantrone-induced	 cell	
death,	 the	 3-dimensional	 PrSC-PC3	 and	 PrSC-22Rv1	 co-cultures	 were	 treated	 with	 the	
combination	of	virus	and	drug.	Because	of	the	multiple	cell	layers,	viral	doses	were	increased	
around	 10-fold	 and	 2-fold	 for	 22Rv1	 and	 PC3	 cells,	 respectively,	 compared	 to	 the	 2-
dimensional	cultures	and	both	virus	and	drug	were	added	2-3	times	over	the	indicated	time-
periods.			






on	 top	of	 the	gel	even	after	8	days	 (Figure	75A).	Mitoxantrone-treatment	at	450nM	was	
added	both	on	top	a	bellow	the	cells	and	resulted	in	a	thinner	cell	layer	with	fewer	invading	




and	 mitoxantrone	 resulted	 in	 decreased	 thickness	 of	 the	 cell	 layer	 when	 compared	 to	
untreated	 control	 cells	 (Figure	 75F	 and	G).	 In	 addition,	 cells	 on	 the	 top	 of	 the	 cell	 layer	






















higher	 than	 the	 highest	 25ppc	 dose	 used	 in	 2-dimensional	mono-cultures	 of	 22Rv1	 cells.	
Infection	 with	 AdΔΔ	 efficiently	 killed	 cells	 in	 3-dimensional	 cultures,	 seen	 as	 decreased	
thickness	 of	 the	 cell	 layer	 and	 decreased	 invasion	 into	 the	 matrix	 (indicated	 with	 black	
arrow),	but	did	not	result	in	a	complete	elimination	of	the	cell	layers	(Figure	76).	Therefore,	a	













and	 stained	with	H/E	 10	days	 after	 seeding	 (Figure	77).	 Cell	 growth	but	 not	 invasion	was	
detected	as	early	as	2	days	after	seeding	(Figure	77A).	The	untreated	PrSC-22Rv1	co-cultures	
showed	 a	 distinct	 morphology	 with	 the	 majority	 of	 cells	 invading	 into	 the	 gel.	 This	
morphology	was	only	detected	 in	 the	untreated	 sample	and	might	be	due	either	 to	high	
levels	of	proliferation	of	the	PrSC-22Rv1	cells	or	to	defects	in	the	collagen/matrigel	during	
preparation	(Figure	77B).	The	number	of	cells	increased	around	4-fold	after	10	days	compared	



























In	 summary,	 these	preliminary	 studies	 in	PC3	and	22Rv1	cells	 co-cultured	with	PrSC	 cells	
indicated	 that	 cell	 killing	 in	 response	 to	mitoxantrone,	 AdΔΔ	or	 the	 combination	 of	 both	

































C-1.	 Green	 channel.	 Magnification	 of	 co-stained	 cell	 (E1A	 positive	 staining).	 C-2.	 Red	 channel.	
Magnification	of	 co-stained	 cell	 (α-SMA).	D.	 Cells	were	 treated	on	day	2	 and	6	after	 seeding	with	
mitoxantrone	at	25nM	and	infected	with	AdΔΔ	at	100ppc.	D-1.	Green	channel.	Magnification	of	co-







3.5.5 The	 early	 autophagy	 marker	 LC3BII	 does	 not	 co-stain	 with	 adenovirus	 E1A	 in	 3-
dimensional	co-cultures	of	PC3	or	22Rv1	cells	with	PrSC	cells.		
	




The	 PrSC-PC3	 co-cultures	 treated	with	 AdΔΔ	 at	 1000ppc,	mitoxantrone	 at	 450nM	or	 the	
combined	treatment	(Figure	75),	were	stained	for	E1A	and	LC3BII	(Figure	79).	E1A	staining	was	
only	 detected	 in	 AdΔΔ	 infected	 cultures,	 both	 in	 cells	 infected	 with	 AdΔΔ	 alone	 and	 in	
combination	 with	 mitoxantrone	 and	 showed	 that	 around	 10-15%	 of	 cells	 were	 infected	
(Figure	79F,	G,	H,	I	and	J).	LC3BII	staining	was	detected	in	cells	regardless	of	treatment.	The	
untreated	cells	showed	around	10%	of	LC3BII	positive	cells	(Figure	79B,	C,	and	J).	There	were	
no	 detectable	 significant	 differences	 in	 LC3BII	 staining	 between	 untreated	 cells,	
mitoxantrone	 alone	 or	 in	 combination	with	 AdΔΔ.	 Infection	with	 AdΔΔ	 alone	 resulted	 in	
decreased	 LC3BII	 staining	 compared	 to	 untreated	 and	 mitoxantrone	 treated	 cells.	

















Staining	 for	LC3BII	and	E1A	was	also	explored	 in	 the	PrSC-22Rv1	co-cultures	 treated	with	





















3.5.6 Summary	of	 the	 studies	on	prostate	 cancer	and	 stromal	 cells	 in	3-dimensional	 co-
cultures.	
	
These	 findings	demonstrated	 that	co-cultures	of	 the	epithelial	prostate	carcinoma	PC3	or	
22Rv1	 cells	 with	 normal	 prostate	 stromal	 PrSC	 cells	 promoted	 cancer	 cell	 growth	 and	
invasion	in	3-dimensional	collagen/matrigel	models.	Treatment	with	mitoxantrone,	infection	
with	 AdΔΔ	 or	 the	 combined	 treatment	 reduced	 cell	 growth	 in	 both	 co-culture	 models	




no	 LC3BII	 staining	 was	 detected	 in	 AdΔΔ-infected	 E1A-expressing	 cells.	 These	 findings	
suggested	 that	 AdΔΔ-infection	 prevented	 LC3BII	 conversion	 and	 consequently	 autophagy	
initiation.	However,	 these	data	 are	preliminary	with	 limited	number	of	 experiments,	 and	
need	 to	 be	 repeated	 to	 finalise	 our	 conclusions.	 AdΔΔ-infection	 was	 demonstrated	 to	
enhance	mitoxantrone-induced	apoptotic	 cell	 killing	and	attenuate	mitoxantrone-induced	
















glycol-containing	 ammonium	 groups	 (PEG-N+R4)	 to	 generate	 positively	 charged	 particles	
(Sanz,	Conde	et	al.	2012).	The	NPs	had	been	designed	to	facilitate	attachment	of	negatively	














viral	 transduction	 at	 all	 tested	 doses	 (10	 and	 50ppc)	 (Figure	 81B).	 Viral	 transduction	was	







In	 summary,	 infection	with	NP-coated	AdGFP	 significantly	 enhanced	 infection	 in	PC3	and	
22Rv1	cells.	This	increase	was	higher	in	PC3	cells.	In	PC3	cells,	precoating	of	AdGFP	with	NPs	
increased	 viral	 uptake	 85-fold,	 38-fold	 and	 13-fold	 for	 10,	 100	 and	 500ppc,	 respectively,	





infected	with	 indicated	doses	of	AdGFP	at	10,	100	and	500ppc	 in	 the	presence	or	absence	of	gold	
nanoparticles.	Averages	±	 SD,	n=3,	Un-paired	 t-test,	 **p<0.01,	 ****p<0.0001.	 B.	22Rv1	 cells	were	







These	 findings	 (section	 3.6.1)	 demonstrated	 that	 NP-coating	 of	 adenovirus	 significantly	
increased	 viral	 infection.	 In	 order	 to	 investigate	 whether	 the	 increased	 viral	 uptake	















to	 combination	 treatment	 in	 the	 absence	 of	 NPs	 (Figure	 82E).	 Coating	 of	 Ad∆∆	with	 NPs	
increased	AdΔΔ	cell	killing	from	16.1	±	4.8	%	to	58.2	±	14.2	%	and	from	63.0	±	7.0	%	to	86.8	
±	 2.6	%	 for	 AdΔΔ	 alone	 or	 in	 combination	with	mitoxantrone,	 respectively.	 Cell	 death	 in	
response	to	mitoxantrone	alone	was	not	modified	in	the	presence	of	NPs.	Moreover,	single	










0.1pmol	 gold	nanoparticles	 (NP).	 Cell	 viability	was	measured	by	MTS	 assay	 4	 days	 after	 infection.	
Averages	±	SD,	n=3,	Unpaired	T-test	*p≤0.05.	B.	Representative	dose-response	curves	to	AdΔΔ	(black)	
and	 AdΔΔ+NP	 (blue)	 from	 A.	 C.	 EC50-values	 generated	 in	 22Rv1	 cells	 treated	 with	 dose-response	











increased	 viral	 replication,	 PC3	 and	 22Rv1	 cells	 were	 infected	 with	 AdΔΔ	 alone	 or	 pre-
incubated	with	NPs	and	assessed	for	viral	replication	by	the	TCID50	assay.	
PC3	 and	 22Rv1	 cells	 were	 infected	 with	 AdΔΔ	 at	 100ppc	 alone	 or	 pre-incubated	 with	








In	 summary,	 a	 non-significant	 increase	 in	 AdΔΔ	 replication	 in	 the	 presence	 of	 NPs	 was	
detected	 in	 PC3	 and,	 to	 a	 lesser	 degree	 in	 22Rv1.	 In	 agreement	with	 the	 infectivity	 data	
(Figure	 81),	 the	 increase	 in	 viral	 replication	 was	 greater	 in	 PC3	 cells	 although	 the	 small	
increases	in	replication	did	not	parallel	the	significant	increases	in	infectivity	and	cell	killing.	
In	contrast	 to	both	 infectivity	and	cell	viability	data,	 the	 increases	 in	 replication	were	not	
significant.	 This	 lack	 of	 significance	 could	 be	 due	 to	 cells	 having	 reached	 their	maximum	
















infection-insensitive	PC3	 cells.	 In	 addition,	 pre-coating	of	AdΔΔ	with	 the	NPs	 significantly	
enhanced	AdΔΔ	 cell	 killing	 efficacy	 in	 22Rv1	 and	 PC3	 cells	 that	was	 further	 enhanced	 or	
maintained	 in	 the	presence	of	mitoxantrone	 in	 PC3	 cells.	 Infection	with	NP-coated	AdΔΔ	
resulted	in	an	insignificant	increase	in	viral	replication	in	PC3.	These	data	suggested	that	the	




The	 coating	 of	 adenoviral	 mutants	 with	 positively	 charged	 nanoparticles	 suggested	 a	
promising	 new	 strategy	 to	 enhance	 viral	 uptake	 and	 thereby	 increase	 the	 potency	 of	
















In	my	 thesis	project	 I	 investigated	 the	 role	of	oncolytic	 adenoviruses	 in	 the	 resistance	 to	
chemotherapy	 treatment	 with	mitoxantrone	 in	 22Rv1,	 PC3	 and	 PC3M	 PCa	 cells	 and	 the	
involvement	of	autophagy.	22Rv1	and	PC3	cells	were	selected	so	that	the	treatment	could	
be	 tested	 in	 both	 treatment-insensitive	 and	 a	 treatment-sensitive	 cell	 lines.	 22Rv1	 cells	
express	AR	and	are	a	model	for	early	stage	PCa,	while	PC3	and	PC3M	cells	are	AR-negative,	
and	 are	 models	 for	 more	 aggressive,	 later	 stage	 PCa	 (Sobel	 and	 Sadar	 2005,	 Chappell,	
Lehmann	et	al.	2012,	Liu,	Zhu	et	al.	2013).	Multiple	therapies	 for	PCa,	 including	hormone	
therapy	 with	 bicalutamide	 (Bennett,	 Stockley	 et	 al.	 2013)	 or	 the	 novel	 enzalutamide	
(Nguyen,	Yang	et	al.	2014);	taxane	chemotherapy	(Farrow,	Yang	et	al.	2014)	and	radiotherapy	
(Koukourakis,	Kalamida	et	al.	2015)	have	been	reported	to	upregulate	autophagy	resulting	
in	 lower	 treatment	efficacy	or	development	of	 treatment	 resistance.	Previously	my	 team	
developed	the	replication-selective	AdΔΔ	(E1ACR2-	and	E1B19K-deleted)	oncolytic	mutant	
that	selectively	replicates	in	cancer	cells	with	deregulated	cell	cycle		(Oberg,	Yanover	et	al.	
2010,	 Cherubini,	 Kallin	 et	 al.	 2011)	 and	 synergised	 with	 the	 chemotherapy	 drugs	
mitoxantrone	and	docetaxel	greatly	enhancing	cell	killing	in	PC3,	DU145,	LNCaP,	and	22Rv1	
PCa	cell	lines.	Ad∆∆	also	promoted	tumour	regression	in	vivo	in	DU145	and	PC3	xenografts	
(Oberg,	 Yanover	 et	 al.	 2010).	 In	 addition,	 my	 team	 reported	 that	 deletion	 of	 the	 anti-
apoptotic	 Bcl-2	 homolog	 E1B19K	 enhanced	 gemcitabine-induced	 apoptotic	 cell	 death	 in	
PT45	 and	 Suit-2	 pancreatic	 carcinoma	 cells	 (Leitner,	 Sweeney	 et	 al.	 2009,	 Pantelidou,	
Cherubini	et	al.	2016).	
In	 my	 project,	 I	 demonstrated	 that	 the	 combined	 treatment	 of	 mitoxantrone	 with	 the	
replication-selective	AdΔΔ	or	the	non-replicating	Ad12S	resulted	in	enhanced	cell	killing	in	
additional	 PCa	 cell	 lines	 by	 promoting	 mitoxantrone-induced	 apoptosis	 and	 attenuating	







required	 for	AdΔΔ-mediated	 sensitization	 to	mitoxantrone.	Preliminary	data	 showed	 that	
the	combined	treatment-induced	enhanced	cell	killing	could	be	replicated	in	3-D	cultures.	










I	 demonstrated	 that	 PC3	 cells	 were	 significantly	 more	 resistant	 to	 adenovirus-induced	
cytotoxicity	 than	22Rv1.	 I	 also	demonstrated	 that	22Rv1	 cells	were	 the	most	 sensitive	 to	
mitoxantrone	treatment	resulting	in	the	lowest	EC50-value	to	mitoxantrone.	22Rv1	and	PC3	
cells	 have	 several	 genotypic	 differences	 that	 may	 explain	 the	 observed	 differences	 in	
sensitivity	 to	 virus	 and	drug-induced	 cell	 death.	 Increased	 resistance	 to	mitoxantrone-	or	
adenovirus-induced	 cytotoxicity	 in	 PC3	 cells	 may	 be	 explained	 by	 lack	 of	 p53	 and	 PTEN	
expression,	which	hampers	 apoptosis	 induction.	 In	 contrast,	 the	 22Rv1	 cells,	which	were	
more	sensitive	to	both	mitoxantrone	and	viruses,	express	both	p53	and	PTEN	(Skjoth	and	
Issinger	 2006,	 Cunningham	 and	 You	 2015).	 Different	 sensitivities	 to	 virus-induced	
cytotoxicity	 can	 also	 be	 explained	 by	 different	 degrees	 of	 infection.	 I	 demonstrated	 that	
infection	with	approximately	100-fold	higher	doses	of	adenovirus	was	required	to	achieve	
similar	 levels	of	 infection	in	PC3	cells,	when	compared	to	the	lower	doses	used	for	22Rv1	













of	higher	 susceptibility	 to	 cell	 killing	due	 to	p53	and	PTEN	expression	and	 increased	viral	
transduction,	which	may	be	explained	by	increased	expression	of	hCAR	and	αvβ5	integrin.		
The	 efficacy	 of	 replication-selective	 oncolytic	 viruses	 was	 reported	 to	 increase	 in	
combination	 with	 chemotherapy	 in	 preclinical	 studies	 and	 clinical	 trials.	 Treatment	 with	
H101	 (E1B55K-	 and	 E3B-deleted)	 adenoviral	 mutant	 in	 combination	 with	 the	








Treatment	 with	 the	 topoisomerase	 II	 inhibitor	mitoxantrone	 induces	 DNA	 double	 strand	
















Vp-16	(etoposide)	resulted	 in	enhancement	of	cell	death	 in	vitro	 (TE-1,	TE-2,	TE-10,	TE-11	
YES-2,	 YES-4,	 YES-5,	 YES-6	 esophageal	 carcinoma	 cells)	 and	 in	 TE-11	 xenografts	 (Ma,	
Kawamura	et	al.	2010).		
Previous	work	 in	our	 team	demonstrated	 that	 the	mutants	 dl922-947	 (E1ACR2-	and	E3B-	
deleted)	 and	 AdΔΔ,	 synergistically	 enhanced	 mitoxantrone-	 and	 docetaxel-induced	 cell	
death	in	vitro	in	PC3,	DU145	and	LNCaP	cells	and	promoted	tumour	regression	in	PC3	and	
DU145	 xenografts	 (Oberg,	 Yanover	 et	 al.	 2010,	 Radhakrishnan,	 Miranda	 et	 al.	 2010).	 In	
agreement	with	these	findings,	 I	demonstrated	that	 the	addition	of	AdΔΔ	to	cells	 treated	
with	increasing	doses	of	mitoxantrone	resulted	in	potent	sensitization	to	the	drug	in	PC3	cells	












values	 to	 Ad12S	 were	 higher	 than	 those	 for	 the	 replicating	 Ad5wt	 or	 AdΔΔ,	 these	 data	
suggested	that	Ad-induced	cytotoxicity	was,	at	least	partially,	dependent	on	viral	replication	
and	cell	lysis,	which	is	not	possible	after	infection	with	Ad12S.		
4.2 AD-MEDIATED	 ATTENUATION	 OF	 MITOXANTRONE-INDUCED	 AUTOPHAGY	 AND	 ITS	
ASSOCIATION	WITH	INCREASED	APOPTOSIS.	
	









autophagy	 initiation	 (Piya,	 White	 et	 al.	 2011).	 More	 recently,	 adenovirus	 (AdΔ24)	 was	
reported	 to	 mediate	 phosphorylation	 of	 JNK1	 and	 JNK2,	 therefore	 promoting	 Bcl-2	
phosphorylation	and	its	dissociation	from	the	Beclin	1-Bcl-2	complex,	resulting	in	autophagy	
induction	(Klein,	Piya	et	al.	2015).	These	reports	agreed	with	the	fact	that	E1B19K-deleted	
adenoviruses	were	not	able	 to	 induce	autophagy	 initiation,	as	 I	 also	 showed	 in	my	work.	





As	 discussed	 at	 the	 beginning	 of	 this	 section,	 chemotherapy	 treatment	 can	 result	 in	
autophagy	 upregulation	 (Farrow,	 Yang	 et	 al.	 2014),	 which	 may	 contribute	 to	 the	
development	of	treatment	resistance	by	promoting	cell	survival.	Preliminary	findings	in	my	
team	(Maya	Pineda	2013)	suggested	that	mitoxantrone-induced	autophagy	was	attenuated	
by	 infection	with	 AdΔΔ	 or	 Ad12S	 in	 PC3	 and	 22Rv1	 cells.	 Therefore,	 we	 speculated	 that	
autophagy-inhibition	 may	 be	 developed	 as	 a	 therapeutic	 strategy	 for	 chemotherapy-
resistant	PCa.	I	found	that	treatment	with	mitoxantrone	resulted	in	autophagy	induction	in	
a	 dose	 dependent	 manner,	 demonstrated	 by	 increased	 LC3BI	 to	 LC3BII	 conversion	 and	
increased	 number	 of	 acidic	 vesicles.	 Interestingly,	 I	 showed	 that	 co-infection	 with	 AdΔΔ	
attenuated	mitoxantrone-induced	 LC3BII	 conversion,	 indicating	 attenuation	 of	 autophagy	
initiation.	 Infection	 with	 Ad12S	 resulted	 in	 similar	 attenuation	 of	 autophagy	 than	 AdΔΔ,	
indicating	 that	 expression	 of	 the	 E1A12S	 protein	 was	 sufficient	 for	 attenuation	 of	
mitoxantrone-induced	LC3BI	to	LC3BII	conversion.	I	also	showed	that	infection	with	Ad5wt	
did	 not	 affect	 mitoxantrone-induced	 LC3BI	 to	 LC3BII	 conversion	 in	 PC3	 and	 22Rv1	 cells,	
indicating	 that	expression	of	 E1B19K	protein,	which	 is	not	present	 in	 the	AdΔΔ	or	Ad12S	
viruses	and	was	reported	to	promote	autophagy	(Piya,	White	et	al.	2011),	might	prevent	E1A	




protein	 VI	 have	 been	 reported	 to	 disrupt	 the	 endosome	 membrane	 during	 viral	





to	 AdΔΔ-mediated	 attenuation	 of	 mitoxantrone-induced	 increased	 fusion	 of	 the	
autophagosome	and	lysosome.		
The	 p62	 protein	 is	 required	 for	 the	 sequestration	 of	 ubiquitinated	 proteins	 into	 the	
autophagosome	and	is	degraded	at	the	end	of	the	autophagic	process	(Pankiv,	Clausen	et	al.	
2007).	I	demonstrated	that	mitoxantrone	treatment	induced	completion	of	the	autophagy	
process	by	degradation	of	 p62	 in	 22Rv1	and	PC3M	cells.	However,	mitoxantrone	did	not	
cause	decreases	in	basal	levels	of	p62	in	PC3	cells.	Also	in	my	work,	AdΔΔ	or	Ad12S	did	not	
prevent	 mitoxantrone-induced	 p62	 degradation	 and,	 under	 some	 conditions,	 further	
promoted	its	degradation.	These	data	might	indicate	that	infection	with	AdΔΔ	or	Ad12S	only	
affected	 initial	 steps	 in	 the	 autophagy	 process.	 Degradation	 of	 p62	 is	 also	 known	 to	 be	
mediated	 by	 proteasomal	 inhibitors,	 independently	 of	 the	 autophagic	 process	 (Klionsky,	
Abdelmohsen	et	al.	2016).	Degradation	of	p62	was	also	suggested	to	be	cell	line	dependent	
and	it	was	observed	that	levels	of	p62	might	not	change	despite	strong	levels	of	autophagy	
induction	 (Klionsky,	 Abdelmohsen	 et	 al.	 2016).	 Therefore,	 although	 p62	 is	 a	 marker	 for	









Expression	 of	 E1A	 can	 promote	 p53	 stabilization	 by	 multiple	 mechanisms	 resulting	 in	
apoptosis	induction	(Putzer,	Stiewe	et	al.	2000,	Chattopadhyay,	Ghosh	et	al.	2001,	Li,	Day	et	
al.	 2004,	 White	 2006).	 E1A-dependent	 release	 of	 E2F	 upregulates	 p14ARF	 expression	
resulting	in	inhibition	of	MDM2-induced	p53-degradation	(Putzer,	Stiewe	et	al.	2000).	E1A	
was	also	reported	to	facilitate	p53	binding	to	MDM4,	preventing	p53	nuclear	export	(Li,	Day	
et	 al.	 2004).	 Finally,	 E1A	 down-regulates	 p21	 and	 MDM2	 resulting	 in	 p53	 stabilization	
(Chattopadhyay,	 Ghosh	 et	 al.	 2001,	 Yamasaki,	 Tazawa	 et	 al.	 2012).	 E1A	 enhances	 TNFα-
dependent	apoptosis	induction	by	down-regulation	of	the	TNF-inhibitor	c-FLIP	and	inhibition	





preventing	mitochondrial	 depolarisation	 (Berk	 2005).	 Our	 team	 previously	 reported	 that	
infection	with	E1B19K-deleted	mutants,	 including	AdΔΔ,	 induced	apoptosis	 in	DU145	and	
22Rv1	PCa	cells	(Oberg,	Yanover	et	al.	2010).	In	addition,	infection	with	AdΔE1B19K	(E1B19K-




et	 al.	 2009).	 In	 agreement	 with	 published	 reports	 (Symes,	 Kurin	 et	 al.	 2008,	 Sánchez,	
Mendoza	et	al.	2009),	I	showed	that	mitoxantrone-treatment	induced	apoptosis	in	all	tested	







my	 team	 that	 demonstrated	 that	 Ad12S	 infection	 enhanced	 mitoxantrone-induced	
mitochondrial	depolarization	in	PC3	and	DU145	PCa	cells	(Miranda,	Maya	Pineda	et	al.	2012).	















that	 AdΔΔ-mediated	 enhancement	 of	 mitoxantrone-induced	 cell	 death	 was	 due	 to	
promotion	of	apoptotic	cell	death	and	prevention	of	autophagy	initiation.	To	the	best	of	my	
knowledge,	 the	 demonstrated	 Ad-dependent	 correlation	 of	 autophagy	 attenuation	 and	
apoptosis	induction	has	not	been	previously	reported.	
4.3 THE	EFFECT	OF	AUTOPHAGY	MODULATION	WITH	RAPAMYCIN	OR	CHLOROQUINE	IN	
CELL	 DEATH	 AND	 IN	 THE	 VIRAL	 LIFE	 CYCLE	 IN	 COMBINATION-TREATED	 PC3	 AND	
22RV1	CELLS	
	
Autophagy	 plays	 a	 dual	 role	 in	 PCa.	 During	 early	 stages,	 autophagy	may	 be	 required	 to	
protect	the	cell	from	accumulation	of	free	radicals.	On	the	contrary,	at	later	stages,	active	
autophagy	 can	 provide	 the	 cell	 with	 new	 nutrients	 and	 promote	 cell	 survival	 (Ziparo,	
Petrungaro	et	al.	2013).	Autophagy	modulation	by	either	inhibition	or	upregulation	of	the	
process	 is	 currently	 being	 studied	 to	 improve	 the	 efficacy	 of	 PCa	 therapies	 (Ziparo,	
Petrungaro	et	al.	2013).	Here	I	showed	that	chloroquine	treatment	enhanced	the	efficacy	of	
mitoxantrone	treatment	alone	and	in	combination	with	AdΔΔ	and	Ad12S	in	22Rv1	and	PC3	
cells	 by	 decreasing	 EC50-values	 to	 mitoxantrone	 and	 enhancing	 mitoxantrone-induced	
apoptosis.	My	 findings	 indicated	 that	 autophagy	 inhibition	might	enhance	 the	efficacy	of	
chemotherapeutic	drugs.	Chloroquine	and	other	autophagy	inhibitors	such	bafilomycin	or	3-
methylladenine	are	currently	being	tested	in	combination	with	standard	therapies	in	several	
















Bcl-2-	 interaction	 (Yee,	Wilkinson	 et	 al.	 2009).	 On	 the	 other	 hand,	 cytoplasmic	 p53	 was	
shown	 to	 inhibit	 autophagy.	p53	deficiency-mediated	autophagy-induction	promoted	 cell	





help	 to	 explain	 why,	 in	 my	 studies,	 rapamycin	 treatment,	 although	 slightly	 enhancing	
autophagy	 induction,	 did	 not	 have	 any	 additional	 effect	 in	 prevention	 of	 cell	 death	 or	
apoptosis	in	22Rv1	cells.	
In	 addition,	 rapamycin-dependent	 prevention	 of	 Ad∆∆-mediated	 sensitization	 to	
mitoxantrone	could	have	been	due	to	the	fact	that	active	autophagy	protected	the	cell	from	
either	viral	infection	or	mitoxantrone	by	directly	degrading	virus	or	drug;	or	by	upregulating	













al	 reported	 that	 adenoviral	 infection	 upregulated	 autophagy	 in	 infected	MDNSC11	 brain	
tumour	stem	cells	to	facilitate	release	of	viral	progeny	(Jiang,	White	et	al.	2008).	Rodriguez-
Rocha	and	colleges	reported	that	autophagy	inhibition	with	3-MA	in	A549	and	H1299	cells	






reports,	 I	 showed	 that	 rapamycin	 treatment	 resulted	 in	 a	 trend	 towards	 increased	 viral	
replication.	Interestingly,	I	also	showed	that	the	combined	treatment	of	AdΔΔ,	mitoxantrone	










(Shin,	 Kim	 et	 al.	 2012).	 In	 addition,	 the	 combination	 of	 Akt	 inhibitors	 with	 autophagy	
inhibitors	 such	 as	 chloroquine,	 3-MA,	 bafilomycin	 or	 with	 Atg7	 knock-down	 resulted	 in	
enhanced	cell	death	and	apoptosis	in	PC3	cells	(Lamoureux,	Thomas	et	al.	2013).		
In	order	to	confirm	the	pro-apoptotic	effect	of	autophagy-inhibition	by	Ad∆∆,	Atg5	and	Atg7,	







confirmed	 that	 autophagy	 inhibition	 promoted	 mitoxantrone-induced	 apoptosis.	
Interestingly,	 I	 found	 that	 autophagy	 inhibition	with	 either	 chloroquine	or	 siAtg7	did	 not	
affect	 basal	 levels	 of	 apoptosis.	 My	 data	 indicated	 that	 promotion	 of	 apoptosis	 under	














signalling	 pathway.	 The	 regulation	 of	 the	 autophagic	 and	 apoptotic	 processes	 is	 tightly	
related.	 Autophagy	 inhibition	 frequently	 correlates	 with	 an	 increase	 in	 apoptosis	 as	 I	














treatment	 resulted	 in	 enhancement	 of	 Ad-mediated	 sensitization	 to	 mitoxantrone	 and	
further	promoted	apoptosis.	Chloroquine	is	a	late-stage	autophagy	inhibitor	that	prevents	
the	fusion	of	the	autophagosome	with	the	lysosome	while	siAtg5	or	siAtg7	inhibit	autophagy	
initiation	 by	 preventing	 LC3BI	 to	 LC3BII	 conversion.	 Consequently,	 it	 is	 reasonable	 that	
inhibition	at	the	two	different	stages	of	the	pathway	resulted	in	different	outcomes.	My	data	









and	was	 not	mimicked	 by	 Atg12	 or	 Beclin	 1	 knock-downs	 (Maycotte,	 Aryal	 et	 al.	 2012).	
Chloroquine	treatment	was	reported	to	induce	lysosome-mediated	apoptosis	in	SH-EP,	SH-
N-AS	 and	 Kelly	 neuroblastoma	 cells	 treated	 with	 the	 PI3K/mTOR	 inhibitor	 BEZ235	
independently	of	autophagy	modulation	 (Seitz,	Hugle	et	al.	2013).	Chloroquine	treatment	
was	 also	 reported	 to	 promote	 cathepsin	 D-dependent	 lysosomal	 malfunction	 and	 cause	
apoptosis	in	p53-negative	LN308	glioma	cells	(Geng,	Kohli	et	al.	2010).	Lysosome-mediated	
apoptosis	is	preceded	by	lysosomal	membrane	permeabilization	(LMP).	LMP	is	a	process	that	
involves	 the	 loss	of	 lysosomal	membrane	 integrity	and	can	be	caused	by	osmotic	 lysis	or	
chemical	surfactants	 (Repnik,	Hafner	Česen	et	al.	2014).	LMP	results	 in	 the	release	 in	 the	
cytosol	 of	 lysosomal	 hydrolases,	 including	 cysteine	 cathepsins,	 which,	 in	 the	 cytosol	 can	
process	 Bid	 into	 t-Bid	 promoting	 depolarization	 of	 the	 mitochondrial	 membrane	 and	
subsequent	apoptosis	(Repnik,	Hafner	Česen	et	al.	2014).	In	addition,	cysteine	cathepsins	can	
degrade	 anti-apoptotic	 Bcl-2	 family	 members	 further	 promoting	 mitochondrial	
depolarization	 (Droga-Mazovec,	 Bojic	 et	 al.	 2008,	 Repnik,	 Hafner	 Česen	 et	 al.	 2014).	
Treatment	 with	 hydroxychloroquine	 was	 reported	 to	 promote	 LMP	 and	 result	 in	
mitochondrial	 membrane	 depolarization	 in	 HeLa	 cells	 (Boya,	 Gonzalez-Polo	 et	 al.	 2003).	
More	recently,	chloroquine	treatment	was	reported	to	promote	LMP	and	reduce	cell	viability	




to	 activate	 p53	 and	 reduce	 tumour	 growth	 in	 mice	 by	 stabilization	 of	 p53	 (Guo,	 Karsli-
Uzunbas	et	al.	2013,	Rao,	Tortola	et	al.	2014).	However,	as	previously	mentioned,	PC3	cells	
are	deficient	in	p53,	and	may	respond	differently	to	cell	death	induction.		
Autophagy	 inhibition	 has	 been	 proposed	 to	 reduce	 adenoviral	 infection	 or	 replication	
(Rodriguez-Rocha,	 Gomez-Gutierrez	 et	 al.	 2011).	 However,	 siAtg5	 or	 siAtg7	 transfection	
resulted	in	no	changes	in	the	expression	of	the	E1A	and	hexon	proteins,	when	compared	to	
the	siNT	control,	indicating	that	the	viral	life	cycle	was	not	affected	and	the	virus	remined	




4.5 THE	 EFFECT	 OF	 BCL-2	 KNOCK-DOWN	 IN	 AUTOPHAGY	 MODULATION	 AND	 AD∆∆	
MEDIATED	SENSITIZATION	TO	MITOXANTRONE	
	
The	 Bcl-2	 protein	may	 play	 an	 important	 role	 in	 in	 the	 crosstalk	 between	 apoptosis	 and	
autophagy	(Marquez	and	Xu	2012).	Bcl-2	is	a	well-known	anti-apoptotic	protein	that	binds	




Gordy	 and	 He	 2012).	 I	 demonstrated	 that	 siRNA-mediated	 Bcl-2	 knock-down	 resulted	 in	
autophagy	 induction,	 shown	 by	 increased	 LC3BI	 to	 LC3BII	 conversion,	 which	 was	 not	
prevented	 by	 Ad∆∆	 infection.	 However,	 I	 found	 that	 siBcl-2	 did	 not	 affect	mitochondrial	
depolarization	 in	 PC3	 cells	 treated	with	mitoxantrone	 or	 the	 combined	 treatment,	when	
compared	to	 the	siNT	control.	As	Bcl-2	 is	an	anti-apoptotic	protein,	 it	was	surprising	 that	
siBcl-2	 did	 not	 enhance	mitochondrial	 depolarization.	 It	 is	 possible	 that	 siBcl-2-mediated	
promotion	 of	 autophagy	may,	 to	 some	 extent,	 prevent	 promotion	 of	 apoptosis	 through	
other	mechanisms.		
Expression	of	 pro-survival	molecules,	 such	 as	Bcl-2,	 Bcl-xL	 and	Mcl-1,	 is	 frequently	 found	





increased	 expression	 of	 Bcl-2	 in	 PC3	 cells,	 that	 was	 associated	 with	 appearance	 of	 drug	
resistance	 (Sobue,	Mizutani	et	 al.	 2016).	Down-regulation	of	Bcl-2	expression	 is	 currently	
being	studied	as	a	therapeutic	strategy	for	PCa	treatment.	Atorvastatin,	in	combination	with	
docetaxel,	 resulted	 in	 a	 strong	 decrease	 in	 Bcl-2	 expression,	 inhibited	 cell	 growth	 and	
promoted	 apoptosis	 in	 PC3	 cells	 (Chen,	 Liu	 et	 al.	 2016).	 Down-regulation	 of	 Bcl-2	 was	
reported	to	successfully	sensitise	LnCaP	cells	to	androgen	deprivation	therapy	and	radiation	
(Shi,	 Gumerlock	 et	 al.	 2001,	 Scott,	 Higdon	 et	 al.	 2002).	 Therefore,	 the	 mitoxantrone-
mediated	down-regulation	of	Bcl-2	expression,	that	I	demonstrated,	would	likely	facilitate	
apoptosis	 induction	 and	 finally	 result	 in	 cell	 death.	 In	 contrast	 with	 these	 reports,	 I	
demonstrated	 that	 Bcl-2	 knock-down	 resulted	 in	 a	 significant	 increase	 in	 EC50-values	 to	
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role	of	 Bcl-2.	 Surprisingly,	 I	 found	 that	Bcl-2	 expression	was	 required	 for	AdΔΔ-mediated	
enhancement	 of	 mitoxantrone-induced	 cell	 killing.	 Knock-down	 of	 Bcl-2	 completely	
prevented	 Ad∆∆-mediated	 sensitization	 to	 the	 drug.	 In	 agreement	 with	my	 sensitization	
data,	I	showed	that	the	combined	treatment	of	mitoxantrone	and	Ad∆∆	did	not	significantly	
enhance	cell	killing	in	siBcl-2	cells,	while	it	significantly	enhanced	cell	killing	in	siNT	cells.	This	
is,	 to	 the	best	of	my	knowledge,	 the	 first	 time	that	Bcl-2	 is	 shown	to	be	 required	 for	Ad-
mediated	sensitization	to	mitoxantrone.	
The	role	of	Bcl-2	expression	in	the	adenoviral	cell	cycle	and	in	Ad-mediated	sensitization	to	




expression	 was	 not	 affected	 in	 Ad∆∆	 single-infected	 PC3	 cells.	 My	 data	 suggested	 that	
expression	 of	 early	 adenoviral	 proteins	 and	 probably	 AdΔΔ	 replication	 was	 impaired	 by	
mitoxantrone	 treatment	 in	 siBcl2	 transfected	 PC3	 cells.	 Impaired	 viral	 expression	 and	
replication	could	partially	explain	the	lack	of	AdΔΔ-mediated	sensitization	to	mitoxantrone.	
I	 also	 demonstrated	 that	 mitoxantrone	 treatment	 resulted	 in	 downregulation	 of	 Bcl-2	
expression	 at	 both	 mRNA	 and	 protein	 levels.	 I	 showed	 that	 the	 decreased	 Bcl-2	 mRNA	
expression	 was	 maintained	 after	 simultaneous	 infection	 with	 either	 Ad5wt	 or	 AdΔΔ.	
However,	I	found	a	trend	towards	attenuation	of	mitoxantrone-induced	decreases	in	Bcl-2	
protein	levels	after	infection	with	AdΔΔ	but	not	with	Ad5wt.	Infection	with	Ad12S	strongly	
counteracted	mitoxantrone-induced	 decreases	 in	 Bcl-2	 protein	 levels,	 indicating	 that	 this	
effect	is	probably	due	to	expression	of	the	E1A12S	protein.	I	also	found	that	single	infection	









AdΔΔ	 enhanced	 mitoxantrone-induced	 cell	 death	 and	 attenuated	 mitoxantrone-induced	
decreased	Bcl-2	expression.	 In	addition,	siBcl-2	prevented	AdΔΔ-mediated	sensitization	to	










(Paludan,	 Schmid	 et	 al.	 2005,	 Chiramel,	 Brady	 et	 al.	 2013).	 Interestingly,	 the	 E3gp19K	
adenoviral	 protein	 attenuates	 the	 host	 immune	 response	 by	 hampering	 antigen	
presentation.	 Expression	 of	 E3gp19K	 blocks	 the	 transport	 of	 MHC	 class	 I	 to	 the	 plasma	
membrane	and	reduces	the	levels	of	cell	surface	receptors	for	natural	killer	cells	(Burgert,	
Maryanski	 et	 al.	 1987,	McSharry,	 Burgert	 et	 al.	 2008).	 Furthermore,	 deletion	of	 E3gp19K	
promoted	 activation	 of	 the	 host	 immune	 response	 by	 enhancing	 tumour	 antigen	
presentation	(Halldén,	Hill	et	al.	2003,	Wang,	Hallden	et	al.	2003,	Lichtenstein,	Toth	et	al.	
2004).	In	addition,	active	autophagy	was	recently	reported	to	be	required	for	MHC	class	II-
mediated	 presentation	 of	 adenoviral	 antigens	 in	 infected	 cells	 (Klein,	 Jiang	 et	 al.	 2016).	
According	to	Klein	et	al.,	autophagy	inhibition	prevented	detection	of	viral-encoded	antigens	
(Klein,	Jiang	et	al.	2016).	Several	adenoviral	genes	appear	to	prevent	autophagy-mediated	




(Pattingre,	 Tassa	 et	 al.	 2005,	 Gordy	 and	He	 2012).	 Beclin	 1	 is	 also	 a	 target	 of	 viral	 Bcl-2	
homologues,	which	may	inhibit	autophagy.	For	example,	the	Bcl-2	homologue	encoded	by	
Kaposi’s	 sarcoma	 associated	 herpesvirus	 (KSHV)	 cannot	 be	 phosphorylated	 by	 JNKs	 and	
therefore,	 upon	 binding	 to	 Beclin	 1,	 maintains	 its	 sequestration	 preventing	 autophagy	
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induction	 (Liang,	E	et	al.	2008,	Mack	and	Munger	2012).	 In	addition,	 the	herpes	 simplex-
encoded	 protein	 Nef	 has	 been	 proposed	 to	 block	 autophagy	 maturation,	 although	 the	
mechanism	 is	 still	 unknown	 (Orvedahl,	 Alexander	 et	 al.	 2007).	 However,	 adenovirus	was	
recently	 reported	 to	 mediate	 phosphorylation	 of	 JNK1	 and	 JNK2	 promoting	 Bcl-2	
phosphorylation	and	its	dissociation	from	the	Beclin	1-Bcl-2	complex	(Klein,	Piya	et	al.	2015).	
This	 interaction	 has	 been	 shown	 to	 induce	 autophagy	 in	 different	 cell	 lines	 (UG87MG,	
U251MG,	A549	and	MEF)	although	those	did	not	include	prostate	cancer	models	(Klein,	Jiang	





2012).	Multiple	DNA	viruses,	 including	adenovirus,	 interact	with	p53	and	 therefore	 could	
indirectly	modulate	autophagy	through	this	pathway	(White	2006,	Mack	and	Munger	2012).	
However,	in	most	cancers,	including	PCa,	p53	is	non-functional	(Lorenzo,	Arnoldussen	et	al.	
2007),	 therefore,	 this	 pathway	 is	 not	 likely	 to	 play	 a	 role	 for	 oncolytic	 adenoviruses.	 I	
demonstrated	that	Ad∆∆	attenuated	mitoxantrone-induced	autophagy	 in	PC3	cells,	which	
are	 p53	 deficient,	 therefore,	 Ad∆∆-mediated	 autophagy	 modulation	 was	 probably	 p53-
independent.	Alternatively,	several	DNA	viruses	such	as	the	Epstein-Barr	virus	(EBV),	human	
papiloma	 virus	 (HPV),	 hepatitis	 B	 virus	 (HBV)	 and	 hepatitis	 C	 virus	 (HCV)	 have	 also	 been	















accurately	 resembled	 the	 tumour	microenvironment	 in	 situ.	 The	 normal	 human	prostate	
stromal	 cells	 (PrSC)	were	grown	 together	with	 the	epithelial	prostate	 carcinoma	PC3	and	
22Rv1	cells	in	a	matrix	composed	of	collagen	type-I	and	matrigel.		
Adenoviruses	hold	natural	tropism	for	epithelial	cells	(Arnberg	2012,	Wold	and	Toth	2013),	
therefore	 I	 investigated	sensitivity	to	virus-induced	cytotoxicity,	viral	 infection,	replication	
and	the	expression	of	the	cellular	surface	receptors	in	PrSC	cells	in	2-dimensional	cultures,	





in	 these	 cells.	 Interestingly,	 I	 showed	 that	 expression	 of	 αvβ3	 and	 αvβ5	 integrins	 did	 not	






et	 al.	 2009,	 Froeling,	Marshall	 et	 al.	 2010,	 Coleman,	Watt	 et	 al.	 2014).	 Fibroblasts	 were	
reported	to	promote	cell	growth	and	invasion	in	these	pancreatic	3-dimensional	models.	The	





resulted	 in	 increased	aggressiveness	 and	mimicked	bone	metastasis	 in	 three-dimensional	
hydrogel	cultures	(Fong,	Wan	et	al.	2016).	I	have	demonstrated	that	the	co-culture	of	either	
PC3	 or	 22Rv1	 with	 PrSC	 in	 3-dimensional	 cultures	 resulted	 in	 increased	 cell	 growth	 and	
proliferation	 into	 the	 matrix	 in	 preliminary	 studies,	 when	 compared	 to	 3-dimensional	
epithelial	monocultures.	My	preliminary	data	agreed	with	published	findings	and	indicated	























both	 virus	 and	 drug	were	 added	 2-3	 times	 over	 the	 indicated	 time-periods	 to	 overcome	
increased	 resistance	 to	 infection	 due	 to	 decreased	 surface/volume	 ratios	 and	 increased	
thickness	 of	 the	matrix.	 Treatment	with	AdΔΔ,	 or	 the	 combination	 treatment	 resulted	 in	
AdΔΔ	infection	in	3-dimensional	cultures,	that	was	demonstrated	with	positive	E1A	staining.	
Infection	of	AdΔΔ	was	detected	in	all	cell	types,	including	PrSC.	













The	main	 issues	 are	 expression	 of	 hCAR,	 which	 is	 found	 in	 numerous	 non-target	 tissues	
(Arnberg	 2012);	 binding	 of	 the	 viral	 vector	 to	 erythrocytes	 (Carlisle,	 Di	 et	 al.	 2009);	
sequestration	of	the	vector	by	Kupffer	cells	in	the	liver	(Tao,	Gao	et	al.	2001,	Xu,	Tian	et	al.	
2008);	 up	 take	 of	 virus	 by	 hepatocytes	 (Waddington,	 McVey	 et	 al.	 2008).	 Finally,	 viral	
transduction	can	be	hampered	by	low	expression	of	hCAR	in	the	target	cells,	as	it	has	been	
demonstrated	in	PC3	cells	(Pandha,	Stockwin	et	al.	2003,	Adam,	Ekblad	et	al.	2012).	











of	 expression	 of	 the	 cell	 surface	 receptors	 used	 by	 adenovirus,	was	 probably	 the	 reason	








adenoviral	 vector	 and	 gold/iron	 magnetic	 nanoparticles	 easily	 penetrated	 the	 plasma	
membrane	 following	 the	 application	 of	 a	 magnetic	 force	 and	 independently	 of	 cellular	
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receptors.	 I	 have	 demonstrated	 that	 the	 coating	 of	 the	 oncolytic	 adenovirus	 AdΔΔ	 with	
positively-charged,	PEG-functionalised	gold	nanoparticles	enhanced	 treatment	efficacy	by	
increasing	 viral	 uptake.	 This	 enhancement	 in	 infection	was	 likely	due	 to	neutralization	of	
negatively-charged	 adenoviral	 particles	 and	 consequent	 facilitation	 of	 non-specific	 viral	
attachment	and	internalitation.	Consequently,	NP-mediated	enhancement	of	viral	infection,	
which,	as	I	demonstrated,	was	higher	in	hCAR-negative	PC3	cells	and	was	possibly	receptor-
independent	 and	 non-specific,	 as	 previously	 reported	 (Kamei,	 Mukai	 et	 al.	 2009).	 This	
hypothesis	 could	 be	 validated	 by	 testing	 viral	 uptake	 in	 hCAR-ablated	 cells.	 The	
chemotherapy	 agent	 5-FU	 was	 reported	 to	 enhance	 adenoviral	 uptake	 in	 a	 receptor-




correlation	 between	 increased	 viral	 uptake	 and	 cytotoxicity	with	 lesser	 increases	 in	 viral	
replication	might	be	due	to	the	fact	that	cells	were	overloaded	with	viral	particles	and	had	
reached	their	maximum	replication	or	gene	expression	capacity.	It	is	also	possible	that	the	
NP-induced	 increased	 AdΔΔ-mediated	 cell	 death	 eliminated	 infected	 cells	 before	 viral	
replication	could	take	place.		
The	gold	nanoparticles	that	I	used	were	functionalised	with	PEG-NR4+	(3000	PEG	molecules	
per	 nanoparticle)	 but	 had	 not	 been	 tested	 in	 combination	 with	 adenovirus	 in	 vivo	 yet.	
Unfortunately,	the	coating	of	either	adenoviral	vectors	(Mok,	Palmer	et	al.	2005,	Kim,	Kim	et	
al.	2012)	or	gold	nanoparticles	(Khlebtsov	and	Dykman	2011)	with	PEG	had	previously	been	
reported	 to	 result	 in	 liver	 accumulation.	 Interestingly,	 the	 functionalization	 of	 gold	
nanoparticles	with	TNF	has	been	reported	to	selectively	target	solid	tumours	(Khlebtsov	and	




I	 have	 shown	 in	 my	 work	 that	 Ad∆∆	 infection	 or	 E1A12S	 expression	 alone	 enhanced	
mitoxantrone-induced	 apoptotic	 cell	 death	 and	 attenuated	 mitoxantrone-induced	








inhibition	with	 either	 chloroquine	 or	Atg7-targeted	 knock-down	enhanced	mitoxantrone-
induced	 apoptosis.	 However,	 siAtg7	 transfection	 did	 not	 result	 in	 any	 effect	 on	 Ad∆∆-
mediated	 sensitization	 to	mitoxantrone.	 Importantly,	 despite	 the	 findings	 indicating	 that	
Ad∆∆	 infection	 promoted	 apoptosis	 and	 attenuated	 autophagy	 in	 mitoxantrone-treated	
cells,	autophagy	inhibition	may	not	be	the	mechanism	behind	the	observed	Ad∆∆-mediated	
sensitization	 to	 mitoxantrone.	 Preliminary	 data	 showed	 that	 the	 combined	 treatment-
induced	enhanced	cell	killing	and	AdΔΔ-mediated	prevention	of	autophagy	were	replicated	
in	3-dimensional	cultures.	
I	 have	 also	 shown	 that	 expression	 of	 the	 Bcl-2	 protein	was	 required	 for	 Ad∆∆-mediated	
sensitization	to	mitoxantrone	 in	PC3	cells	possibly	because	of	 the	attenuation	of	E1A	and	




















confirmed	by	 testing	 additional	 time-points	 (shorter	 and	 longer)	 or	 slightly	 lower	




• Apoptosis	 experiments	 should	 be	 correlated	 with	 cell	 viability	 detection	 under	
similar	conditions	to	confirm	if	the	increased	mitochondrial	depolarization	correlates	
with	 increased	 cell	 death	 or	 decreased	 cell	 proliferation.	 Cell	 death	 or	 cell	
proliferation	 could	 be	measured	 at	 later	 time	 points,	 and	 possibly	 by	 alternative	
methods	such	as	trypan	blue	or	crystal	violet.		






















in	 siBeclin	 1	 transfected	 cells	 to	 investigate	 the	 role	of	 the	 autophagy	modulator	
Beclin	1	in	Ad∆∆-mediated	enhancement	of	mitoxantrone-induced	cell	death.		
• Ad∆∆	 infection	 and	 E1A12S	 expression	 were	 shown	 to	 attenuate	 mitoxantrone-
induced	decreases	in	expression	of	Bcl-2	at	the	protein	level	but	not	at	the	mRNA	
level.	The	effect	of	the	combination	treatment	in	Bcl-2	expression	could	be	further	
studied	 with	 the	 use	 of	 proteasome	 inhibitors	 or	 ribosome	 inhibitors	 to	 further	
confirm	if	E1A	expression	can	stabilise	the	Bcl-2	protein.		
• Infection	 with	 AdΔ24	 (E1ACR2	 deleted)	 has	 been	 reported	 to	 promote	
phosphorylation	of	Bcl-2	therefore	disrupting	the	Bcl-2-Beclin	1	complex	(Klein,	Piya	
et	al.	2015).	The	study	of	Bcl-2	phosphorylation	status	as	a	result	of	the	combination	
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